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LIST OF FIGURES1
The purpose of this report is to provide policymakers, program leaders and staff, health administrators, scientists,
and others with information that may help them understand the nature and extent of illegal drug use, associated
behaviors, and problems that now affect our Nation’s racial/ethnic minority populations and the current non-
Hispanic White majority population. Its content has been culled from the best and most recent reports on 
these topics.
Data sources for this report include the U.S. Census and large- and small-scale epidemiological studies that have
been collecting and analyzing data on the incidence, prevalence, morbidity, mortality, and other adverse health
consequences of illegal drug use in the United States, with a general restriction to investigations with ample cov-
erage of two or more racial/ethnic populations. Study sponsors comprise an array of Federal agencies, including
the U.S. Bureau of the Census (the Census Bureau); the National Institute on Drug Abuse (NIDA); the Centers
for Disease Control and Prevention (CDC) and its constituent units, such as the National Center for Health
Statistics; the Department of Education; the Department of Justice; the National Institute of Justice (NIJ); and
the Substance Abuse and Mental Health Services Administration (SAMHSA). NIDA-sponsored research pro-
grams of special prominence in this report include the Monitoring the Future (MTF) project and the Native
American youth surveys conducted by the Tri-Ethnic Center for Prevention Research in Fort Collins, Colorado.
Information on youth’s attitudes toward drugs also is included, based on surveys conducted by the Partnership
for a Drug-Free America via its Partnership Attitude Tracking Survey (PATS).
The context for this report includes major demographic changes now affecting the United States. These changes
started during the 20th century and will persist through the current century. For example, by 2030, racial/
ethnic minorities are expected to constitute one-half of the K–12 student population of the United States. In a
complementary demographic shift, the non-Hispanic White share of the total U.S. population is expected to
decline from 75 percent in the early 1990s to 60 percent in 2030, 50 percent between 2050 and 2060, and 
40 percent by 2100. By that year, non-Hispanic Whites will have become a racial/ethnic minority population of
the United States (U.S. Bureau of the Census 2000a). This demographic transformation of the U.S. population
and the composition of its minority populations warrant the attention of our policymakers and program planners,
who must help our Nation understand and cope with the changing social and demographic context of our daily
lives at home, in the workplace, and in our communities.
An historical perspective provides further context for this report. After the Second World War, medical, non-
medical, and extramedical domestic use of legitimate pharmaceutical products increased. These products, 
available over the counter or by prescription, included over-the-counter benzedrine inhalers and amphetamine-
containing diet pills, as well as over-the-counter and prescription sedative (calming) and hypnotic (sleep-
enhancing) medicines containing barbiturates and newer synthetic drugs. There was no assertion of a strong
association linking use of these drugs to racial/ethnic minorities. Sustained problems associated with extramedical
use of these drugs and concerns about potentially burgeoning use of heroin, marijuana, and LSD fostered a
renewal of Federal interest.
In the United States, the era of military conflict and war in Vietnam was marked by an increase in marijuana
smoking and LSD use, in addition to continued problems with psychostimulants and sedative-hypnotic 
medicines. New illegal drug use patterns surfaced in the form of recreational use of methylenedioxymetham-
phetamine (MDMA, “ecstasy”) and other hallucinogenic and psychostimulant drugs (e.g., mescaline and crystal
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methamphetamine) and cocaine hydrochloride powder (e.g., see National Commission on Marihuana and
Drug Abuse 1972, 1973).
During the early 1970s, the complex social context of illegal drug use was recognized in the work of a new
National Commission on Marihuana and Drug Abuse, which identified marijuana smoking and other illegal
drug use as a “signal of misunderstanding” between the generations and diverse subgroups of our Nation
(National Commission on Marihuana and Drug Abuse 1972, 1973). However, despite important scholarly 
and empirical contributions to our understanding of illegal drug use in the United States, the results of the 
commission’s work mainly were seen in isolated changes of local and State policies toward marijuana use and in
general improvements within the Federal apparatus for nationwide surveillance of illegal drug use and renovation
of Federal responsibility for support of drug-related services and scientific research on illegal drug use.
The Federal surveillance apparatus fostered by the National Commission on Marihuana and Drug Abuse proved
to be a robust contribution, in part because surveillance responsibilities soon were housed within newly estab-
lished, science-oriented NIDA, before it became part of the National Institutes of Health (NIH) in 1992. One
of the benefits of this work was a much-improved base of evidence on the epidemiology of illegal drug use and
drug problems in the general population, starting with a national survey of illegal drug use completed for 
the commission in the early 1970s. After NIDA was formed in 1974, the first national survey of household 
residents evolved into a survey series that became the National Household Survey on Drug Abuse (NHSDA).
This survey now is the major instrument for epidemiological surveillance of illegal drug use in the United States
and is the responsibility of the Office of Applied Studies (OAS) within SAMHSA.
For its part, the former Bureau of Narcotics and Dangerous Drugs and current Drug Enforcement
Administration (BNDD/DEA) fostered development of the Drug Abuse Warning Network (DAWN), a form
of early sentinel surveillance to detect emerging patterns of illegal drug use that pose hazards to public health
and safety. Once developed by BNDD/DEA, DAWN surveillance responsibilities were transferred to NIDA
and then to OAS within SAMHSA. In use for about three decades, DAWN collects and reports information on
casualties secondary to illegal drug use. Sources for this information are autopsy records of medical examiners
and clinical records of hospitals with emergency rooms that have responsibility for management of drug 
overdoses and other drug-related emergency crises such as bad trips and acute infectious diseases.
Illegal drug use by high-school seniors also was recognized by the national commission as an important topic
for surveillance, due in part to a recognition that the future leadership of any country depends heavily on its
secondary school graduates. Soon after the first national survey of illegal drug use among secondary students,
the University of Michigan inaugurated the MTF series of surveys of 12th-graders in 1975. These surveys were
accompanied by a series of annual reports and monograph-length books based on a NIDA-funded repetition of
the annual surveys for over 25 years. In recent years, the MTF surveys have expanded to include samples of 
8th, 10th, and 12th grade.
After a decade of sustained surveillance via NHSDA, DAWN, and MTF, the Anti-Drug Abuse Act of 1986 and
the Anti-Drug Abuse Act of 1988 fostered a deliberate focus on the illegal drug use of racial/ethnic minority
populations and patients in drug treatment programs. Epidemiologic data about alcohol and other drug use
among youth and adult minorities have slowly been emerging, but more attention is needed to adequately
understand the nature and scope of illegal drug use and associated problems for these populations.
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From these surveillance systems and specialized studies, we have learned that population subgroups experiencing
high rates of illegal drug use and associated problems often are constrained by limited employment opportunities,
poverty, illiteracy or low education level, and other unhealthy environmental conditions, such as disadvantaged
neighborhoods and lack of social capital (Anthony and Helzer, in press for 2002). For some drugs (but not all),
the prevalence of illegal drug use sometimes is higher in urban areas than in suburban or rural areas. Because
minorities, particularly African Americans and Hispanics, often are concentrated in central city areas, one might
think that they are at greater risk for illegal drug use and, ultimately, more at risk for associated negative social
and health consequences. This report examines these and other preconceptions about racial/ethnic minority
populations in the United States and includes a careful selection of published evidence on the subject.
DEFINITION OF RACE AND ETHNICITY
Any serious treatment of the topic of illegal drug use and racial/ethnic minorities must address current definitions
of race and ethnicity, which are under increasing scrutiny. In addition, measurement procedures for race and
ethnicity are changing as these concepts evolve. For example, in the U.S. Census, administrative statistics, and
research projects, the head of a household or individual respondents are permitted to identify themselves in 
designations of race and ethnicity. Congruent with this approach, many scientists assert that race is a mere
“social construct” and claim that the boundaries between different races depend more on perceptions within a
social psychological context and less on fundamental biological differences. A similar claim is advanced in the
argument that genetics research has successfully delegitimized claims that races are categorically distinct human
groupings (e.g., see Begley 1995; Condit et al. 2001).
Although prominent in standard vital statistics and disease surveillance operations for almost two centuries, our
concepts of race and ethnicity represent a longstanding source of social controversy. Definitions and measure-
ment procedures for these concepts continue to vary considerably by investigation, with no strong consensus to
support one concept or approach over another, even in programs directed toward conditions with race-lined
genetic susceptibilities such as sickle-cell disease (e.g., see Condit et al. 2001).
In the United States, administrators responsible for national-level vital statistics and disease surveillance systems
tend to steer clear of the controversies that arise in discussions of race and ethnicity. They generally have 
followed the standards outlined in Statistical Policy Directive No. 15, issued by the Office of Management 
and Budget (OMB) (U.S. Department of Commerce 1978). More recent standards have been issued,
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are being incorporated as revisions of the national-level vital statistics and disease surveillance systems. However,
the data available for this report largely were gathered using protocols based on the prior standards for classifi-
cation of race and ethnicity.
According to the 1978 directive, the four primary racial categories are American Indian/Alaska Native,
Asian/Pacific Islander, African American or Black, and White. The directive identifies Hispanic origin as an 
ethnicity, which in this context is defined as the nationality group or country of birth of a person or a person’s
parents or ancestors before arrival in the United States. Persons of Hispanic origin may be of any race. 
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Management and Budget Concerning Changes to the Standards for the Classification of Federal Data on Race and Ethnicity.”
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The definitions for the four race categories, as specified under Directive No. 15, are as follows:
● American Indian/Alaska Native—a person having origins in any of the original peoples of North America
who maintains cultural identification through tribal affiliations or community recognition; 
● Asian/Pacific Islander—a person having origins in any of the original peoples of the Far East, Southeast
Asia, the Indian subcontinent, or the Pacific Islands;
● Black or African American—a person having origins in any of the racial groups of Africa; and
● White—a person having origins in any of the original peoples of Europe, North Africa, or the Middle East.
These race categories may be combined with an ethnicity definition that distinguishes Hispanic individuals
from those who are non-Hispanic, in accord with Directive No. 15:
● Hispanic—a person of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish 
culture or origin, regardless of race. 
Although these classification standards from 1978 have been used in many projects, they have been criticized
for their failure to reflect the growing diversity of our Nation’s population and their lack of sensitivity to dis-
tinctions within the broadly stated groups (e.g., subgroups within the Asian/Pacific Islander and American
Indian/Alaska Native groups). During the last decades of the 20th century, immigration to the United States
from Mexico, Central and South America, the Caribbean, and Asia reached historic proportions. In addition,
as a result of the increase in interracial marriages, the number of persons born of mixed race or ethnicity has
grown. Directive 15 also has been criticized as failing to be scientific. In response to these and other criticisms,
OMB initiated a new review of the classification standards for data on race and ethnicity in June 1993.
As part of the review process, OMB established the Interagency Committee for the Review of the Racial and
Ethnic Standards in March 1994 to facilitate Federal agency participation in the review process. The committee’s
30 members were employees of the agencies that represent the diverse Federal needs for data on race and 
ethnicity, including statutory requirements for such data. Two major elements of the process were (1) public
comment on present definitions and (2) research and testing to assess the possible effects of recommended
changes on the quality and usefulness of the resulting data. The goal of the committee’s work was to produce
definitions resulting in consistent, publicly accepted data on race and ethnicity to meet the needs of the Federal
Government and the public, while recognizing the diversity of the population and respecting individual dignity.
This section details the Interagency Committee’s recommendations for changes in racial and ethnic categories
for use by the U.S. Government. The Census Bureau incorporated many of these changes into the 2000 census.
According to the Interagency Committee’s recommendations, the minimum categories for data on race and 
ethnicity or Federal statistics and program administrative reporting are defined as follows:
● American Indian or Alaska Native—a person having origins in any of the original peoples of North and
South America (including Central America) who maintains cultural identification through tribal affiliations
or community recognition;
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● Asian or Pacific Islander—a person having origins in any of the original peoples of the Far East, Southeast
Asia, the Indian subcontinent, or the Pacific Islands. These areas include, for example, China, India, Japan,
Korea, the Philippine Islands, Hawaii, and Samoa;
● Black or African American—a person having origins in any of the Black racial groups of Africa;
● Hispanic—a person of Mexican, Puerto Rican, Cuban, Central or South American, or other Spanish 
culture or origin, regardless of race; and
● White—a person having origins in any of the original peoples of Europe, North Africa, or the Middle East.
The recommended changes for data collection also include an emphasis on data quality. The committee 
recommended that when race and ethnicity data are collected separately, ethnicity data should be collected first.
In addition, the minimum designations for ethnicity and race are as follows:
● Ethnicity 
– Hispanic origin
– Not of Hispanic origin; and
● Race 
– American Indian or Alaska Native
– Asian or Pacific Islander
– Black or African American
– White
In addition, persons are allowed but are not required to report more than one race. A minimum of one additional
racial category, designated “more than one race” has been recommended to report the aggregate number of 
multiple race responses. This classification system allows for the collection of data on special subgroups, such as
“Hispanic and one or more races” and “More than one race.”
For the full text of the committee’s analysis and recommendations, readers should refer to Appendix 2 of the
Federal Register for July 9, 1997. These recommendations, designed to provide minimum standards for Federal
data on race and ethnicity, address options for reporting by respondents, formats of questions, and several
aspects of specific categories, including possible additions, revised terminology, and changes in definition. The
Census Bureau has provided an overview of its implementation of these recommendations for the 2000 census
(U.S. Bureau of the Census 2001a).
The following population statistics and information on drug use among members of each race/ethnicity are
summarized from existing reports and provide a context for the data discussed later in this report. A summary of
Asian/Pacific Islander information is provided for completeness only; data available on drug use within this seg-
ment of the U.S. population remain very limited, although promising new investigations are being conducted
by OAS within SAMHSA and by investigators supported by NIH and CDC.
5Introduction
Notwithstanding the importance of summarizing national statistics in terms of broadly defined racial and ethnic
subgroups, this report takes for granted that considerable heterogeneity and variation exist within the several
racial groups and ethnic categories used in reporting statistics from recent surveys. Throughout this report, we
draw the reader’s attention to the clear heterogeneity and variation within minority populations of the United
States. Statements that might be true, on average, for these aggregated populations may be wholly untrue for
individual subgroups within the aggregate. For example, we know considerably more about the illegal drug use
of American Indians than that of Alaska Natives. Broadly stated generalizations about the aggregate category 
for “American Indian/Alaska Native” populations may hold for some tribes of American Indians but not for
others, or may hold for American Indians in general but not for Alaska Natives. Distinctions of this type, and
the possibilities for variation within aggregate minority populations, are essential to remember, even as we make
use of the aggregations to understand health disparities that might exist within and across racial and ethnic 
populations of the United States.
The report also is informed by a NIDA position statement on health disparities and the relationships between
health disparities and the use of tobacco, alcohol, and illegal drugs. A copy of this statement is found in
Appendix 1.
American Indians/Alaska Natives
At the turn of the century, 220,000 American Indians/Alaska Natives lived in the United States; the 1990 and
2000 census counts indicate that this population had grown to approximately 2 million, two times the 1970
count (U.S. Bureau of the Census 1991, 2000a). This exceptional increase may be traced to improved health
care for all ages, a robust birth rate, reduced infant mortality, and possible greater willingness to report Native
American ancestry in each of the most recent decennial census enumerations.
Several social and demographic facts are pertinent. For example, in 1994, the birth rate among American
Indians/Alaska Natives was 13 percent higher than that of the country at large (U.S. Bureau of the Census
1996). The median age of the American Indian/Alaska Native population was 24.2 years in 1990, compared
with 34.4 years for U.S. Whites (Indian Health Service 1994). Sixty-two percent of American Indians now 
live away from traditional native communities or reservations, and most groups are small with not much 
land (Robbins 1994). Indian culture and physical characteristics, though believed by many to be homogeneous,
are best described as diverse. By the mid-1900s, there were more than 300 federally recognized tribes
(Hirschfelder and Montano 1993). By 1997, there were more than 550 federally recognized tribes (U.S. Bureau
of Indian Affairs 1997). 
Serious concern exists that American Indian/Alaska Native populations have not been well represented in
national statistics and surveillance activities for drug involvement (e.g., too few American Indian/Alaska Native
participants in the surveys). In addition, the statistics and surveys generally have not attended to suspected 
variation in drug involvement within and across tribal groups in this minority population. Responding to these
concerns, NIDA has sponsored research at the Tri-Ethnic Center for Prevention Research in Fort Collins,
Colorado, and other studies designed to include specific coverage of American Indian or Alaska Native minority
group members. These studies have suggested heavy use of alcohol, tobacco, and other drugs as serious public
health problems within these populations (Beauvais et al. 1989; Blum et al. 1992; Fleming et al. 1996; Indian
Health Service 1994; U.S. Department of Health and Human Services 1998; Stillner et al. 1999). Some
research indicates more excessive drinking and illegal drug use among American Indians and Alaska Natives than
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among most, if not all, other racial/ethnic minority groups in the United States, even when the younger median
age of the American Indian/Alaska Native population group is taken into account (U.S. Office for Substance
Abuse Prevention 1990; Bachman et al. 2001).
Excess prevalence of illegal drug use in the American Indian/Alaska Native population also is suggested in evidence
from the most recent NHSDA, from calendar year 2000. According to NHSDA 2000, an estimated 14 million
Americans age 12 and older were active and current illegal drug users (i.e., with a history of using drugs illegally
during the 1-month interval before survey assessment). Estimated as a proportion, this value for “past month”
or “current” use is slightly more than 6 percent of the total population age 12 and older. The corresponding 
survey estimate for active and current illegal drug use among American Indian/Alaska Natives is 12.6 percent
(Substance Abuse and Mental Health Services Administration 2001b). In surveys focused solely on young people,
prevalence estimates for drug involvement in the month before assessment also show that American
Indian/Alaska Native youth use marijuana, cocaine, cigarettes, and alcohol at two or more times the observed
values for Hispanic and non-Hispanic Whites and Blacks. In a recent study of young adolescents in North
Carolina, cumulative occurrence of alcohol, tobacco, marijuana, and other drug use among American Indians
exceeded the occurrence rates observed for non-Hispanic White and African-American groups (Federman et al.
1997). According to the national MTF study, by 12th grade an estimated 40 to 52 percent of American
Indian/Alaska Native students smoke tobacco. Corresponding values for African-American students range from
10 to 20 percent (Bachman et al. 2001).
The higher prevalence values observed for American Indian/Alaska Native populations have been described by
Robbins (1994) as cutting across many different subgroups of this aggregate category, affecting both sexes, 
and possibly nourishing cycles of poverty and disease. Regrettably, American Indian/Alaska Native youth have 
been observed to begin using tobacco cigarettes and alcohol at an earlier age than their White counterparts
(Young 1988) and to try marijuana at an earlier age than White youth (U.S. Office for Substance Abuse
Prevention 1990).
We already have mentioned the theme of heterogeneity or variation within aggregate racial/ethnic minority 
populations of the United States. The national statistics reported in this chapter and throughout this report are
based mainly on data for American Indians, with few Alaska Natives included in the national surveys. Although
several important recent focused studies of Alaska Native populations have been done (e.g., Stillner et al. 1999),
it is difficult to compare results from these studies with those from nationally representative sample surveys
because of differences in sampling plans, assessment methods, and other details of approach. Indeed, in reports
from recent student surveys conducted for CDC, the prevalence of drug involvement among Alaska Native 
students was not found to be appreciably different from that of other students living in Alaska (Alaska
Department of Health and Social Services 1995). For such reasons, it is not now possible to make a compre-
hensive comparison of illegal drug involvement and associated problems for subgroups within the American
Indian/Alaska Native population. It is important to remember that statistical summaries about this population
may be true, on average, but may not apply to specific individual tribal groups or other subgroupings within
this population. Written with the hope that readers will keep this issue firmly in mind, the remainder of this
report highlights comparisons between population-averaged values for the American Indian/Alaska Native 




Asian/Pacific Islanders comprise more than 60 separate racial/ethnic groups and subgroups. As was true for the
American Indian/Alaska Native population, these groups are heterogeneous and considerable variation exists
within the aggregate category described by the term “Asian/Pacific Islander” (Sue 1987). This heterogeneity
encompasses dramatic variations in drug involvement (e.g., see National Center for Health Statistics 2000; U.S.
Department of Health and Human Services 1998), not only within the continental United States, but also
across subgroups as diverse as the Chamorro people of Guam and the Commonwealth of the Northern Mariana
Islands (CNMI), native Hawaiians, the Samoans of American Samoa, and the Yapese, Chuukese, Kosraeans,
and Pohnpeians of the Federated States of Micronesia.
Several illustrations underscore the heterogeneity within the broad Asian/Pacific Islander category used in the
U.S. Census and in surveillance operations of the Federal Government. During the late 1980s and early 1990s, on
Guam and Saipan in the Mariana Island chain of western Micronesia, serious outbreaks of methamphetamine
use occurred in the form of “ice smoking,” fueled by major supply lines from the Philippines and Japan, and
coincident with early growth of Hawaii’s methamphetamine problems (Furr et al. 2000). Despite regular travel
between Hawaii, Micronesia, and Samoa, and within Micronesia, ice smoking never has posed major public
health or safety problems in the more eastern parts of Micronesia such as Pohnpei, Chuuk, and Kosrae, 
nor in American Samoa, where methamphetamine trafficking and use has been observed in no more than 
limited outbreaks. 
In addition, for decades, the chewing of betel nut for psychoactive purposes has been a common daily practice
in the CNMI, Palau, and other parts of western Micronesia. However, betel nut has become a growing public
health concern on Pohnpei and Chuuk in eastern Micronesia only within recent years and has had little salience
on the islands of American Samoa or Hawaii. Drinking of intoxicating beverages derived from Piper methysticum
(kava, sakau-en-Pohnpei) has receded from a former visible prominence in daily life for most residents of Tutuila,
the most populous island of American Samoa. Yet it still is prominent within nearby Western Samoa and to
some extent within the Manu’a island group of American Samoa and has become a public health concern on
Pohnpei (but is not common within the nearby states of Kosrae and Chuuk). Drinking of such beverages may
be increasing in the Hawaiian islands, but it is rare within the Commonwealth of the Northern Mariana Islands
and Guam (Arria and Anthony 1999).
When the statistics on different groups are aggregated into a single category, it is possible to say that during the
1990s Asian/Pacific Islanders had one of the fastest growth rates among all racial/ethnic groups identified by the
Census Bureau. In recent years, Southeast Asian refugees, Filipinos, and Koreans have been the fastest growing
Asian groups. To the extent that people of Southeast Asian, Filipino, and Korean heritage retain distinctive 
patterns of alcohol and other drug use, changes of this type will be accompanied by changes in the alcohol and
other drug use patterns of the Asian/Pacific Islander subgroup as a whole (Kim et al. 1995).
Until recently, information on drug use among Asian/Pacific Islanders generally has come to us from isolated
surveys conducted by individual researchers, although recent increases in sample size for national surveys now
provide greater coverage of drug involvement within this group. For example, based on the most recently 
published data from NHSDA 2000, it is possible to perceive important variations within the Asian/Pacific
Islander population. As stated above, slightly more than 6 percent of Americans age 12 and older are current
illegal drug users, and the corresponding value for American Indian/Alaska Natives is 12.6 percent. For
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Asian/Pacific Islanders, the value is 2.7 percent. Notwithstanding the overall low value for Asian/Pacific
Islanders in general, it is noteworthy that an estimated 6.9 percent of Korean Americans are current illegal drug
users, a value that is not appreciably different from the population mean or average value for all persons 
(6.3 percent). For Chinese Americans, the corresponding estimate is just 1 percent; for Asian Indian Americans,
2.1 percent; for Filipino Americans, about 3 percent; for Vietnamese Americans, 4.3 percent, and for Japanese
Americans, 5 percent (Substance Abuse and Mental Health Services Administration 2001b).
The main reason for this increased resolving power of the NHSDA findings for Asian/Pacific Islander subgroups
is a recent major increase in the survey’s sample size. For the most part, nationally representative sample surveys
with 4,000 to 5,000 respondents will have a resolving power that yields reasonably precise estimates for the most
populous Asian/Pacific Islander subgroups of the United States, such as Chinese and Vietnamese, but even
larger samples are needed to disaggregate the statistics for Korean, Japanese, and other Asian heritage subgroups
not listed specifically. In the near future, D.T. Takeuchi and colleagues will have completed a nationally repre-
sentative sample survey of the larger Asian- and Hispanic-American population subgroups, which will provide
national estimates on illegal drug involvement to compare with and augment current estimates from the
NHSDA (D.T. Takeuchi, “National Latino and Asian American Study,” National Institute of Mental Health
[NIMH] grant MH62207, 2000). 
The just-described estimates from NHSDA 2000 are generally consistent with a widely held belief that illegal
drug use among Asian/Pacific Islanders occurs less frequently than for other segments of the U.S. population,
although it is noteworthy that estimates for Korean Americans and Japanese Americans are not too different
from the general population estimates. Until recently, it was thought that the underrepresentation of
Asian/Pacific Islanders among alcohol and other drug users in general population surveys might have something
to due with social stigma and a possibility that Asian/Pacific Islander American drug users are less likely to 
self-identify or pursue treatment services because such services are culturally inappropriate (Kuramoto 1994).
Indeed, when cross-national comparisons of prevalence of problem drinking and alcohol dependence have been
made, men in certain Asian countries (e.g., South Korea) have been observed to have extremely high values 
compared with men in the United States and most other countries (Anthony and Helzer 1995). Nonetheless,
especially with illegal drug use, recent epidemiological survey data indicate that prevalence of drug involvement
actually is generally lower among young Asian/Pacific Islanders than among White non-Hispanic American 
residents. This finding holds not only for NHSDA surveys but also for those of school-attending youths 
(e.g., see Bachman et al. 2001). Of course, because all results from these surveys are based on self-report data,
concerns about variation in cultural values and social stigma have not been completely ruled out. These 
variations, in part, may account for some of the observed low prevalence values for certain Asian/Pacific Islander
populations in the United States.
Within this report, it occasionally has been necessary to classify Asian/Pacific Islanders within the residual
“Other” category for individuals who do not meet the criteria for Hispanic or non-Hispanic Whites or Blacks.
This aggregate “Other” category is needed when specific estimates for Asian/Pacific Islanders are not possible
(e.g., because sample size has been too small in all but the most recent surveys of illegal drug use). For many of
the heterogeneous subgroups collected together within the “Other” category, this practice of aggregation can
change with increasing availability of larger NHSDA sample sizes, with aggregation across years of the NHSDA
surveys (e.g., see Delva et al. 1998; Obot et al. 1999; Obot and Anthony 2000), and with completion of 
studies such as the NIMH-sponsored national survey of Latinos and Asian Americans mentioned above.
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African Americans
As is the case with Asian and Pacific Islander populations of the United States, our national statistics tend to
convey information about African Americans in a single grouped category, despite what we know of the con-
siderable heterogeneity within African-American communities of the United States. National statistics on illegal
drug use now generally fail to reflect this heterogeneity. It is only within smaller specialized and possibly non-
representative studies that we can gain a picture of variations that exist across citizens of African heritage who
have been U.S. residents for more than 200 years versus recent African-heritage immigrants from communities
as diverse as Butajira in Ethiopia, where khat use is common (Alem et al. 1999), or Sao Paulo in Brazil, where
the inhalant lanca is used by young people (Mesquita et al. 1998). There are some recent national surveys in
which the investigators have attempted to study heterogeneity in mental health and drug problems across
African-American subgroups defined in terms of Hispanic and Caribbean origins (e.g., J.S. Jackson, “National
Survey of African American Mental Health,” NIMH grant, 1999). Data from these surveys are not yet 
available for presentation in this year’s report.
Summarized in relation to an aggregate category for all members of the subgroup, non-Hispanic African
Americans comprise 12.2 percent of the total U.S. population (U.S. Bureau of the Census 2000). The non-
Hispanic African-American share of the total U.S. population is expected to increase to 13 percent by 2030 and
to remain stable at that level through the 21st century (U.S. Bureau of the Census 2000a).
The recent NHSDA 2000 prevalence estimates for recent illegal drug use are roughly equivalent for non-
Hispanic African Americans and Whites: slightly more than 6 percent of these population members qualify as
active and current illegal drug users in the month before survey assessment. By comparison, African-American
high-school seniors consistently have been found to have lower estimates than White high-school seniors for
prevalence of alcohol, tobacco, and other drug use. This finding also is true among African-American youth in
lower grades, where less dropping out has occurred.
Without contradiction of these findings, it can be said that illegal drug use and drug trafficking continue to be
major problems within African American communities of the U.S. (Johnston et al. 2001a-e; Ensminger,
Anthony and McCord 1997). Some studies have given an impression that African Americans who use alcohol
and other drugs experience higher rates of drug-related health problems than do users from other ethnic groups
(e.g., see Herd 1989). Other studies indicate that the estimated rate of transition from drug use to drug 
dependence is not generally greater for African Americans, even for those living within inner city neighborhoods
(e.g., see Anthony et al. 1994; Ensminger et al. 1997). There is some reason to believe that general impressions
about African Americans and drug problems are based on partial evidence, traced back to racial profiling and
other administrative practices that lead to overrepresentation of African Americans in criminal justice statistics
and in public drug treatment programs where admissions draw heavily on referrals from the courts (e.g., see
Blumstein and Beck 1999). Concern also has been expressed that African-American youth might be less willing
to participate in surveys and less likely to provide accurate information about their drug-using histories. 
For these reasons, it is important to note that the illegal drug-taking experiences of African Americans might be
disproportionately underrepresented in some of the data sources used in this report, including surveys such as
the MTF study. Lillie-Blanton et al. (1993) and others have expressed concern that findings from these data
sources may not accurately reflect the true nature and extent of the drug use problems in this population.
Wallace and Muroff (2002) have added important new information on the possibility of race-related conditions
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of risk and protection against illegal drug use, with a focus on the experience of African-American children 
and teenagers.
Hispanics
The report already has mentioned heterogeneity within the broad categories of American Indian/Alaska Natives,
Asian/Pacific Islanders, and African Americans. To be sure, the same heterogeneity characterizes the Hispanic
American segment of the U.S. population, as well as the non-Hispanic White population. For example, Sokol-
Katz and Ulbrich (1992) observed no relationship between family structure and alcohol or drug use among 
adolescents of Cuban heritage, but found that Mexican and Puerto Rican youth had more drug involvement
when they were living in female-headed households. Freeman and colleagues (1999) recently reported differ-
ences in drug-taking patterns, AIDS knowledge, and HIV risk behaviors among recently immigrated drug users
of Cuban, Mexican, or Puerto Rican heritage. Nielsen (2000) analyzed recent NHSDA 1993 data and found
that Mexican-American men and women were somewhat more likely to have drinking problems and to drink
more heavily than their counterparts in Cuban, Puerto Rican, and Central or South American Hispanic sub-
groups of the population. In the most recent NHSDA 2000 estimates, Puerto Ricans were more likely to be
current illegal drug users (10.1 percent) than their counterparts in the general population age 12 years and older
(Substance Abuse and Mental Health Services Administration 2001a). Interestingly, Cuban Americans were less
likely to be illegal drug users (3.7 percent), and intermediate values were observed for Americans of Mexican
heritage (5.5 percent) and Central or South American origin (4.1 percent). Therefore, attention to diversity
within the Hispanic population is an important but often neglected feature of our national statistical summaries
on the drug experiences of racial and ethnic minority groups in the United States. It can be especially useful to
analyze the Hispanic data by country of origin, level of acculturation, and immigrant versus U.S.-born status.
However, to date, little information of this type has been reported; virtually all tables in this report present 
statistics on the aggregate Hispanic population.
As noted in the introductory paragraphs of this section, demographic projections give us special reason to pay
attention to the Hispanic segments of the U.S. population in the 21st century. Hispanics have become one 
of the fastest growing segments of the U.S. population. In 1995, Hispanics comprised 10 percent of the total
U.S. population. By 2000, that value had grown to 12 percent and it is expected to double (to 24 percent) by
2050. Population projections indicate that by 2100 Hispanics will constitute one-third of the U.S. population
(U.S. Bureau of the Census 1996, 2000a). 
It also is important to note that Hispanics comprise one of the youngest segments of the U.S. population. The
median age of Hispanics is 26.6 years, compared with 35.9 years for the U.S. population overall (U.S. Bureau
of the Census 2000b). As is true for other minority populations of the United States, this demographic fact is
important for studies of illegal drug use because the estimated risk of becoming a drug user and the estimated
risk of becoming drug dependent are at peak values between the ages of 15 and 29 (e.g., see Wagner and
Anthony 2002).
Poverty rates for Hispanics tend to be higher than rates among non-Hispanic Whites. Some 20 to 30 percent
of Hispanic families fall below the poverty level, versus under 10 percent for non-Hispanic White families
(Mayers et al. 1993; U.S. Bureau of the Census 2000c). In addition, no more than about 50 percent of 
the Hispanic population has completed 4 years or more of high school, versus more than 75 percent of 
non-Hispanics having achieved this education level. Wide socioeconomic disparities also exist among Hispanic
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subgroups, such as Puerto Ricans, Mexican Americans, and Cuban Americans. These disparities must be con-
sidered when interpreting data on the health status of Hispanic population members of the United States, but
they are rarely taken into account in statistical summaries.
Studies of young people indicate a tendency toward higher prevalence of several forms of drug involvement
among Hispanic adolescents than among their counterparts in the non-Hispanic African-American and White
segments of the population. Stresses associated with what often are more constrained economic conditions,
combined with lower educational attainment, a generally higher degree of drug availability, and the possible
impact of racism on self-esteem are believed to make Hispanics particularly vulnerable to alcohol and other drug
use and associated problems (Delgado 1995). Recent data on active and current illegal drug use of 12th-graders
indicate Hispanic high-school seniors have the highest prevalence estimates for use for cocaine, crack, other
cocaine, and heroin (Johnston et al. 2001a-e; Monitoring the Future 2000).
OVERVIEW OF DRUG USE AND DRUG-RELATED PROBLEMS
As indicated by the above statistics, 20th-century epidemics of drug taking in the United States have not spared
its racial/ethnic minority populations; moreover, for some subgroups evidence exists of excess risk. Concern
about illegal drug use as well as tobacco and alcohol use among members of diverse racial/ethnic groups now
accompanies a general concern about health disparities that can be readily observed within the U.S. population
(Spiegler et al. 1989; U.S. Department of Health and Human Services 1998; U.S. Department of Health and
Human Services 2000).
There can be little question that illegal drug use is linked to these observed health disparities. Alcohol, tobacco,
and illegal drug use threatens users with many negative health-related consequences—not only cancers, cardio-
vascular diseases and stroke, but also fatal and nonfatal overdose, hepatitis, bacterial endocarditis, HIV infection
and AIDS, and other diseases associated with high-risk behavior and sexual transmission. Drug use has been
linked to increased risk of intentional and unintentional injuries, complications in pregnancy and delivery, and
psychiatric disturbances, ranging from acute panic attacks to chronic mood disturbances. In addition, illegal
drug use is associated with negative effects on employment, school achievement, socioeconomic status, and 
family stability, if only because illegal drug use, once detected, can lead to school suspension or expulsion, 
and to arrest, conviction, and incarceration for drug-related crimes (e.g., see Blumstein and Beck 1999). It is
difficult to assess all of the complex and sometimes reciprocal linkages between illegal drug use and these 
negative health and social experiences, but there is little doubt that illegal drug use contributes to an increased
probability of arrest, conviction, and incarceration for members of racial/ethnic minority populations in the
United States and to associated health and social disparities. As such, illegal drug use is linked either directly or
indirectly to these disparities.
The linkages that connect illegal drug use with observed health and social disparities affecting racial/ethnic
minority populations of the United States generate a need for more information about the drug involvement 
of these populations and other phenomena associated with these behaviors, such as criminal offending, poor
educational achievement, and other personal and social circumstances. This report presents a selection of 
available evidence that may promote a better understanding of illegal drug use across and within racial/ethnic
minority populations of the United States. An overview of the NIDA research mission, research priorities, and
action plans for health disparities is presented in Appendices 1 and 2.
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METHODS
This report presents a selection of current available evidence on illegal drug use and drug-related problems
among racial/ethnic groups residing in the United States. The information was obtained from published and
unpublished data from an array of governmental and nongovernmental agencies and organizations. In each case,
the sponsoring agency or organization collected data using its own methods and procedures. Therefore, data
vary with respect to source, collection method, definitions, and reference period. Although a detailed description
and comprehensive evaluation for each data source is beyond the scope of this report, summaries of data sources
used and a general overview of their designs appear below. More complete and detailed descriptions can be
obtained from the sponsoring agencies and organizations.
Total population estimates from most of the studies contributing to this report are generally precise, with relatively
small sampling errors. Nonetheless, in some instances, estimates for specific racial/ethnic subgroups may be
based on small numbers and are relatively imprecise with associated larger sampling errors. It has not always
been possible to gauge the magnitude of these errors or their impact on the evidence presented in this report.
Where possible, the tables include footnotes that describe each sample under study and data-collection method
to help the reader evaluate the data. The reader should note that columns of numbers might not add up to their
totals because of rounding.
The data presented in the report consist primarily of prevalence proportions and corresponding summary 
statistics from national data sources. Some of the tables contain data tabulated specifically for this report, includ-
ing data from NHSDA, MTF, the Youth Risk Behavior Survey (YRBS), the National Longitudinal Survey of
Youth (NLSY), the Arrestee Drug Abuse Monitoring (ADAM) program, and DAWN. Other tables present
information previously published. Standard error estimates are not presented in the tables; however, they have
been calculated for a majority of the national data sets. For those tables produced for this report, estimates with
large relative standard errors and very low precision generally have been omitted to reduce the possibility that
errors of interpretation will occur. The discussions accompanying the tables highlight only data findings and 
are not exhaustive. There is limited speculative discussion on the potential substantial and methodological 
explanations for the findings, and interpretation of programmatic or policy implications is left to the reader.
DATA SOURCES
Brief descriptions of each data source used in this report are provided below. For more detailed information on
the data sources, readers may contact the sponsoring organizations. A general comment that applies to virtually
all of these data sources involves the experience of Americans who represent linguistic minorities and whose 
preferred language is not English. In some instances, the administrators of these data sources have devised both
English and Spanish versions of their data-collection procedures and assessment instruments, but for the most
part these procedures are conducted in English. Some observers have noted that the validity of these data may
be questionable when the survey respondent or other data source speaks English not at all or only as a second,
infrequently used language.
Census of the United States
The U.S. Census Bureau has conducted censuses of the population in the United States every 10 years since
1790, with assessment of mental health and alcoholism issues starting during the interval from 1830 to 1880
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(Anthony and Van Etten 1998). In both the 1990 and 2000 census, data were collected on sex, race, age, and
marital status from 100 percent of the enumerated population of the country. More detailed information on
topics such as income, education, housing, occupation, and industry were collected from a representative 
sample of the total population. For example, in 1990, across most of the country, one out of six households
received a more detailed census form. In places estimated to have a population of under 2,500 residents, 
50 percent of households received the more detailed questionnaire.
For more information on the 1990 and 2000 censuses, see U.S. Bureau of the Census, 1990 Census of the
Population, General Population Characteristics, Series 1990, CP-1, and the corresponding reports on the 2000
census, or write U.S. Bureau of the Census, Population Division, Washington, DC 20233.
National Household Survey on Drug Abuse
NHSDA collects data on the use of tobacco cigarettes, smokeless tobacco, and alcoholic beverages, as well as on
marijuana, heroin, and other illegal drug use, based on survey responses from a representative sample of U.S.
residents age 12 and older, with exclusion of certain nonhousehold segments of the population (e.g., homeless
individuals). NHSDA began in 1971 under the auspices of the National Commission on Marijuana and Drug
Abuse. NIDA sponsored the survey from 1974 to September 1992. Since October 1992, the survey has been
sponsored by SAMHSA and is the responsibility of OAS, which is within SAMHSA.
Since 1991, NHSDA has covered the U.S. civilian noninstitutionalized population age 12 and older. This
includes civilians living on military bases and persons living in noninstitutionalized group quarters, such as 
college dormitories, rooming houses, and shelters. Hawaii and Alaska were included for the first time in 1991.
In 1994 and in several subsequent years, the survey methodology was changed and refined in a manner that
may have induced changes in the time series of evidence, with an intention of improving the quality of the 
evidence. With respect to some of the changes, it has been possible to construct the survey with both the old
and the new methods and generate two sets of estimates for comparison. For this reason, there sometimes are
two sets of estimates based on the 1994 data. The first set, called the 1994-A estimates, was based on the same
questionnaire and editing method as had been used in 1993. The second set, called the 1994-B estimates, was
based on a new questionnaire and editing methods. For the most part, the OAS staff has been attentive to these
changes and refinements and developed adjustment procedures to compensate for artifactual variation associated
with change in methods. A description of the adjustment method associated with the 1994 methodological
refinements can be found in NHSDA Advance Report Number 18, Appendix A, available from SAMHSA
(Substance Abuse and Mental Health Administration 1996).
In general, NHSDA over the years has employed a multistage probability sample design, with participation of
90 to 95 percent of households designated for that stage of sampling, and with participation of 70 to 80 percent
of respondents designated for sampling within households. Over the past 15 years, the NHSDA sample size has
grown from under 10,000 respondents per year before 1990 to more than 70,000 respondents per year since
2000. For example, almost 170,000 household addresses were screened in 2002 for eligibility and then sampled;
the reported response rate for screened households is 92.8 percent. A total of 71,764 designated respondents
were  sampled and were interviewed within screened households, yielding a 73.9-percent individual level
response rate.
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For many years, young people (e.g., ages 12–17 years), African Americans, and Hispanics have been oversampled
to improve the precision of NHSDA estimates for these population subgroups. In recent years, the sampling
plan was redesigned to yield survey-based estimates for a selection of States and the District of Columbia, with
synthetic estimates for other states. Features of oversampling, multistage sampling, clustering within sampled
segments, multiple respondents within households, and survey nonresponse are taken into account via appropriate
estimation procedures for proportions, means, and their variances.
For most of its history, NHSDA has relied on a self-report answer sheet methodology to elicit information from
individual respondents. In brief, according to the standard NHSDA protocol, an interviewer on the survey field
staff followed standardized procedures to sample and recruit each designated respondent in accord with directions
approved by an Institutional Review Board for protection of human subjects. The interviewer then secured a
private location within or close by the household and completed the interview either as a face-to-face interview
or as a questionnaire assessment. In many instances, the face-to-face interview involved the interviewers reading
the standardized interview questions and the respondent marking the answers on an individualized precoded
answer sheet before filing the completed answer sheet in a sealed envelope. This procedure provided an addi-
tional level of protection because the interviewer read the questions but did not know the respondent’s answers.
In other instances, a questionnaire approach was used, with the interviewer not even reading the questions and
having no “interviewing” role per se; the respondent read the questions privately and then marked the answer
sheet and sealed the sheet in the envelope. Sometimes, due to illiteracy or vision problems, the interviewer 
conducted the interview in a standard face-to-face manner, not only reading the questions aloud and listening
for an answer, but also marking the answer on behalf of the respondent. 
Methodological experiments in the mid-1990s suggested that increased completeness and accuracy of reporting
might be gained by changing the method to that of an audio computer-assisted personal interview (ACASI).
Starting in 1999, virtually all NHSDA interviews have been completed with the ACASI method, by which the
field staff member first samples, recruits, and secures informed consent from each designated respondent.
Thereafter, the task has been to set up the laptop computer for a private ACASI assessment session, during
which the interviewer is nearby but unable to hear or see the question-answer sequence of the ACASI interview.
Of course, the respondent still has options and may request the traditional face-to-face interview (e.g., when
there are vision problems or computer illiteracy). Nevertheless, in most instances, the interviewer’s role during
the interview assessment has been suppressed and the respondent interacts solely with the computer during the
assessment interval. 
For more information on NHSDA, see any of their recent reports, which include abbreviated descriptions of
the methods, or refer to the more detailed appendix materials and methodological reports. Many of these 
materials are available on the SAMHSA Web site at www.samhsa.gov/oas. Alternately, readers may request 
hardcopy reports by writing to the Office of Applied Studies, Substance Abuse and Mental Health Services
Administration, Room 16-105, 5600 Fishers Lane, Rockville, MD 20857.
Partnership Attitude Tracking Survey
PATS originally was designed to measure the extent to which the Partnership for a Drug-Free America’s media
campaign might be successful in changing attitudes toward illegal drug use. Its current purpose is to monitor,
on an ongoing basis, the behavior and attitudes of young people and adults toward drugs. PATS is one of the
Nation’s largest surveys on attitudes toward illegal drugs and the only national level research tool for measuring
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the attitudes of students in grades 4–6. In the 1996 PATS studies, 12,292 interviews were conducted. Since
then, each year the PATS sample has included 2,000 to 3,000 children in grades 4–6; 6,000 to 8,000 teenagers
in grades 7–12; and 700 to 900 adults. 
PATS consists of a series of studies conducted from 1988 to the present. In the earliest installments, interview
methods were used to secure information from respondents sampled from schools or homes. In more recent
years, all of the assessments have been via self-administered anonymous questionnaires, completed with due
attention to confidentiality requirements.
When PATS samples students in schools, it does so in three parts: a national sample of approximately 100
schools, a supplemental sample of about 25 schools in heavily African-American areas, and a supplemental sam-
ple of about 25 schools in heavily Hispanic areas. The PATS in-home surveys of adults focus on a randomly
selected parent living within a sampled household, with a child or children under age 19.
For more information on PATS and its methods, visit its Web site at www.drugfreeamerica.org, email to 
webmail@drugfree.org, or write to Partnership for a Drug Free America, Suite 1601, 405 Lexington Avenue,
New York, NY 10174.
Monitoring the Future Study
This large-scale epidemiological survey of illegal student drug use was initiated in 1975 and has been conducted
annually through a NIDA grant awarded to the University of Michigan’s Institute for Social Research. The MTF
survey is based on a nationally representative probability sample of public- and private-school students in the
contiguous United States. The survey originally included only high-school seniors, but 8th- and 10th-grade
samples were added in the 1990–1991 school year to survey students who might drop out before graduating.
The measures and procedures employed have been standardized and applied consistently to the data collection
since 1975. The survey design also includes a longitudinal study of a subsample of each graduating class. This
element of the research design allows monitoring of the maturational factors associated with drug abuse. The
followup data for high-school graduates is divided into two groups: those who went to college and those who
did not go to college after graduating from high school. The adult portion of the annual report provides many
tables that allow comparisons to be made between these two groups.
This survey is ongoing. The latest data available when this report was prepared are from the 1999–2000 school
year surveys. Each year, for the national survey of 8th-graders, 150 to 160 schools are sampled, and 17,000 to
19,000 students are surveyed. For the 10th-graders, 120 to 160 high schools are sampled, and approximately
13,000 to 16,000 students are surveyed. For the 12th-graders, 130 to 140 schools are sampled and 12,000 to
15,000 students are surveyed. The data in routine MTF reports are not available on a State or sub-State level,
and the confidentiality of individual schools and students is protected. A report on the data is released 6 to 8
months after the end of a school year and initially is disseminated by NIDA press release, with subsequent
release in annual report format. The annual report includes long-term trend data. In general, MTF data on 
the 8th-, 10th-, and 12th-graders are published in one volume with an overview report and a comprehensive
main report; data on the young adults and college students are published in a second volume. Methodological
reports and book-length monographs augment the annual statistical report from the NIDA-supported MTF
research group.
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For more information on the MTF study, see National Survey Results on Drug Use from the Monitoring the Future
Study, 1975–2001, as well as annual reports, press releases, and occasional books, which can be located via 
www.monitoringthefuture.org or by writing to NIDA, Division of Epidemiology, Services and Prevention
Research, 6001 Executive Boulevard, Suite 525, MSC 9589, Bethesda, MD 20892.
National Longitudinal Survey of Youth
NLSY is an ongoing longitudinal study sponsored by the Bureau of Labor Statistics. Annual interviews have
been conducted with a national sample of approximately 12,000 men and women who were 14–21 years of age
in January 1979. Yearly interviews have been conducted with more than 90 percent of the original respondents
since 1979. The 1988, 1992, 1994, and 1998 surveys include information about drug use obtained in the 1984
interview along with complete pregnancy records for women, including information about prenatal care, 
alcohol and tobacco use during pregnancy, and the length and weight of each child at birth. An additional 5,500
children of the female participants have been evaluated for cognitive, socioemotional, and physiologic aspects
of their development. NIDA and the Bureau of Labor Statistics developed an interagency agreement to add sets
of questions about illegal drug use for the 1988, 1992, 1994, and 1998 rounds of NLSY. These questions assess
characteristics such as the recency and frequency of marijuana and cocaine use. Also included are questions
about the use of marijuana and cocaine during pregnancy for those who gave birth since 1987.
For more information on NLSY, visit www.bls.gov/nls or write to the Center for Human Resource Research,
Ohio State University, 921 Chatham Lane, Suite 200, Columbus, OH 43221. 
Dropout Statistics
The Department of Education’s National Center for Education Statistics (NCES) collects and reports annually
on statistics and other data related to education in the United States and other countries, including school
dropout rates. In most years, NCES dropout data have included event rates and status rates. The event rate
measures the proportion of students who drop out of school in a single year without completing high school.
The status rate measures the proportion of the population that has not completed high school and is not
enrolled at one point in time regardless of when they dropped out.
For more information on dropout statistics, see Dropout Rates in the United States 1995, National Center for
Educational Statistics 97-473, visit www.necs.ed.gov, or write to the National Center for Educational Statistics,
U.S. Department of Education, Office of Educational Research and Improvement, 555 New Jersey Avenue,
NW, Washington, DC 20208.
American Indian/Alaska Native Statistics
There is no single comprehensive Federal effort to collect data on drug use within the American Indian/Alaska
Native populations of the United States. Consequently, data on American Indian/Alaska Native populations
were obtained for this report from publications by Beauvais and colleagues (1985a-b, 1989; see also Beauvais
2001) and from recent data issued by the MTF study and NHSDA. Beauvais’ research team has collected data
on drug use rates among American Indian youth since 1975. In addition to monitoring levels of use, they have
conducted studies examining the etiology of drug and alcohol use in this population (e.g., see Beauvais et al.
1989). The data for this project are gathered through anonymous self-report surveys administered in school
classes. The survey includes questions about lifetime history of using 11 drugs. Currently active use, depth of
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involvement, and patterns of use are assessed for the more frequently used drugs. Other topic areas involve 
correlates of drug use, including variables such as demographics, attitudes toward drugs, peer and family 
influence, general deviance, cultural identification, school adjustment, personal adjustment, and attitudes
toward the future. 
Due to the difficulty involved in obtaining permission to conduct the survey on individual reservations,
researchers are not able to guarantee that the sample is nationally representative of the total American
Indian/Alaska Native population. To compensate for this problem, 2 years of data often are combined to 
borrow information across the survey years and to increase the representativeness and precision of the sample.
The project team is confident that this procedure of borrowing information across survey years promotes 
consistency of the drug use rates across tribes and over time.
For more information on Native American data, visit www.colostate.edu/depts/TEC or write to the Tri-Ethnic
Center for Prevention Research, C-78 Clark Building, Psychology Department, Colorado State University, Fort
Collins, CO 80523.
Youth Risk Behavior Survey
YRBS is a component of the Youth Risk Behavior Surveillance System (YRBSS), maintained by CDC. YRBSS
comprises three complementary components: (1) national school-based surveys, (2) State and local school-based
surveys, and (3) a national household-based survey. Each of these components has provided useful information
about various subpopulations of adolescents in the United States.
The school-based survey first was conducted in 1990, and the household-based survey was initiated in 1992.
The school-based survey is conducted biennially in odd-numbered years among national probability samples of
students in grades 9–12 from public and private schools. Schools with a large proportion of Black and Hispanic
students are oversampled to provide stable estimates for these subgroups. For this report, the most recently 
available data are from the 1999 YRBS.
For more information on YRBSS, write to Centers for Disease Control and Prevention, 4770 Buford Highway,
NE, Atlanta, GA, or visit www.cdc.gov/nccdphp/dash/yrbs and the CDC Web site.
Drug Abuse Warning Network
Starting with a pilot study and then expanding to more participating sites, DAWN was originated as a surveil-
lance system by DEA, which operated the network from 1973 through 1979. Thereafter, NIDA assumed
responsibility for DAWN operations from 1980 through 1991. Since 1992, SAMHSA has operated DAWN,
which now functions as a surveillance system for drug-related events in hospital emergency room (ER) and 
medical examiner facilities. DAWN collects information on the occurrence of drug-related casualties that have
resulted in a medical crisis or death. Since its inception, DAWN’s major objectives have included monitoring
illegal drug use patterns and trends (especially newly emerging patterns), identifying specific drugs associated
with adverse drug-related events, and assessing drug-related consequences and other health hazards of 
illegal drug use.
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Hospital ERs eligible for DAWN participation are in non-Federal, short-stay general hospitals and must be open
24 hours a day. Since 1988, the DAWN ER data have been collected from a representative sample of these 
hospitals, including 21 oversampled metropolitan area hospitals. Data from this sample are used to generate
national estimates of the total number of ER drug use episodes and drug mentions in all such hospitals.
Within each participating facility, a designated DAWN reporter is responsible for identifying drug abuse
episodes by reviewing official records, transcribing, and submitting data on each case. Data collected by DAWN
include the drug(s) involved in the ER episode; sex, age, and race/ethnicity of patients; reasons for the ER visit;
single or multiple drug use; and the route of administration.
For more information on DAWN, see Drug Abuse Warning Network Annual Medical Examiner Data: 1999
or write to the Office of Applied Studies, Substance Abuse and Mental Health Services Administration, 
Room 16C-06, 5600 Fishers Lane, Rockville, MD 20857. Information is also available at
www.samhsa.gov/oas/dawn.htm.
AIDS Surveillance Data
CDC maintains AIDS surveillance data by using information collected by health departments in each state, 
territory, and the District of Columbia. Although surveillance activities range from passive to active, most areas
employ multifaceted active surveillance programs, which include the following four major reporting sources 
of AIDS information: (1) hospitals and hospital-based physicians, (2) physicians in nonhospital practice, 
(3) public and private clinics, (4) and medical record systems (e.g., death certificates, tumor registries, hospital
discharge abstracts, and communicable disease reports). Using a standard confidential case report form, the
health departments collect information without personal identifiers; this information then is coded and 
computerized either at CDC or at health departments, which transmit the information electronically to CDC.
AIDS surveillance data are used to detect epidemiologic trends to identify unusual cases requiring followup and
for quarterly publication in CDC’s HIV/AIDS Surveillance Report. Studies to determine the completeness of
reporting of AIDS cases that meet the national surveillance definition suggest reporting at greater than or equal
to 90 percent. The number of deaths among AIDS cases reported to CDC’s AIDS Surveillance System differs
from the number of HIV infection deaths based on the National Vital Statistics System. The major reasons for
these differences are (1) not all persons diagnosed with AIDS are reported to the AIDS Surveillance System, 
(2) not all deaths of persons with AIDS are due to AIDS, and (3) not all deaths due to HIV infection are
reported as such on the death certificate.
For more information on AIDS surveillance, write to CDC National AIDS Clearinghouse, P.O. Box 6003,
Rockville, MD 20849-6003 or to Chief, Surveillance Branch, Division of HIV/AIDS, National Center for HIV,
AIDS, STD, and TB, Centers for Disease Control and Prevention, Atlanta, GA 30333. Information is also
available at www.cdc.gov/hiv/dhap.htm.
Arrestee Drug Abuse Monitoring Program
As a refinement of a surveillance system formerly known as the Drug Use Forecasting program, ADAM measures
recent drug use among booked arrestees at multiple sites in major metropolitan areas across the United States.
Originally, there were 20 to 25 ADAM sites within the United States; today, 35 cities are represented in the
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ADAM domestic surveillance network and there are participating international sites as well. Pending availability
of funds through NIJ, plans are in place to expand ADAM to more than 70 sites.
ADAM’s primary purpose has been to monitor illegal drug use among booked arrestees in major U.S. cities. It
provides information about the effectiveness of local drug policies and practices and offers a solid basis for
resource allocation decisions. By collecting urine samples and interviewing arrestees on a quarterly basis, ADAM
has become a consistent tool for tracking drug use trends among this difficult-to-study population of users.
Arrestee participation is voluntary and anonymous. The ADAM sampling strategy is site specific, and partici-
pants are not necessarily statistically representative of all arrestees. All female arrestees are eligible to be included
in the ADAM sample. However, the large numbers of male arrestees require that a selection be made. Males
arrested for vagrancy, loitering, and traffic violations may be excluded and generally have been. Other arrestees
are chosen by type of charge using the following priority: (1) nondrug felony charges, (2) nondrug misdemeanor
charges, (3) drug felony charges, and (4) warrants for any charge. To prevent oversampling arrestees with a high
propensity for drug use, only 20 percent of males arrested and charged with drug offenses are interviewed. In
consequence, it is likely that ADAM data underestimate the proportion of arrestees who have used drugs less
recently, because urinalysis reveals the presence of most drugs only within 48 to 72 hours of their use.
On average, 80 to 90 percent of designated arrestees have agreed to participate in the ADAM assessments, with
80 percent providing a urine sample. The total sample of booked arrestees in the ADAM program from 1987
through 1999 included 337,450 adults, of which 247,655 were males and 89,795 were females. In some sites,
there is a supplementary ADAM program for juvenile arrestees.
The ADAM sample should not be regarded as a random sample of booked arrestees; it was determined early in
the ADAM program’s development that selecting random samples would not be feasible in the environment in
which the program would have to operate. In most sites, 225 males are now interviewed each quarter. For female
arrestees, the goal is to interview at least 100.
For more information on the ADAM program, write to the U.S. Department of Justice, National Institute of
Justice, 633 Indiana Avenue, N.W., Washington, DC 20531. Information also is available at www.adam-nij.net.
ORGANIZATION OF THIS REPORT
The remaining chapters of this report present detailed data on drug use among U.S. racial/ethnic groups, based
on the above data sources and ancillary studies. Chapter 2 presents basic population statistics from the Census
Bureau and projections for racial/ethnic minorities in the United States. This information is useful for deter-
mining the relative size of the major racial/ethnic populations within the United States and for comparing
demographic factors such as family income.
Chapter 3 provides an overview of drug use patterns for the total U.S. population and for the four racial pop-
ulation groups and two ethnic categories defined in the first sections of this chapter. Data for Chapter 3 were
obtained from NHSDA, which has become the most comprehensive source of population-level illegal drug use
prevalence data available in the United States. Chapter 3 also includes estimates for (1) prevalence proportions
based on recently active illegal drug use in the United States (i.e., illegal drug use in the month before the 
survey assessment) and (2) the cumulative occurrence of illegal drug use. Estimates of cumulative occurrence are
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derived by estimating the cumulative number of illegal drug users who report either a recent or a past history
of illegal drug use, where cumulative number is the total number of individuals whose lifetime history includes
at least one occasion of illegal drug use.
One useful way to think about cumulative occurrence of illegal drug use starts by conceptualizing the prevalence
proportion for recently active or current illegal drug use (i.e., use in the month before the survey assessment).
This prevalence proportion often is called “1-month prevalence” or “past-month prevalence” of illegal drug use
because it is an index of the fraction of the population who have used illegal drugs at least one time in the month
before assessment. We then can extend the time frame to encompass the year before the survey assessment,
deriving a “1-year prevalence” or “past-year prevalence” of illegal drug use. Notice that these time intervals are
fixed at 1 month and 1 year. For “1-month prevalence” the interval stretches back 1 month before the date of
assessment. For “1-year prevalence” the interval stretches back to 1 year before the date of assessment.
Extending this concept, we can think about a time interval that stretches back to the birth of the respondent,
but here we no longer have a fixed span of time (i.e., 1 month, or 1 year). Instead, we have the number of 
years that have spanned the gap from an individual’s birth to the time of assessment. This is the nature of the
“cumulative occurrence” estimate. It covers the time span from the individual’s birth to the date of the survey
assessment. Individuals who report having used drugs illegally are counted in the numerator of a ratio for the
cumulative occurrence of illegal drug use; all individuals are counted in the denominator of the ratio. Because
the span for assessment covers the complete interval from birth to the time of assessment, the “cumulative 
occurrence” estimate sometimes is called the “lifetime prevalence” estimate.
One of the complications of all of these estimates is that they do not reflect the experience of illegal drug users
who have died as a result of their illegal drug use, in association with their illegal drug use, or unconnected to
their illegal drug use. All of these estimates from cross-sectional survey data are based on individuals who have
survived to the date of assessment. These estimates must be interpreted with this limitation in mind, no matter
how they are constructed and what they are called.
In some instances, corresponding estimates are presented for tobacco and alcoholic beverages for comparative
purposes. When appropriate, estimates are presented for a prevalence proportion that is based on the number
of individuals who have engaged in illegal drug use during the year before assessment (sometimes called 
“past-year prevalence”). Proportions of this type may be interpreted as a fraction (or percentage) of the total
study population under study, or as a fraction (or percentage) of a specific population subgroup of interest 
(e.g., African Americans age 12 and older). Throughout this report, the concept of illegal drug use encompasses
the use of Schedule I drugs such as marijuana and heroin, regarded by the Federal Government as having no
acceptable medical use in the United States, plus Schedule II drugs such as cocaine, regarded as having accept-
able medical uses but with essentially similar levels of risk to public health or safety, as well as other controlled
drugs such as barbiturates and the amphetamines. The latter have been thought to pose somewhat lower levels
of risk to public health or safety as compared to heroin or cocaine. 
Illegal drug use also encompasses extramedical use of prescribed drugs, such as methylphenidate (Ritalin
®),
when consumed for recreational purposes or for nonmedical or extramedical reasons that go beyond the bound-
aries of medically prescribed use (e.g., for suicide attempts), as well as the use of inhalant drugs such as glue or
ether when the intent is to get high or for other related extramedical purposes. Anthony and colleagues (1994) 
provide a detailed description of the concept of “extramedical drug use” as a complement to the concept of 
21Introduction
“illegal drug use,” with attention to the recreational use of inhalants and other chemicals that do not necessarily
represent illegal uses of the chemicals but that may pose risks for public health and safety. The notion of
“extramedical” drug use is needed because sometimes a patient has taken a medicine that a doctor has prescribed
and become dependent by taking more than the doctor had intended (e.g., to secure effective pain relief).
Strictly speaking, this patient behavior fails to qualify as “nonmedical drug use” because the patient is adminis-
tering the drug for reasons that the doctor intended. However, it is “extramedical” use in the sense that the
patient has exceeded the prescribed dosage regimen in an misguided attempt to secure effective pain relief when
the prescribed dosage level is not working as it should (Anthony et al. 1994). The term “nonmedical” might
imply that this patient sought an effect such as “getting high,” which would be beyond the boundaries of the
prescribed indication, whereas the term “extramedical” simply implies that the patient might be administering
the medicine to secure a medically legitimate result or indication (i.e., effective pain relief), even if the patient
ends up taking more than the doctor prescribed to achieve this result. That is, the notion of “nonmedical drug
use” groups patients who are seeking the pain relief intended by a doctor with those who use the prescribed
medicines to get high. The notion of “extramedical use” provides an additional element of elaboration and
encompasses the patient who might be taking more than was prescribed—not to get high, but to achieve the
physician’s desired result of effective pain relief.
Chapter 4 of this report examines illegal drug use, attitudes about drugs, and drug-related behaviors among
minority youth; it also includes data on the overall prevalence of drug use among youth. These data originate
from several sources including the Census Bureau, MTF study, NLSY, NHSDA, and PATS.
Chapter 5 presents data on risk behaviors such as dropping out of school, driving under the influence of alcohol
or drugs, and engaging in high-risk sexual behaviors. Data sources for this chapter were the Department of
Education, NHSDA, and YRBS.
Chapter 6 examines the adverse health consequences of drug use. Data sources for this chapter were DAWN
and CDC’s AIDS Surveillance System. This chapter presents prevalence estimates on drug-related medical
emergencies, drug-related deaths, and information on the medical consequences of drug use.
Chapter 7 addresses drug use and crime. Data on the drug use history of booked arrestees and the percent of
arrestees who committed their offense under the influence of drugs are presented in this chapter. Data were
obtained from the ADAM program.
Chapter 8 summarizes this report and presents future programmatic and research needs pertinent to illegal drug
use and associated problems. A discussion of limitations to the understanding of illegal drug use of minority
populations is offered, along with a summary of issues that merit consideration when conducting research and
interpreting results on illegal and extramedical drug use of racial/ethnic minority populations.
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This chapter presents census data on the general population residing in the United States and projections for
the population growth rate of racial/ethnic minorities.  Also presented in this chapter are data on the percentage
of the population living below the poverty threshold.  The distribution of racial/ethnic groups in the United
States is changing. As noted in Chapter 1, rigorously derived population projections show that major demo-
graphic changes will continue through the 21st century  (U.S. Bureau of the Census 2000a).  The non-Hispanic
White share of the population is projected to decline steadily, as Asian/Pacific Islander and Hispanic populations
increase in number and proportional representation; the non-Hispanic African-American share will remain 
relatively stable over this period.  Coincident with general growth in the size of the U.S. population, it is estimated
that the African-American population will roughly double—from about 30 million in 2000 to 60 to 70 million
in 2080. By comparison, the Hispanic population will more than triple—growing from about 30 million in
2000 to almost 100 million in 2050; the Asian/Pacific Islander population will also more than triple—increasing
from about 10 to 11 million in 2000 to more than 30 million in 2050 (U.S. Bureau of the Census 2000a).
Racial and ethnic minority groups in the United States do not share identical circumstances of daily life and 
residential location. Residential location is of special importance in studies of the nature and extent of illegal
drug use because sometimes considerable urban-rural differences exist in the distribution and dynamics of drug
involvement within the United States, as well as variations in drugs of choice (e.g., see James et al 2002;
Johnston et al. 1993). Some drugs, such as sustained-release oxycodone (OxyContin
®) have become major
problems in rural areas, whereas most metropolitan areas have been less affected by this drug (National Institute
on Drug Abuse 2001a). In addition, within U.S. cities, there sometimes are extreme versions of social and 
cultural conditions and processes conducive to drug trafficking, availability of drugs, and drug taking, such as
limited opportunities for lucrative employment in otherwise impoverished neighborhoods (e.g., see Levitt and
Venkatesh 2000), neighborhood disadvantage, disorganization, and constraints on collective efficacy and social
capital (Newcomb 1995; Sampson et al. 1997).
Of course, drug distribution and drug use have not been limited to urban areas; rural areas have been affected
as well. For example, prevalence of tobacco smoking is greatest in rural America (Substance Abuse and Mental
Health Services Administration 1999b, 2000c-d, 2001b). Marijuana cultivation became commonplace in rural
America, starting before 1950 with legal wartime cultivation of hemp for rope. Marijuana’s position as an illegal
rural cash crop increased in the last quarter of the 20th century, and it now is grown and distributed widely in
rural areas throughout most of the continental United States and Hawaii (Joy et al. 1999). In theory, cocaine
also can be grown in some of the more mountainous parts of the United States. However, climate, altitude, and
other circumstances have constrained domestic cultivation of cocaine (Montagne 1991). Hence, cocaine supply,
distribution, and use have become more prominent among the social problems facing urban rather than rural
residents of the United States.
Census Bureau data indicate that minorities were overrepresented in central cities and metropolitan areas. For
example, about one-half of the U.S. population lives in large standard metropolitan statistical areas with a 
population of 1 million people or more. Non-Hispanic Whites now account for about 70 percent of the total
U.S. population (71.4 percent), but only one-fifth (21.7 percent) of Whites live in central cities. In contrast,
African Americans account for about 12 percent of the total U.S. population, more than one-half (55 percent)
of whom live in central cities (McKinnon and Humes 2000).
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POPULATION STATISTICS
Based on estimates from the Census Bureau (1990), Table 1 presents percentage distributions for the resident
population of the United States by race/ethnicity for 1990 and projections for selected years from 2000 to 2100.
These data indicate that the Asian/Pacific Islander segment of the U.S. population will experience the greatest
proportional change between 2000 and 2100, followed by persons of Hispanic origin.  If these projections hold,
non-Hispanic Whites will no longer be a majority population within the United States sometime between 2050
and 2060.
Table 2 displays 1993, 1995, 1997, 1999, and 2000 weighted average poverty thresholds estimated from the
1980 and 1990 censuses, by size of family unit.  Families or individuals with incomes below their appropriate
thresholds are classified as below the poverty level.  These thresholds are updated annually to reflect changes in
the Consumer Price Index for all suburban consumers.  The table shows that in 2000, the average poverty
threshold for a family of four was $17,601, an increase of about 19 percent from 1993 (U.S. Bureau of the
Census 2001b, 2000c).
Table 3 presents the 2000 income thresholds below which people are classified as living in poverty, by family
size and number of related children under age 18.  In 2000, the poverty threshold for a single person under age
65 was $8,958 per year, and the poverty threshold for a family of four with two children under age 18 was
$17,463 per year.
Table 4 presents the percentage and number of people in the United States living below poverty level by
racial/ethnic group, as shown in Census Bureau data from 1990 through 2000.  The proportion of individuals
classified below the poverty level decreased over this period, from 13.5 percent in 1990 to 11.3 percent in 2000,
reflecting a period of economic expansion that ended in 2000–2001. A comparison of poverty level by race/
ethnicity indicates that less than 25 percent of African Americans were living in poverty in 2000, compared with
relatively stable values of 30 percent to 33 percent between 1973 and 1993. The proportion of Hispanic people
living in poverty was relatively stable between 1980 and 1998, with values between 25 percent and 31 percent,
but declined to 21.2 percent in 2000. Whites have the lowest proportion of people living in poverty. This 
proportion increased from 8.4 percent in 1973 to 12.2 percent in 1993, but declined to 9.4 percent by 2000
(U.S. Bureau of the Census 2000c).
Table 4 also presents the proportions of female-headed families with children under age 18 who are living in
poverty.  In 2000, just under one-half of African-American and Hispanic households with children under age
18 and no husband present lived below the poverty level (the figure for both groups is 41.1 percent).
Furthermore, African-American and Hispanic children under age 18 were two to three times more likely than
White children to live below the poverty level in 2000 (30.7 percent and 27.3 percent, respectively, compared
with 12.4 percent for Whites).
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SUMMARY
Census Bureau data draw attention to important demographic, social, and economic features of our Nation’s
population. Racial/ethnic minorities tend to be overrepresented within the central cities of the United States,
where certain drugs (such as cocaine) pose more challenges for public health and safety. Demographic projec-
tions indicate that the distribution of racial/ethnic minorities in the U.S. population is changing significantly.
Recent and projected growth of the Asian/Pacific Islander and the non-Hispanic White segments of the U.S.
population deserve special note.
On average, racial/ethnic minorities tend to be at greater economic disadvantage than are non-Hispanic Whites.
About 10 percent of Whites were living in poverty in 2000, whereas the corresponding value is about 25 per-
cent for both non-Hispanic African-American and Hispanic people.  In addition, almost one-half of non-
Hispanic African-American and Hispanic households with children under age 18 and no husband present lived
below the poverty level; non-Hispanic African-American and Hispanic children under age 18 were some two to
three times more likely than non-Hispanic White children to live below the poverty level.
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Table 1. Estimated Percentage Distribution of U.S. Population, 
by Race/Ethnicity and Hispanic Origin: 1990–2100
a
Non-Hispanic
Year Total Population  African- Asian American/  American 
(thousands) American Pacific  Islander Indian
b White Hispanic
1990 249,402 11.8 2.8 0.7 75.6 9.0
2000 275,306 12.2 3.9 0.7 71.4 11.8
2005 287,715 12.3 4.3 0.8 69.3 13.3
2010 299,861 12.5 4.8 0.8 67.3 14.6
2015 312,268 12.7 5.3 0.8 65.5 15.8
2020 324,926 12.8 5.7 0.8 63.8 17.0
2030 351,070 13.0 6.7 0.8 60.1 19.4
2040 377,349 13.1 7.8 0.8 56.3 21.9
2050 403,686 13.2 8.9 0.8 52.8 24.3
2060 432,010 13.3 9.8 0.8 49.6 26.6
2070 463,639 13.2 10.6 0.8 46.8 28.6
2080 497,829 13.1 11.3 0.8 44.4 30.4
2090 533,605 13.1 12.0 0.8 42.2 32.0
2100 570,954 13.0 12.6 0.7 40.3 33.3
aAll population figures for 2000 and after are based on the 1990 census.
bIncludes Eskimos and Aleuts.
SOURCE: Population Projections Program, Population Division, U.S. Bureau of the Census, 2002a.
Table 2. Weighted Average Poverty Thresholds, by Size of Family: Selected Years
Weighted Average Poverty Thresholds (in dollars)
Family Size 1993 1995 1997 1999 2000
One person 7,363 7,763 8,178 8,500 8,787
Under 65 years 7,518 7,710 8,350 8,667 8,958
65 years and over 6,930 7,108 7,698 7,991 8,259
Two persons 9,414 9,661 10,468 10,869 11,234
Householder under 65 years 9,728 9,976 10,806 11,214 11,591
Householder 65 years and over 8,740 8,976 9,709 10,080 10,414
Three persons 11,522 11,821 12,803 13,290 13,737
Four persons 14,763 15,141 16,404 17,028 17,601
Five persons 17,449 17,900 19,387 20,115 20,804
Six persons 19,718 20,235 21,880 22,719 23,491
Seven persons 22,383 22,923 24,825 25,815 26,783
Eight persons 24,836 25,427 27,713 28,788 29,941
Nine persons or more 29,529 30,300 32,705 34,075 35,574
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Table 4. Person and Families Living Below Poverty Level, According to Selected
Characteristics, Race, and Hispanic Origin: 1990–2000
NOTES: The Black and White race groups include persons of both Hispanic and non-Hispanic origin. Conversely, persons of Hispanic 
origin may be of any race.
SOURCE: U.S. Bureau of the Census, 2000c.
Selected Characteristics 
and Race/Ethnicity 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Percent Below Poverty
All races 13.5 14.2 14.5 15.1 14.5 13.8 13.7 13.3 12.7 11.8 11.3
White 10.7 11.3 11.6 12.2 11.7 11.2 11.2 11.0 10.5 9.8 9.4
Black 31.9 32.7 33.3 33.1 30.6 29.3 28.4 26.5 26.1 23.6 22.1
Hispanic 28.1 28.7 29.3 30.6 30.7 30.3 29.4 27.1 25.6 22.8 21.2
Related children under 18 years of age in families
All races 19.9 21.1 21.1 22.0 21.2 20.2 19.8 19.2 18.3 16.3 15.7
White 15.1 16.1 16.0 17.0 16.3 15.5 15.5 15.4 14.4 12.9 12.4
Black 44.2 45.6 46.3 45.9 43.3 41.5 39.5 36.8 36.4 32.7 30.7
Hispanic 37.7 39.8 38.8 39.9 41.1 39.3 39.9 36.4 33.6 29.9 27.3
Families with female householder, no husband present, and children under 18 years of age
All races 44.5 47.1 45.7 46.1 44.0 41.5 41.9 41.0 38.7 35.7 32.5
White 37.9 39.6 39.1 39.6 38.3 35.6 36.9 37.6 33.8 30.1 27.5
Black 56.1 60.5 57.2 57.7 53.9 53.2 51.0 46.9 47.5 46.1 41.1
Hispanic 58.2 60.1 57.4 60.5 59.2 59.3 59.7 54.2 52.2 46.6 41.4
Number Below Poverty (in thousands)
All races 33,585 35,708 36,880 39,265 38,059 36,425 36,529 35,574 34,476 32,258 31,139
White 22,326 23,747 24,523 26,226 25,379 24,423 24,650 24,396 23,454 21,922 21,291
Black 9,837 10,242 10,613 10,877 10,196 9,872 9,694 9,116 9,091 8,360 7,901
Hispanic 6,006 6,339 6,655 8,126 8,416 8,574 8,697 8,308 8,070 7,439 7,155
Related children under 18 years of age in families
All races 12,715 13,658 13,876 14,961 14,610 13,999 13,764 13,422 12,845 11,510 11,086
White 7,696 8,316 8,333 9,123 8,826 8,474 8,488 8,441 7,935 7,123 6.873
Black 4,412 4,637 4,850 5,030 4,787 4,644 4,411 4,116 4,073 3,644 3,454
Hispanic 2,750 2,977 2,946 3,666 3,966 3,938 4,090 3,865 3,670 3,382 3,173
Families with female householder, no husband present, and children under 18 years of age
All races 3,426 3,767 3,761 4,034 3,816 3,634 3,755 3,614 3,456 3,116 2,767
White 1,814 1,969 1,980 2,123 2,064 1,980 2,032 2,069 1,926 1,656 1,475
Black 1,513 1,676 1,659 1,780 1,591 1,533 1,593 1,436 1,397 1,333 1,164
Hispanic 536 584 543 706 700 735 760 701 707 630 54129
This chapter provides an overview of drug use patterns for the U.S. population. The overview mainly draws on
data from the Substance Abuse and Mental Health Administration’s (SAMHSA) National Household Survey
on Drug Abuse (NHSDA), which has become the premier source of epidemiological evidence on recent drug
use in the United States. Each year, using methods that help promote accuracy of reporting and confidentiality
of the results, NHSDA staff draws large population samples and solicits participation of respondents sampled
for the survey from among all civilian noninstitutionalized residents age 12 and older. These designated respon-
dents, selected to yield a national representative sample, are asked to answer standardized questions about their
use of alcohol, tobacco, and other drugs. The chapter also presents data on attitudes and perceptions toward
drug use as surveyed by the Partnership for a Drug-Free America’s Partnership Attitude Tracking Survey (PATS),
as well as vital statistics abstracted from birth certificates in selected states. 
For the most part, survey-based estimates presented in this chapter are for “prevalence” proportions that describe
the nature and extent of illegal drug, alcohol, and tobacco use in the United States. One set of estimates is used
to describe the cumulative occurrence or “lifetime prevalence” of illegal drug use in the population. These estimates
answer the question, “Within the current population or population group being surveyed, what proportion has
either a past history of illegal drug use or recently active illegal drug use?” 
In contrast, estimates for “1-month prevalence” pertain to the most recent 1-month interval up to and including
the date of survey assessment of each individual survey participant. The estimates for “1-month prevalence”
answer questions of the following form: “Within the current population or population group being surveyed,
what proportion has a recent history of illegal drug use?” and “What proportion of the survey population is a
‘current’ illegal drug user?” Estimates for “1-year prevalence” shift the focus of this question to the 1-year interval
up to and including the date of survey assessment.
In this report’s estimates, the use of glue, gases, and inhalant drugs to get high generally has been combined with
extramedical or illegal use of internationally and federally controlled drugs. Foremost among the internationally
and federally controlled drugs are marijuana and hashish, heroin, LSD, and certain other hallucinogenic drugs,
all of which have been assigned to high-level Schedule I controls designated for drugs that have no federally 
recognized safe use in the practice of medicine; their only legal use is in research approved by national 
governmental authorities.
Other schedules of the international and Federal regulations encompass a broad array of prescription and over-
the-counter (nonprescription) medicines with clearly legitimate medical uses. This group includes cocaine and
other anesthetics; morphine, codeine, oxycodone, and other pain-relieving and cough-suppressing medicines;
barbiturates and other sleep-promoting or calmative preparations; tranquilizers and other anxiety-relieving 
medicines or muscle relaxants; and methylphenidate and other psychostimulant medicines used to treat atten-
tion deficit disorder with hyperactivity and narcolepsy, or administered as diet aids. Any use of marijuana, LSD,
or heroin qualifies as illegal under U.S. law, but cocaine, tranquilizers, sleeping pills, pain relievers, and many
psychostimulants have legal medicinal uses.
In most epidemiological studies, the use of these internationally and federally regulated medicines is considered
illegal or extramedical when the user intends to get high or to commit suicide, when the motive for intoxication
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leads to taking more than the doctor prescribed, and when the medicine is used for intoxicating or withdrawal-
relieving effects that are beyond the boundaries of the medical prescription. These forms of extramedical drug
use, beyond the boundaries of the medical prescription, generally are grouped with nonresearch use of Schedule
I drugs in a category called “illegal drug use” even if the drug user ordinarily would not be prosecuted (e.g., in
an incident of unsuccessful suicide attempt by overdose). 
Epidemiological information is crucial to our understanding of the nature and scope of alcohol, tobacco, and
illegal drug use. Information on illegal drug use generally is derived from population surveys because the use of
alcohol, tobacco, and other drugs cannot be probed deeply in the traditional sources of epidemiological data on
morbidity and mortality, such as hospital or clinic records, death certificates, and national registries. A large
majority of illegal drug users seek care from primary care health providers in any given year. Nonetheless, health
professionals largely do not talk with the patient about illegal drug use, with such use remaining undetected or
unmentioned and thus never becoming part of official medical records available for epidemiological scrutiny
(e.g., see Anthony and Helzer 1991, 1995; Anthony 2000).
Necessarily, reliance on survey-based estimates provokes legitimate concern about the sources of error in the 
survey data, just as epidemiologists tend to be concerned about sources of error in medical records and vital 
statistics. One source of error can be understood in relation to the difficulty of surveying potentially important
population subgroups, such as homeless individuals and incarcerated prisoners. Numerically, these subgroups
represent small fractions of the total U.S. population. However, research on these subgroups tends to disclose
large values for cumulative occurrence and prevalence of alcohol and tobacco use, as well as illegal drug taking
(e.g., see Anthony and Helzer 1991).
One way to constrain this source of error is to respecify the population of interest. For example, the NHSDA
population generally is described as a national survey of the U.S. “civilian, non-institutionalized population age
12 and older,” which excludes subgroups like incarcerated prisoners. This distinction between the total U.S.
population and the specified NHSDA population is important to recall in interpreting NHSDA statistics.
Figure 1 from the NHSDA 2000 provides evidence that this distinction may be important.
Although the NHSDA population has been defined to exclude incarcerated prisoners and other institutionalized
citizens, the adult survey respondents include recently released prisoners who are parolees or on probation or
supervised release at the time of assessment. As shown in Figure 1, recently incarcerated individuals now on
supervised release, parole, or probation are more likely to be recent illegal drug users (Substance Abuse and
Mental Health Administration 2001b). Once the analysis takes into account male-female and age differences
between these recently incarcerated individuals and the rest of the corresponding civilian noninstitutionalized
population, the recent prisoners are two to three times more likely to have been recent illegal or extramedical
drug users (i.e., use in the month prior to survey).
Epidemiological surveillance operations based on sample surveys face another potential source of error, which
is displayed in confidence intervals that can be constructed for each survey estimate. These confidence intervals
serve to index the precision of each estimate; when properly calculated, the intervals provide general boundary
conditions for each prevalence estimate from the surveys. Any single prevalence number from a survey sample
is not quite accurate, if only because of random fluctuations when a sample of several thousand individuals is
used to represent characteristics of millions of individuals in the total population. However, we can have more
certainty about the accuracy of the confidence intervals, in that each interval encompasses a range of estimates.
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In general, all else being equal and up to a point, the width of the confidence interval becomes smaller with
increases in effective sample size, and the interval allows us to make a roughly accurate assessment of the mag-
nitude of alcohol, tobacco, and illegal drug use in the population being surveyed at the same time, even when
we cannot be entirely confident about the accuracy of the reported prevalence number. To illustrate, in the
NHSDA 1999 report, we learn that an estimated 10.2 percent of those ages 20–25 in the U.S. civilian nonin-
stitutionalized population never have tried alcohol, tobacco cigarettes, or marijuana (i.e., about 90 percent had
used one or more of these drugs). The value of 10.2 percent is the best NHSDA estimate, and it demonstrates
that use of these drugs is prevalent among young adults in our Nation. However, we can be almost totally con-
fident that 10.2 percent is not exactly correct. The true value might be 10.21 percent or 10.19 percent or even
9 percent or 11 percent, because even a sample of hundreds of thousands would be too small to yield absolute
certainty about a population of millions. The reported NHSDA 95-percent confidence interval for this estimate
of 10.2 percent runs from a lower bound of 9.5 percent to an upper bound of 10.9 percent, which provides a
boundary of rough accuracy and precision. It is appropriate to summarize the survey result by saying that about
9 to 11 percent of young adults in the survey population have never used any of these three drugs. It would be
inappropriate to claim that exactly 10.2 percent of young adult Americans have never used any of these three
drugs.
For any given subgroup of the population, the width of the confidence interval will tend to increase as effective
sample size decreases, up to a point. For example, the just-described national estimate of 10.2 percent (95-percent
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Figure 1. Estimated Prevalence of Illegal Drug Use for Parolees and 












































SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administrations, Office of Applied 
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confidence interval = 9.5–10.9 percent) can be compared to State-level estimates, for which the sample size is
smaller. To illustrate, the NHSDA 1999 estimate for the State of Kansas, 10.8 percent, is no more than slightly
larger than the same year’s national estimate of 10.2 percent. Nonetheless, the national estimate draws strength
from almost 67,000 NHSDA survey participants, whereas the Kansas estimate is based on statistical projections
from a sample of fewer than 2,000 Kansans and has been strengthened via an estimation procedure that borrows
information from participants residing in other States. Whereas the Kansas estimate is almost the same value as
the U.S. estimate (10.8 percent versus 10.2 percent), the smaller number of Kansas respondents yields a 95-percent
confidence interval that is quite wide: 7.4–15.4 percent (Substance Abuse and Mental Health Administration
2001b). Hence, the numerical difference between the national estimate of 10.2 percent and the Kansas estimate
of 10.8 percent cannot be taken seriously, even though the Kansas estimate is numerically larger.
Epidemiologically and statistically speaking within the limits of these observed data, the national estimate and
the Kansas estimate are indistinguishable.
In contrast, the corresponding NHSDA estimate for individuals ages 20–25 residing in the State of Utah is 
34.9 percent, with a 95-percent confidence interval from 29.6 percent to 40.7 percent. That is, an estimated 
29 to 41 percent of young adult Utahns have never tried alcohol, tobacco, or marijuana. There is a large separation
between the 95-percent confidence interval derived for these Utahns versus corresponding intervals for young
adults in Kansas and the entire Nation. On this basis, we can have some confidence when we say that the cumu-
lative occurrence of drug experience for young adult Utahns in the civilian noninstitutionalized population is
substantially lower than cumulative occurrence of drug experience among young adult Kansans or among young
adults in corresponding civilian noninstitutionalized populations elsewhere in the United States.
As it happens, when survey-based confidence intervals for epidemiological survey estimates are taken into
account and used as a gauge of the population prevalence of illegal drug use in the United States, the width of
the confidence intervals generally is so large that the intervals tend to accommodate the survey undercoverage
of homeless individuals or incarcerated prisoners. That is, when all drug-using homeless individuals and prisoners
are added to the total population prevalence estimates, the resulting sum generally falls within confidence intervals
derived for the civilian noninstitutionalized population. This conclusion can be derived via mathematics and
simulation studies, but in addition, Anthony and Helzer (1991) have provided an empirical demonstration,
drawing on data from epidemiological surveys in which both noninstitutionalized and institutionalized U.S.
populations were assessed using the same methods and by the same survey research teams. Prevalence estimates
based on civilian noninstitutionalized populations did not change appreciably when they were “corrected” to
include prevalence data from institutionalized persons.
A topic for future research includes reassessment of this situation for racial and ethnic minority populations 
in the United States. Based on the analyses reported by Anthony and Helzer (1991), it is possible to be fairly
confident that 95-percent confidence intervals based on surveys of civilian noninstitutionalized U.S. residents
do not understate the prevalence of illegal drug use in the United States. Estimates corrected for exclusion of
the homeless and institutionalized U.S. populations fall within the bounds of these confidence intervals.
However, minority population subgroups, especially young African-American males, are overrepresented among
incarcerated prisoners (e.g., see Blumstein and Beck 1999). Hence, it is possible that survey-derived 95-percent
confidence intervals for minority subgroups are differentially influenced by exclusion of the homeless and 
prisoners. This open question for future research deserves careful attention, given the well-known racial/ethnic
imbalances of the U.S. incarcerated population relative to the civilian noninstitutionalized population.
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Even if the NHSDA population could be redefined to include institutionalized and homeless persons, there
would be good reason to regard the survey estimates as understatements about the nature and scope of illegal
drug use in the United States, due to the various sources of survey error described above and elsewhere 
(e.g., Substance Abuse and Mental Health Administration 2001a), the fact that sampled respondents can
decline to participate in accord with principles for protection of human subjects, and to reliance on self-report
methods. A similar situation has been found in surveys of alcohol use, which tend to understate the actual 
volume of alcoholic beverages consumed, as independently assessed via sales tax receipts. These sources of error
also make it difficult to compare the nature and scope of alcohol, tobacco, and illegal drug use across racial and
ethnic minority subgroups because it is not possible to be sure that population coverage and accuracy of 
self-report are equally distributed across these subgroups. Nevertheless, as described in this chapter, many of the
survey-based statistics on nature and scope of alcohol, tobacco, and illegal drug use are illuminating. The 
statistics often challenge popular beliefs about these topics, and they help identify gaps in our epidemiological
evidence that merit attention in future research.
One set of popular beliefs already has been discussed in Chapter 1 and in prior editions of this report. For exam-
ple, despite considerable heterogeneity and subgroup variation within the main racial/ethnic categories used in
official U.S. statistics, a popular belief persists that African Americans and Hispanic Americans are substantially
more likely to be involved in illegal drug use than are non-Hispanic Whites, and that Asian Americans are less
likely to be illegal drug users. Recently produced epidemiological estimates from NHSDA 1999–2000 survey
findings tend to challenge at least some of these beliefs.
For example, based on the NHSDA 1999–2000 data, an estimated 6.4 percent of non-Hispanic Whites have
recently engaged in illegal drug use; corresponding estimates for non-Hispanic African Americans and Hispanic
Americans are virtually indistinguishable from these values, once precision of the estimates has been taken into
account (e.g., via 95-percent confidence intervals). The only Hispanic Americans showing numerically greater
1-month prevalence of illegal drug use are those of Puerto Rican heritage (10.1 percent). Otherwise, observed
1-month prevalence values for Hispanic-American subgroups are no different or tend to be smaller than the 
corresponding values for non-Hispanic Whites and Black (Figure 2).
Another important observation from Figure 2 is the excess 1-month prevalence estimate, close to 12 percent,
observed for American Indian/Alaska Native members of the population, as compared with other subgroups.
Whether this excess frequency of recent illegal drug use is due to a greater accuracy of reporting by American
Indian/Alaska Native survey respondents is an open question. Further, even if there is comparable accuracy of
reporting, we will need more definitive evidence from future replications of the national survey. However, the
observed excess might be identifying a difference of public health importance with respect to orientation of 
public health intervention programs for American Indians and Alaska Natives in the United States—a topic we
will return to later in this report.
Figure 2 also demonstrates noteworthy variation within the Asian subgroups of the U.S. population under survey
in NHSDA, with data on Pacific Islanders missing because there were too few Pacific Islander respondents for
precise estimation. In NHSDA 2000, the estimated prevalence proportion for Native Hawaiian and other
Pacific Islander group is 6.2 percent, close to the value for non-Hispanic Whites, whereas the estimate for the
Asian subgroup within the Asian/Pacific Islander population is 2.7 percent. Hence, in general, Asian Americans
appear to be less likely to report recent illegal drug use than other U.S. population groups. However, this 
generalization does not hold true for Korean Americans, for whom the 1-month prevalence estimate from 
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combined 1999–2000 data (6.9 percent) is not appreciably different from the values observed for non-Hispanic
Whites and Blacks (e.g., see Figure 1 and Substance Abuse and Mental Health Administration 2001a).
A remarkably similar profile of subgroup variation can be seen in Figure 3, which presents the most recent
NHSDA 1999–2000 prevalence estimates for tobacco cigarette smoking. Here, with respect to recent tobacco
smoking, we again see an excess prevalence for the American Indian/Alaska Native subgroup (about 40 percent),
whereas the estimates for non-Hispanic Whites and Blacks in the same age range are 25.9 percent and 23.3 per-
cent, respectively. The estimate for Korean-American youth ages 12–20 is 27 percent, the largest value observed
among Asian-American subgroups. Grouping all Asian subgroups, the corresponding estimate is 16.5 percent
(Substance Abuse and Mental Health Administration 2001a).
Notwithstanding the observed variation within and across these relatively refined subcategories within the official
broad categories, the remainder of this chapter generally presents epidemiological statistics for the broad three,
four, or five categories used in past official U.S. statistics on racial and ethnic issues (e.g., White, Black, Other).
However,  while reviewing the estimates for these broad categories, readers should recall that Figures 2 and 
3 challenge popular preconceptions and beliefs about the nature and scope of illegal drug use among racial/
ethnic minorities in this country and throw new light on subgroup variation within these broad categories.
What is true for Hispanic Americans in general may not hold for subgroups within the Hispanic-American 
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Figure 2. Estimated Prevalence of Recent Illegal Drug Use by Race/Ethnicity: 1999–2000
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SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administrations, Office of Applied 
Studies, 2001b.Drug Use in the General Population
population (e.g., those of Puerto Rican or of Cuban heritage), just as what is true for Asian/Pacific Islanders in
general may not hold for Korean Americans, Chinese Americans, or the separate summary categories that 
distinguish Asian Americans from Americans of Pacific Island heritage.
We also note that the NHSDA reports provide no confidence intervals for these estimates across racial/ethnic
subgroups. One of the first items on an agenda for future inquiry will be to clarify whether the subgroup 
variations, depicted in these figures and elsewhere in this report, are large enough for us to be confident that
illegal drug use is more prevalent in one subgroup versus another. Based on these recent NHSDA data, we can
be fairly confident that non-Hispanic Whites, Blacks, Pacific Islanders, and Korean Americans have roughly
equivalent prevalence of recently active illegal and extramedical drug use. However, the other numerical estimates
suggest considerable heterogeneity across and within racial/ethnic minority subgroups, with a dramatic excess
among American Indians/Alaska Natives. Once confidence intervals are available, it will be possible to make
more definitive claims about the observed numerical variation from group to group.
In addition to presenting data by race and ethnicity, this chapter presents data by age and sex. These data provide
a framework for comparing drug use across and within race, ethnicity, age, and sex groups. Although race/
ethnicity is the focus of this report, it is important to note both age and sex differences occur irrespective of race
or ethnicity. For illegal drug use, the peak periods for risk of starting drug use are during adolescence and young
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Figure 3. Estimated Prevalence of Recent Tobacco Cigarette Smoking, 
by Race/Ethnicity: 1999–2000
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adulthood. Consequently, young people often are targeted in prevention programming because they are an 
especially high-risk group for initiation of illegal drug use, alcohol use, and smoking tobacco. In addition, male-
female differences in risk and prevalence of drug use also have been found in many surveys. In general, boys
have tended to initiate drug use earlier than girls and to use slightly greater quantities. For many drugs (but not
all), this pattern of male-female differences in drug use is maintained throughout much of adulthood.
PREVALENCE OF DRUG USE
Most of the subsequent statistics in this chapter are based on data from NHSDA 1998, the most recent survey
for which public use datasets are available for analysis. In 1998, the NHSDA sample included almost 12,000
non-Hispanic Whites, nearly 6,000 non-Hispanic Blacks, almost 7,000 Hispanic Americans, and slightly 
more than 1,100 participants in the other main racial/ethnic minority groups. Table 5 presents these values 
and corresponding population size estimates based on the U.S. Census, which show that NHSDA includes an
“oversampling” of racial/ethnic minority groups to ensure a sufficient number of minorities for precise estimation.
The tabled values also indicate NHSDA oversampling of young people, which ensures a sufficient number of
adolescents for precise estimation. As noted above, it is widely believed that NHSDA estimates of the prevalence
of illegal drug use are conservative in that some high-risk subgroups are not included in the NHSDA sample
(e.g., prison inmates and the homeless). Because drug use is a sensitive illegal activity and social tolerance for
drug use varies considerably over time, it also might be expected that some respondents deny illegal drug use
even when they have been users. Overexaggeration also is a potential source of error in reporting, although such
errors have been observed mainly in drug surveys of young adolescents (e.g., see Harrison and Hughes 1997;
Anthony et al. 2000).
The issue of accuracy in self-reports takes on special importance in research on ethnicity. The concept of ethnicity
encompasses socially shared and learned modes of interpersonal interaction and styles of communication, which
appear in various forms. Without clarification of these potential sources of error in self-report survey data, it is
difficult to be confident about the meaning of observed ethnic variation in prevalence estimates for illegal drug
use (e.g., larger estimates for American Indians/Alaska Natives and smaller estimates for African Americans). 
At  the same or similar levels of drug involvement, we might find that members of historically 
disadvantaged minority groups are more or less likely to acknowledge that they have engaged in illegal drug 
use (Harrison and Hughes 1997).
NHSDA estimates for lifetime and past-month prevalence of drug use among members of the general population
age 12 and older are presented in Table 6. In 1998, for example, an estimated 78 million people age 12 and
older had engaged in illegal drug use at some point in their lifetimes. For the recent interval of 1 month up to
and including the day of survey assessment, an estimated 13.6 million had been recently active illegal drug users
(Table 6). Corresponding estimates from NHSDA 2000 are 86 to 87 million with a history of illegal drug use
and 14 million with recently active illegal drug use (Substance Abuse and Mental Health Administration
2001b).
For many years, marijuana has been prominent among illegally used drugs. Marijuana has been called a “gateway”
drug because its use often precedes other illegal drug use (e.g., cocaine and heroin), perhaps not because 
marijuana kindles biological cravings for other drugs but more because marijuana use is part of a more general
social fabric (e.g., see Kandel et al. 1987; Joy et al. 1999). In some investigations, long-term marijuana use has
been linked to serious health problems, such as emphysema (e.g., Joy et al. 1999).
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As depicted in Table 6, in 1998, an estimated 72 million Americans had tried marijuana at least one time, and
an estimated 11 million were recently active marijuana users. (Here and elsewhere in this report, “recently
active” use means use occurring in the month just before the assessment.) Among all Americans age 12 and
older, the corresponding “cumulative occurrence” or lifetime prevalence of marijuana use was 33 percent in
1998 and the corresponding 1-month prevalence estimate was 5 percent (Table 6). That is, one-third already
had become marijuana users; one in 20 had started to use marijuana at some point in time and had engaged in
marijuana use during the month just before assessment. Corresponding estimates from NHSDA 2000 are not
appreciably different: an estimated 76 million, or just over 34 percent with a history of marijuana use and an
estimated 10 million, or about 5 percent with recently active marijuana use (Substance Abuse and Mental
Health Administration, 2001b).
Table 6 also presents prevalence estimates for illegal use of cocaine, which includes cocaine hydrochloride powder
and crack-cocaine. Cocaine is of special health importance because within the first 1 to 2 years of use, an estimated
5 to 6 percent of cocaine users develop the clinical syndrome of cocaine dependence (Wagner and Anthony
2001). An estimated one in six cocaine users had developed cocaine dependence within 10 to 20 years of initial
cocaine use (Anthony et al. 1994; Wagner and Anthony 2002).
Among drugs used illegally and surveyed in NHSDA, cocaine is second in prevalence only to marijuana. Based
on the NHSDA 1998 data presented in Table 6, an estimated 23 million Americans age 12 and older had tried
cocaine at least once (10.6 percent), and an estimated 4.4 million had tried smoking crack-cocaine at least one
time (2.0 percent). Re-estimated via NHSDA 2000, these values are 24.9 million for all forms of cocaine use,
or an estimated 11.2 percent of the survey population, and 5.3 million for crack-cocaine use specifically, or 
2.4 percent (Substance Abuse and Mental Health Administration, 2001b). 
During 1998, an estimated 1.75 million (0.8 percent) people age 12 and older had used cocaine recently and an
estimated 400,000 to 500,000 (0.3 percent) had used crack-cocaine recently (Table 6). Corresponding estimates
based on NHSDA 2000 are 1.2 million (0.5 percent) for cocaine generally and 265,000 (0.1 percent) for crack-
cocaine (Substance Abuse and Mental Health Administration 2001b).
In recent years, use of LSD and other hallucinogenic drugs has become almost as common as cocaine use in the
United States. For example, in 1998 an estimated 22 million Americans had tried LSD or other hallucinogenic
drugs at least one time (9.9 percent), as compared to the 23 million who had used cocaine (10.6 percent) 
(Table 6). For recently active use as estimated from the 1998 survey, an estimated 1.5 million recently have 
used hallucinogenic drugs (0.7 percent), compared with 1.75 million, or 0.8 percent, with recent cocaine use
(Table 6). Based on NHSDA 2000, an estimated 26 million (11.7 percent) had used hallucinogens at least one
time, as compared to the 24.9 million (11.2 percent) who had used cocaine at least one time. However, regarding
recently active drug use estimated in the most recent NHSDA statistics from 2000, almost 1 million individuals
used hallucinogens in the month up to and including the date of the interview assessment (0.4 percent); com-
parable hallucinogen values from 1998 were 1.5 million, or 0.7 percent (Table 6 and Substance Abuse and
Mental Health Administration 2001b).
Controlled drugs available by prescription or over the counter also may be used for illegal or extramedical 
reasons. For example, based on NHSDA 1998, an estimated 11 to 12 million Americans (5.3 percent) had tried
analgesic (pain-relieving) drugs at least one time to get high or for other extramedical reasons; an estimated 
1.7 million (0.8 percent) had engaged in recently active extramedical use of these analgesic medicines (Table 6).
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Corresponding NHSDA 2000 values are 19.2 million (8.6 percent) for lifetime history of use and 2.8 million
(1.2 percent) for recently active use in the month before survey assessment (Substance Abuse and Mental Health
Administration, 2001b).
The use of pain-relieving pharmaceuticals for nonmedical reasons recently has become a more prominent 
issue in American society, due to concern about diversion and illegal use of sustained-release oxycodone
(OxyContin
®), especially in rural America but also in several cities, including Boston (e.g., see National Institute
on Drug Abuse 2001). Based on the most recently published NHSDA survey reports, there has been a recent
increase in extramedical use of OxyContin
®, from an estimated 220,000 extramedical users in 1999 to almost
400,000 users in 2000 (Substance Abuse and Mental Health Administration 2001b). We do not yet know
whether this oxycodone phenomenon will become more dominant in the national level statistics or will be 
constrained to more local and isolated outbreaks. This is a topic deserving future epidemiological inquiry.
Psychostimulants, a drug group that includes prescription medicines like methylphenidate (Ritalin), as well as
illegally produced methamphetamine (e.g., “ice”), also are prominent among drugs used illegally or extramedically.
In 1998, an estimated 9.6 million (4.7 percent) had used these psychostimulants illegally or extramedically
(Table 6). The corresponding estimates from NHSDA 2000 are 14.7 million, or 6.6 percent (Substance Abuse
and Mental Health Administration 2001b). For recently active use, in 1998 an estimated 633,000 (0.3 percent)
engaged in illegal or extramedical use of psychostimulant drugs in the month before survey assessment, compared
with an estimated 790,000 (0.4 percent) in 2000 (Table 6; Substance Abuse and Mental Health Administration
2001b).
Tranquilizing or antianxiety medicines also are prominent among prescription medicines used illegally or
extramedically. In 1998, an estimated 600,00 to 700,000 individuals (0.3 percent of the survey population) had
engaged in recently active illegal or extramedical use of these tranquilizing medicines (Table 6). By comparison,
the estimates from NHSDA 2000 are 1 million recently active users in the month before survey assessment, or
0.4 percent of the survey population (Substance Abuse and Mental Health Administration 2001b).
Sleeping preparations and other sedative medicines were somewhat less likely to be represented among recently
active illegal and extramedical drug users. In 1998, roughly 200,000 individuals (about 0.1 percent of the survey
population) used sedatives illegally or extramedically. Based on NHSDA 2000, the corresponding estimates are
180,000, still about 0.1 percent of the survey population (Substance Abuse and Mental Health Administration
2001b).
Alcohol is by far the most frequently used drug in the United States. In addition to its purchase and consumption
being legal for those age 21 and older, alcoholic beverages are readily available and socially acceptable in most
parts of the United States. These beverages generally are relatively inexpensive, as compared with the unit dose
prices for many other intoxicating drugs. Data from NHSDA 1998 indicate that slightly more than 80 percent
of the population age 12 and older have tried alcohol at least one time, and just over one-half of the survey pop-
ulation (51.7 percent) consumed alcohol in the month before the survey (Table 6). Corresponding values from
NHSDA 2000 are 81 percent and 47 percent (Substance Abuse and Mental Health Administration 2001b).
Although smoking tobacco is not illegal, this drug is of concern because of its well-established reinforcing func-
tions and negative effects on health. For example, an estimated one in three tobacco smokers has developed a
clinical syndrome of tobacco dependence (Anthony et al. 1994). In addition, tobacco smoking is implicated in
progression toward later illegal drug use (Kandel and Davies 1991).Drug Use in the General Population
According to estimates from NHSDA 1998, slightly more than 150 million Americans in the survey population
(69 to 70 percent) had tried tobacco cigarettes at least one time, and more than 60 million (27 to 28 percent)
were recently active tobacco smokers in the month before the survey (Table 6). Estimates from the NHSDA
2000 indicate no marked change in these estimates, with 148,000 individuals having a history of tobacco 
smoking and an estimated 56,000 considered recently active smokers (Substance Abuse and Mental Health
Administration 2001b).
Estimated male-female differences and age-specific prevalence of past-month alcohol, tobacco, and illegal drug
are depicted in Table 7. In general, the largest prevalence estimates for recently active use are observed for young
adults ages 18–25 and for males. For all drug groups depicted in Table 7, the illegal drug use prevalence 
estimates for individuals age 35 and older are lower than values observed for younger age groups, due in part to
a combination of effects associated with birth cohorts, secular periods, and aging. The variation by age is some-
what less pronounced for alcohol and tobacco, although the lower values observed for adolescents ages 12–17
signify opportunities for preventive interventions during the childhood and early adolescent years.
Generally observed male-female differences in the Table 7 estimates are least pronounced for tobacco cigarettes.
In 1998, an estimated 29 to 30 percent of men in the survey population were recently active tobacco cigarette
smokers. The corresponding estimate for women is 25.7 percent (Table 7). This male-female difference
remained relatively stable at about 4 to 5 percentage points during the last years of the 20th century. Based on
NHSDA 2000, an estimated 27 percent of males age 12 and older in the survey population had smoked tobacco
cigarettes in the month before survey assessment, compared with an estimated 23 percent of females in the 
survey population (Substance Abuse and Mental Health Administration 2001b).
Table 8 expands the epidemiological description to encompass features of race and ethnicity, based on new
analyses of public use datasets distributed after completion of the NHSDA 1998 data gathering and completed
specifically for this report. Public use datasets from NHSDA 1999 and 2000 have not yet been released, so it has
not been possible for this report to include estimates based on these more recent data. Nonetheless, the general
epidemiological patterns depicted in evidence from these analyses are not expected to change dramatically from
year to year, with some important exceptions. One important exception involves dynamic epidemiological
changes in the incidence of drug use, as observed in the late 1980s with cocaine. Whereas lifetime prevalence
of cocaine use remained relatively stable or declined somewhat during the 1980s when national-level statistics
were  examined, data on the number of new initiates show dramatic changes across different race-
ethnicity groups. For example, as depicted in Figure 4, data reveal that for non-Hispanic Whites, the number
of new initiates reached a peak in the late 1970s and early 1980s, while the number of new Black and Hispanic
initiates remained at lower levels. It was not until several years after peak incidence among Whites that the 
incidence curves for Blacks and Hispanics showed their peaks (Figure 4). Hence, the national epidemic of
cocaine use in the United States really can be subdivided into more than one epidemic, with an earlier epidemic
and earlier peak for non-Hispanic Whites and a later epidemic and later peak for Blacks and Hispanics (Gfroerer
and Brodsky 1992; figure adapted from Gfroerer and Brodsky 1992).
Notwithstanding the dynamic epidemiological conditions that were evolving during the 1980s and early 1990s,
it generally is true that patterns of race- and ethnicity-related alcohol, tobacco, and illegal drug use tend not to
change over short spans of time. Until new analyses of the 1999 and 2000 NHSDA data have been completed,
the NHSDA 1998 estimates provide the best available epidemiological descriptions for racial/ethnic minority
population groups in America. As depicted in Table 8, and based on summaries across the broad five racial/
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ethnic categories (rather than looking for subgroup variation within these categories), the estimates show that
Asian/Pacific Islanders tend to have the lowest prevalence of past-month drug use. For example, as seen in the
last column of Table 8, the prevalence estimate for recently active illegal drug use is 2.8 percent for Asian/Pacific
Islanders, versus estimates that range from 6.1 percent to 9.3 percent for the other subgroups listed in the table.
Similar contrasts of varying magnitude can be seen for recently active use of marijuana, cocaine, and alcoholic
beverages, heavy use of alcoholic beverages, and tobacco cigarette smoking (Table 8, last column). Numerical
estimates for the American Indian/Alaska Native subgroup tend to display the largest values in the last column
of Table 8, except for recently active drinking of alcoholic beverages. However, without confidence intervals and
statistical adjustment for differences in the age distributions of these subgroups, it is difficult to assess whether
American Indians and Alaska Natives have higher prevalence than the other subgroups.
In addition, as discussed by Lillie-Blanton et al. (1993), the observed variation in drug experience across racial-
ethnic subgroups may be a function of socially shared neighborhood characteristics that are extrinsic with
respect to race and ethnicity. That is, in analyses that did not take neighborhood into account, Lillie-Blanton
and colleagues found that Blacks were more likely than Whites to have become crack-cocaine users. However,
comparing Blacks and Whites living in the same neighborhood areas (i.e., with neighborhood-matching), there
were no such Black-White differences in occurrence of crack-cocaine use. Flewelling and colleagues (1992)
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Figure 4. Estimated Number of New Users of Cocaine for Three 
Population Subgroups: 1976–1989
NOTE: This figure has been prepared for this report, based on results from retrospective age of onset analyses of NHSDA data (Gfroerer 
and Brodsky 1992).The number of White, non-Hispanic new initiates is shown on the y-axis to the left.The numbers of Black 



















































































HispanicDrug Use in the General Population
reported similar conclusions based on analyses with statistical adjustments for characteristics of census tracts as
measured in the U.S. Census (Lillie-Blanton et al. 1993). Interpretation of racial/ethnic variations, as depicted
in Table 8, remains uncertain until statistical precision of the estimates has been taken into account; misinter-
pretation of the evidence is possible without comparison to estimates that control for features of social context
and socioeconomic circumstances.
The data in Table 8 also are generally consistent with the patterns of age-specific variation seen in Table 7. For
example, estimates for past-month illegal drug use show the largest values for individuals ages 18–25. This
observed excess prevalence among this age group is due in part to peak periods of risk of initiating illegal drug
use during the middle and later years of adolescence and in part to the epidemiological fact that many adoles-
cent drug users sustain their illegal drug use into young adulthood, sometimes in association with development
of drug dependence syndromes (e.g., see Wagner and Anthony 2002; Substance Abuse and Mental Health
Administration 2001a). The lower values observed after age 34 are due in part to the lower risk of initiating 
illegal drug use in these years, as well as the lower risk of becoming drug dependent after young adulthood 
(e.g., see Eaton et al. 1989; Warner et al. 1995; Wagner and Anthony 2002).
Comparison of male-female differences shown in the next-to-last columns of Table 8 shows a general male excess
in prevalence of recently active illegal drug use, alcohol use, heavy alcohol use (defined as “5 or more drinks on
the same occasion on at least 5 or more days in the month prior to assessment”), and tobacco cigarette smoking,
across all racial/ethnic groups under study. For example, looking across the five racial/ethnic groups, for marijuana
and cocaine use, men are some one-and-a-half to three times more likely than women to be recently active 
marijuana users and to be recently active cocaine users. One exception is seen among American Indians/Alaska
Natives, where the ratio of prevalence estimates is more than tenfold (Table 8).
To some extent, this pattern of male excess prevalence for illegal drug use may be traced back to males being
more likely to have opportunities to try marijuana, cocaine, and other controlled drugs. To date, the epidemi-
ological evidence from the United States indicates that males are more likely than females to have opportunities
to initiate illegal drug use, but females are generally just as likely as males to initiate illegal drug use once the
opportunity is presented (Van Etten and Anthony 2001). In addition, with the most controlled drugs, women
are just as likely to become drug dependent once they initiate extramedical drug use. There may be a female
excess in risk of developing dependence on prescription medicines, once extramedical use of these medicines has
started, but these medicines are not included in the list of drugs in Table 8 (e.g., see Anthony et al. 1994).
A general age-related decline can be observed in comparing Table 8 estimates for individuals ages 26–34 with
those for adults age 35 and older. Noteworthy exceptions are apparent for several drugs and groups, where there
may be no age-related difference at all. One exception involves prevalence of recently active cocaine use among
American Indian/Alaska Natives, for whom the estimate is 0.3 percent for individuals ages 25–34 and 1.5 percent
for adults age 35 and older. Another exception involving the American Indian/Alaska Native population group
involves heavy alcohol use, with a prevalence of 16 percent for individuals ages 26–34 and 14.3 percent for older
adults. These exceptions are noteworthy because in general the above-mentioned effects of aging, birth cohort
differences, and secular periods tend to contribute to lower prevalence estimates among older adults. In
American Indian/Alaska Native populations, these general effects may be cancelled to some extent by excess
mortality risk for middle-aged members of this racial/ethnic minority group and (more speculatively) by excess
risk of alcohol or other drug dependence.
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The exceptions observed for tobacco cigarette smoking in Table 8 also are noteworthy. Among Black Americans
and Hispanic Americans, no age-related decline in prevalence of recently active tobacco cigarette smoking is 
evident in comparing individuals ages 26–34 with older adults age 35 and older. If the age-related declines
observed for non-Hispanic Whites are attributed to effective public health interventions, it is possible that the
impact of these interventions has not been so prominent among these racial/ethnic minority groups.
Across all age groups, American Indian/Alaska Natives exhibit the highest prevalence estimates for past-month
use of marijuana. This observation requires replication as well as error checking and evaluation in relation to
confidence intervals. Once the NHSDA 1998 data are subdivided by recently active (past month) drug use, age,
and race/ethnicity, the numbers of American Indian/Alaska Native recently active drug users in each age group
become quite small and the corresponding estimates become quite imprecise.
The apparent excess prevalence of recently active cocaine use among African Americans ages 26–34 has been
observed since the early 1990s. The lower prevalence of cocaine use among the youngest African Americans 
also has been noted. These are epidemiological patterns that merit attention in planning for public health 
intervention. Nonetheless, as noted already within this chapter, with neighborhood matching or statistical
adjustment for neighborhood characteristics, the excess occurrence of cocaine use among African Americans 
is much attenuated. An excess, if any, might be traced back to greater street-level cocaine availability and 
relatively uncontrolled drug dealing in still-segregated neighborhoods with a high density of African Americans
(e.g., see Lillie-Blanton et al. 1991; Ensminger et al. 1997).
Table 9 presents a detailed look at recently active (past month) use of alcohol, tobacco, and other drugs within
the U.S. Hispanic population, with subgroupings for six Hispanic subgroups. There is some value in presentation
of prevalence estimates for these Hispanic subgroups, but caution must be voiced. Compared with prior annual
NHSDA surveys, the NHSDA 1998 dataset was unusual in the number of Hispanic respondents (n=6,795).
Nonetheless, once six subgroups are created and additional subdivisions into four age groups are made, the
number of illegal drug users within each subgroup is limited, as is the total size of each subgroup. In consequence,
the confidence intervals for most of the age-specific estimates in Table 9 are wide, and the observed variation may
well be an artifact. Nevertheless, several general conclusions are warranted. For example, as depicted in the last
column of Table 9, for recently active illegal drug use, considerable subgroup variation in prevalence exists across
the various Hispanic heritage groups. For example, the lowest prevalence estimates are observed for U.S. Hispanic
residents of South American and Cuban heritage: 2.1 percent and 3.4 percent, respectively. These lower values
are observed not only for all members of these subgroups (last column) but also for males and females (next-to-
last columns). The largest estimates are obtained for the “Other” group of Hispanic residents and for those of
Puerto Rican heritage: 8.2 percent and 6.9 percent, respectively (shown in the last and next-to-last columns 
of Table 9). The excess prevalence of illegal drug use among South Americans is especially interesting because
this group’s value cannot be explained by their marijuana and cocaine use. Adding the marijuana and cocaine
prevalence values for the “Other” group yields a sum of just 5.1 percent, not large enough to account for the
8.2 percent estimate for “any illegal drug use,” even if none of the marijuana users consumed cocaine and none
of the cocaine users consumed marijuana—an unlikely circumstance. Hence, some other form of illegal drug
use must be contributing to the observed general excess prevalence in relation to illegal drug use—perhaps
inhalant drugs as described by Mesquita and colleagues (1997) or extramedical use of prescription medicines as
described by Nappy and Carlini (1993) and others.
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Hispanic residents of Puerto Rican heritage also have relatively higher prevalence estimates for marijuana,
cocaine, and tobacco cigarette smoking. This excess prevalence among Puerto Ricans is observed for marijuana
and tobacco smoking for both males and females, but the observed excess prevalence of recently active cocaine
use is seen for males of Puerto Rican heritage but not females. This epidemiological pattern merits greater 
attention in future research. As depicted in Figure 2, the apparent excess prevalence of illegal drug use among
U.S. Hispanic residents of Puerto Rican heritage has been replicated independently in the data from NHSDA
1999–2000, and also was seen in data from NHSDA 1996. Associated implications for planning of public
health interventions will become more clear once there are more probing analyses of these initial epidemiological
observations, with attention to social context, geographic locations, and other circumstances, conditions, and
processes associated with illegal drug use in this population subgroup.
Based on data in Table 9 from NHSDA 1998, persons of South and Central American heritage had the highest
prevalence values for recently active consumption of alcohol (46 percent and 47.2 percent, respectively), but it
was U.S. Hispanic residents of Mexican heritage who had the highest prevalence of recently active heavy alcohol
use (7.4 percent). The South and Central American values for heavy alcohol consumption were intermediate in
level (4.1 percent), and Cuban-Americans had the lowest prevalence of heavy alcohol consumption (1.7 percent).
The data on male-female differences among Hispanic subgroups show a pattern that is generally consistent with
sex-specific estimates for other racial/ethnic minority groups (Table 9). That is, in general, Hispanic females
have a lower prevalence of recently active drug use for all drug categories compared with males. In many con-
trasts, Hispanic males are two to three times more likely to be recently active drug users. Women of Cuban-
American heritage have the lowest prevalence estimates observed for marijuana, cocaine, and heavy alcohol use. 
As noted in the initial description of Table 9, imprecision in these epidemiological estimates prompts some 
hesitation in the interpretation of the observed variation across age groups within the Hispanic subgroups.
Nevertheless, it is noteworthy that the general pattern of age-specific variation described in relation to the 
Table 8 estimates also is apparent for many of the Hispanic subgroups depicted in Table 9. One interesting 
age-specific relationship is seen in relation to recently active heavy alcohol consumption. There is relatively
invariant prevalence of recently active heavy alcohol use across the three adult age groups of Mexican Americans,
with values of 9.2 percent for individuals ages 18–25, 8.6 percent for those ages 26–34, and 7.5 percent for
adults age 35 and older. There is a sharp decline from the value observed for individuals ages 18–25 of Puerto
Rican heritage, compared with values observed for older adults (11.9 percent to 5.4 percent to 6.1 percent) in
this subgroup. With other subgroups for which there is an adequate number of participants, the age-specific
estimates show age-related declines among non-Hispanic Whites and most of the other groups represented in
Table 8.
In many public health reports, women ages 15–44 are considered to be of childbearing age. Table 10 presents
NHSDA 1998 estimates for the prevalence of drug use among women ages 15–44 by age, race/ethnicity, and
metropolitan/nonmetropolitan location. Estimates for lifetime history of illegal drug use indicate that use is
highest among White women (51.2 percent), followed by African-American women (36.0 percent), Hispanic
women (26.2 percent), and women of other race/ethnicity groups (20.2 percent). Recently active illegal drug
use showed a somewhat different pattern across these groups, with a slightly higher prevalence of past-month
illegal drug use for both non-Hispanic White and African-American women (7.6 percent and 8.1 percent,
respectively), compared with Hispanic women and women in the “Other” group (6.1 percent and 3.0 percent,
respectively). In general, prevalence estimates for illegal drug use and for recently active use of marijuana and
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cocaine were highest among women ages 15–24. There were several exceptions, and a noteworthy pattern of
age-specific estimates was observed for recently active cocaine use among African-American women. Among
that group, an estimated 0.4 percent of women ages 15–24 were recently active cocaine users, compared with
2.2 percent and 2.1 percent for individuals ages 25–29 and 30–44, respectively. The lower prevalence value for
the youngest women is not seen in the age-specific estimates for non-Hispanic White women or for Hispanic
women. Within these two groups, the youngest women are the most likely to be recently active cocaine users.
Observed variations across metropolitan and nonmetropolitan areas also are noteworthy in several instances. For
example, among non-Hispanic White women and African-American women, there is a general tendency toward
higher prevalence of illegal drug use in metropolitan areas than in nonmetropolitan areas. This pattern is not
seen for women of Hispanic heritage nor for women in the “Other” racial/ethnicity group (Table 10).
From vital statistics data abstracted from birth certificates in selected States, it is possible to add a different per-
spective on the drug use of women in the childbearing years. These statistics disclose trends in the prevalence of
tobacco smoking during pregnancy among mothers of live-born infants. From 1993 through 1999, there were
modest declines in these estimates (Table 11), which represent a continuation of declines observed between
1989 through 1993 (National Institute on Drug Abuse 1998). For example, evaluating the estimates for all
mothers of live-born infants (last row of Table 11), the proportion that smoked during pregnancy in 1993 was
almost 16 percent. By comparison, the value observed in 1999 was 12 to 13 percent.
Supplementing the NHSDA statistics, these epidemiological data add more information about heterogeneity
within the broad racial/ethnicity subgroups generally displayed in official statistics. To illustrate, in these data,
the observed prevalence of smoking during pregnancy is substantially greater for Hawaiian and part-Hawaiian
women than for the other Asian and Pacific Islander groups represented in the table. Whether this impression
is a result of a sampling artifact or other errors remains an open question for future research. It is possible that
this type of subgroup variation might be due to methodological difficulties in vital statistics, such as incomplete
coverage of Hawaiian versus other Asian live-borns in the birth certificate database. It certainly is true that 
completeness and accuracy of information on birth certificates can vary from place to place and time to time.
For example, it may be possible that birth certificate processes and recording of tobacco smoking status of the
mothers is more complete in public health districts serving Hawaiian mothers and live-born infants than in
other areas of the country.
ATTITUDES AND PERCEPTIONS
In accord with sociological concepts elaborated by George Herbert Mead, several social  psychological theories
of drug-taking link an individual’s attitudes about drug use and perceptions of the harmfulness of drug use to
the individual’s risk of becoming and remaining a drug user. Recent economic theories also incorporate links
between subjective assessments of the utility of drug-taking behavior, both short- and long-term, and the prob-
ability of choosing to initiate or sustain drug use. According to most of these theories, when people anticipate
or perceive there are risks of harm attached to drug-using behaviors, they are less likely to engage in those
behaviors.
Ecological analyses of national-level statistics yield evidence consistent with these theories. For example, time
trends in perceived harmfulness of drug use are linked with time trends in prevalence of drug use, even when
perceived availability of drugs remains constant or is held constant statistically.
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These theories and data have prompted speculation about the possibility of preventing or reducing youth’s drug
use by manipulating attitudes or perceptions about the harmfulness of drug use, either through family process,
peer communication, drug education programs, or mass media and other social marketing campaigns. Of
course, it is possible that alternative processes are at work in generating the observed data. For example, mass
media campaigns and drug prevention efforts often are redoubled during periods of increasing prevalence of
drug use, but concurrent with these periods are processes of personal exposure to the casualties of drug use. To
the extent that a youth has an older brother, other relative, or friend who becomes a casualty of drug use, the
harmfulness of drug use may acquire an immediacy that has substantial impact on the likelihood of future drug
use. Of course, as prevalence of drug use begins to mount, these personal experiences with the harm and casualties
associated with drug use also increase, all else held constant. Consequently, perceptions of harmfulness of 
drug use may be more influenced by increasing prevalence of drug use and personal observation of drug-related
casualties and less influenced by concurrent mass media or drug prevention campaigns. 
Theories about the links between perceived harmfulness and prevalence of illegal drug use remain incomplete
to the extent that they fail to account for these reciprocities between prevalence of drug use at the population
level and perceptions about harmfulness of drug use at the individual level. Nevertheless, theoretical concerns
aside, there is good reason to speculate about whether drug prevention campaigns might be aided by a better
understanding of the interrelationships between a person’s attitudes and perceptions about drug use and the per-
son’s individual-level probability of becoming a drug user. For this reason, several studies have been measuring
attitudes and perceptions about drug use in an effort to track and improve understanding of their relationships
with drug-taking behavior.
PATS is an ongoing national study that seeks information about the attitudes of students and parents, as well
as estimates of drug-related behavior in these populations. For example, in 2000, more than 7,000 students in
the middle- and high-school grades (7–12) answered questions administered as part of the PATS classroom 
surveys. Parents generally are interviewed at home. In some years, the PATS survey has extended to children in
primary school (grades 4–6), but this was not the case in 2000, the 13th wave of this research project since its
initiation in 1986.
Table 12 presents estimates from PATS, as reported from 1997 through 2000. For example, in the first row of
Table 12, it is possible to see a downward trend in the proportion of youth (grades 4–6) who report that mari-
juana is easy to get, with general parallel trends for Whites (columns 1–4), Blacks (columns 5–8), and Hispanics
(columns 9–12). The trends for teens and for parents are not as regular. For example, among White parents
asked whether marijuana was very easy for their children to get, the estimate for 1997 was 27 percent, and in
2000 it was 25 percent—not a large enough difference to be remarkable. Similarly among Black parents, the
corresponding values were 33 percent and 31 percent, with values of 36 percent and 42 percent in 1998 and
1999, respectively. It might be said that White teens perceived reduced availability of marijuana between 1997
(60 percent) and 2000 (54 percent), but the corresponding trends for Black and Hispanic teens were relatively
more stable.
The patterns for cocaine and crack are of note and show possible variation across the racial/ethnic subgroups.
For example, in 1997, an estimated 14 percent of White youth in grades 4–6 reported that cocaine and crack-
cocaine were easy to get, and 17 percent of White parents reported congruent impressions about cocaine/crack
availability to their children. By 1999, the estimate based on the youth’s reports was only 7 to 8 percent (close
to a value of 6 percent observed in 1993), and in 2000, the estimate based on parents’ reports was 9 percent.
45Drug Use in the General Population
Downward shifts of somewhat smaller magnitude can be seen in the estimates for Black youth and parents, but
there are no similar shifts in the Hispanic segment of the PATS sample. Whether these estimates on perceived
availability of marijuana and cocaine actually reflect prevailing availability in the communities surveyed remains
an open research question, but the apparent numerical difference across these several racial/ethnic groups is
provocative and warrants more detailed scrutiny (e.g., confidence interval estimation and investigation of other
circumstances, conditions, and processes). When seen in the context of differences between reports of Black
youths and their parents, the apparent general congruence between reports of Hispanic youth and their parents
also merits investigation. Many Black parents sampled have a sense that cocaine and crack are very easy for their
children to get, but less than half as many children see it that way. The same patterns of child-parent incon-
gruence and congruence are seen in the estimates for marijuana availability (Table 12).
Perception of risk is quantified in PATS by the estimated proportion of grade-school children and teens who
associate great risk or danger with the use of various drugs, and by the corresponding proportion for parents
who are asked to describe their child’s perceptions about the dangers of drug use. The PATS assessments asked
grade-school children to report their perceptions of the risks and dangers of cocaine and crack use separately,
while teens and parents were asked to report about cocaine and crack as a single entity. As depicted in Table 13,
from 1997 to 1999, there was general stability in the proportion of youths in grades 4–6 and teens in grades
7–12 who reported that marijuana use is dangerous. For example, in the first row of Table 13, fluctuation occurs
around a value of about 80 percent for White children, 75 percent for Black children, and 75 to 77 percent for
Hispanic children. Without confidence intervals, it is difficult to judge whether the observed variation in these
statistics is meaningful. The general stability in the parents’ reports of their child’s perceptions about the danger
of marijuana use also is noteworthy, with somewhat larger values in 1997 for White and Black parents, but with
no clear pattern among Hispanic parents.
It also is noteworthy that the children do not assign greater danger and risk values to use of cocaine and crack
or heroin than use of marijuana. These perceptions of danger and risk do not reflect what is known about the
relative likelihood of becoming dependent on cocaine or heroin versus marijuana or the relative likelihood of
drug-related death in association with these three drugs (e.g., see Anthony et al. 1994; Wagner and Anthony
2002; Chapter 6, this report). The children’s relatively lower danger and risk evaluations of inhalant drugs also
deserve more detailed investigations, given the public health importance of inhalant drug use in childhood and
adolescence (e.g., see Neumark et al. 1998). These lower evaluations of danger associated with inhalant use also
were seen in the PATS data from 1993 through 1996 (National Institute on Drug Abuse 1998).
Table 14 reports the PATS estimates for the proportion of youth and teens that report being afraid of taking
drugs. In general, youth in grades 4–6 are more likely to report being afraid than are teens in grades 7–12. This
is true for all three of the reported racial/ethnic groups. The estimates across the years reported in Table 14 
(i.e., from 1997 to 2000) are generally stable, with no marked upward or downward change from year to year.
The belief that “smoking marijuana is okay sometimes” has been generally stable across these years. One excep-
tion can be seen in the last columns of Table 14, where it appears that Hispanic youths became less likely to
report agreement with this statement 1997 to 1999. However, no similar difference across these years was seen
for Hispanic teens or for the parents. White and Black parents were slightly more likely than their teens and
younger children to agree with the statement that it is okay to smoke marijuana sometimes. This discrepancy
between parents and children was not seen for the Hispanic group, except in 1997, when the younger children
showed the relatively high and perhaps anomalous agreement value of 29 percent.
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Fluctuation has occurred in the observed numerical proportions, but in general between 1997 and 2000, there are
relatively stable estimates for the statement “If parents use marijuana, their children are likely to use marijuana.”
For example, among White parents, an estimated 75 percent agreed somewhat or strongly with this statement in
1997 and the corresponding value for 2000 was 72 percent. It is noteworthy that Black parents are substantially
less likely to agree with this statement than are White and Hispanic parents (Table 14).
Table 14 also shows general stability in respondents’ agreement with the statement “It’s really hard to give my
child reasons not to use marijuana.” Across the years, between 14 and 20 percent of White parents endorsed
this statement, compared with about 18 to 25 percent of Black parents. However, there were marked fluctuations
for the Hispanic parents, with a value of 36 percent observed in 1999 and a value of 13 percent observed in
2000. Information about confidence intervals and possible differences in sampling plans or methods for
Hispanic parents across these years will be required before a difference of this magnitude can be interpreted.
PATS respondents also are asked if they want to hang around people who use drugs; responses are presented in
Table 14. Generally, there is stability in the reports of youth and teens on this aspect of interpersonal relations
and values toward drugs. What is more striking is the difference in values for the younger students in grades 4–6
versus those of the older students in grades 7–12. Whites, Blacks, and Hispanics in older grades have greater
acceptance of social relationships with drug-using people.
Data on youth’s and teens’ attitudes toward selling drugs to make money also are presented in Table 14. These
estimates for younger and older students complement the just-reported values on social relationships with 
drug-using people. In contrast to youth in grades 4–6, a much greater percentage of teens feel it is okay to sell
drugs to make money. This finding is consistent across racial/ethnic groupings for the 2 years (1997 and 1998)
in which this comparison can be made.
Comparing the percentage of children and teens in different racial/ethnic groups who feel it is okay to sell drugs
indicates that White students are less favorably disposed to drug dealing than are Black and Hispanic students.
For example, in 2000, an estimated 17 percent of White teens reported strongly or somewhat agreeing with the
statement that it is okay to sell drugs to make money. In that same year, an estimated 27 percent of Black teens
and an estimated 24 percent of Hispanic teens expressed these values.
SUMMARY
Data from NHSDA have started to shed new light on variations within the four or five main racial/ethnic
groupings that typically have been used in summaries of epidemiological evidence about illegal drug use, alcohol,
and tobacco smoking. Several patterns are beginning to emerge, including challenges to preconceptions and
beliefs about greater occurrence and prevalence of illegal drug use among Blacks and Hispanics than among
non-Hispanic White members of the U.S. civilian noninstitutionalized population. Several observations are
noteworthy and merit sustained inquiry, including the prominence of Puerto Ricans among Hispanic illegal
drug users; the pattern of age-specific prevalence estimates for recently active cocaine use among African
Americans, including women of child-bearing age; and the apparent excess prevalence of illegal drug use among
American Indian/Alaska Native groups. In many respects, these data raise more questions than they answer.
PATS data were examined to ascertain information on attitudes of youth, teens, and parents about drug use.
Youth, teens, and parents were asked about the perceived ease of obtaining several illicit drugs; statements
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reflecting attitudes toward drug use, drug users, and drug dealers; and assessments of the relative danger or risk
associated with different drugs. In general, patterns of general stability characterize these statistics; nevertheless,
noteworthy variations are evident between children, teens, and their parents, sometimes reflecting discrepancies
that merit more study because they might provide new information for use in planning drug prevention programs.
In addition, interesting differences define attitudes of primary school and older students toward social relation-
ships with drug users and acceptability of drug dealing to make money. The general observation that Black and
Hispanic teens are more likely than White teens to accept drug dealing as a means of earning money is striking.
Whether this attitude of acceptance is an artifact of sampling or other methodological features of the PATS
approach must be investigated in more detail before this intriguing observation can be translated into public
health action. If confirmed, the observation should provoke planning and implementation of new intervention
programs directed toward shaping the orientation of social networks to address personal involvement in drug
supply and distribution.
Finally, the age-related variation in perceptions about the harmfulness of marijuana, cocaine, heroin, and
inhalants is striking. To some extent, younger students misperceive the relative danger and risk associated with
use of marijuana versus cocaine, heroin, and inhalant drugs, if danger and risk are evaluated based on evidence
about adverse health consequences. However, if danger and risk refer to the likelihood of apprehension by 
the criminal justice agencies and the adverse consequences of conviction and incarceration, it is possible that
younger children’s appraisals have some factual basis.
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Table 6. Estimated Prevalence of Use of Selected Drugs Among Persons 
Age 12 and Older in the United States: 1998
Ever Used Used in Past Month
Population Population
Drug Percent Estimate Percent Estimate 
(in thousands) (in thousands)
Any illegal drug use 35.8 78,123 6.2 13,615
Marijuana 33.0 72,070 5.0 11,016
Hallucinogens 9.9 21,607 0.7 1,514
Inhalants 5.8 12,589 0.3 713
Cocaine 10.6 23,089 0.8 1,750
Crack 2.0 4,476 0.2 437
Heroin 1.1 2,371 0.1 130
Nonmedical use of 
Stimulants 4.4 9,614 0.3 633
Sedatives 2.1 4,640 0.1 210
Tranquilizers 3.5 7,726 0.3 655
Analgesics 5.3 11,595 0.8 1,709
Alcohol 81.3 177,512 51.7 112,850
Cigarettes 69.7 152,313 27.7 60,406
SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied
Studies, 1998 public use dataset, 2000a.
Table 7. Estimated Prevalence of Past-Month Drug Use in the United States, 
by Age and Sex (by percent): 1998
Age Group Sex
All Ages,
Drug 12–17 18–25 26–34 35+ Male Female Both Sexes
Any illegal drug  9.9 16.1 7.0 3.3 8.1 4.5 6.2
Marijuana 8.3 13.8 5.5 2.5 6.7 3.5 5.0
Cocaine 0.8 2.0 1.2 0.5 1.1 0.5 0.8
Alcohol 19.1 60.0 60.9 53.1 58.7 45.1 51.7
Heavy alcohol 2.9 13.4 6.9 4.2 9.3 2.3 5.7
Cigarettes 18.2 41.6 32.5 25.1 29.7 25.7 27.7
NOTE: Heavy alcohol use has been defined as “5 or more drinks on the same occasion on at least 5 or more days in the month prior to 
assessment,” in accord with the National Household Survey on Drug Abuse specifications on pp. 99 and 102 of source materials.
SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied 
Studies, 1998 public use dataset, 2000a.Drug Use in the General Population
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Table 8. Estimated Prevalence of Past-Month Drug Use in the United States, 
by Age, Sex, and Race/Ethnicity (by percent): 1998
Age Group Sex
All Ages,
Drug 12–17 18–25 26–34 35+ Male Female Both Sexes
Any illicit drug
White, non-Hispanic 10.3 17.6 7.1 3.2 7.7 4.5 6.1
Black, non-Hispanic 9.9 17.1 9.4 4.8 12.0 5.2 8.2
American Indian/Alaska Native 16.3 24.9 15.5 6.0 16.6 5.4 9.3
Asian/Pacific Islander 5.2 7.3 2.8 0.7 3.7 1.8 2.8
Hispanic 9.9 11.1 5.4 3.5 7.7 4.5 6.1
Marijuana
White, non-Hispanic 8.7 14.9 5.7 2.5 6.5 3.6 5.0
Black, non-Hispanic 8.3 15.2 7.4 3.3 9.9 3.8 6.6
American Indian/Alaska Native 10.3 23.3 12.9 5.4 13.5 5.0 8.0
Asian/Pacific Islander 3.7 7.3 2.8 0.7 3.3 1.8 2.6
Hispanic 7.6 9.0 3.2 2.4 5.7 3.2 4.5
Cocaine
White, non-Hispanic 0.9 2.2 1.0 0.3 0.9 0.5 0.7
Black, non-Hispanic * 0.6 2.7 1.3 1.7 0.9 1.3
American Indian/Alaska Native 2.0 2.3 0.3 1.5 3.7 0.2 1.4
Asian/Pacific Islander * 0.3 * * 0.1 0.0 0.0
Hispanic 1.4 2.7 1.1 0.9 1.8 0.8 1.3
Alcohol
White, non-Hispanic 20.9 65.0 65.2 56.2 61.2 49.7 55.3
Black, non-Hispanic 13.1 50.3 54.8 38.3 49.0 32.3 39.8
American Indian/Alaska Native 32.1 67.4 50.7 40.9 69.1 29.2 43.3
Asian/Pacific Islander 10.5 44.0 37.5 36.7 39.9 29.2 34.5
Hispanic 18.9 50.8 53.1 47.7 56.8 33.6 45.4
Heavy alcohol**
White, non-Hispanic 3.4 16.7 7.1 4.2 9.3 2.5 6.0
Black, non-Hispanic 0.7 6.3 7.8 4.6 8.3 1.8 4.9
American Indian/Alaska Native 5.2 12.3 16.0 14.3 31.9 3.7 13.7
Asian/Pacific Islander 1.7 4.2 4.8 2.1 5.8 0.1 2.9
Hispanic 2.4 10.5 7.7 5.8 10.3 2.0 6.5
Tobacco cigarettes
White, non-Hispanic 20.5 46.9 34.1 24.1 28.9 26.9 27.9
Black, non-Hispanic 13.7 30.7 31.5 32.2 33.8 25.9 29.4
American Indian/Alaska Native 24.7 54.5 46.1 26.8 35.2 29.0 31.2
Asian/Pacific Islander 8.7 27.1 30.7 21.6 30.1 15.1 22.5
Hispanic 15.1 31.5 25.4 27.0 31.4 20.0 25.8
*Low precision, no estimate reported.
**Heavy alcohol use has been defined as “5 or more drinks on the same occasion on at least 5 or more days in the month prior to 
assessment,” in accord with the National Household Survey on Drug Abuse specifications on pp. 99 and 102 of source materials.
SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied
Studies, 1998 public use dataset, 2000a.Drug Use in the General Population
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Table 9. Estimated Prevalence of Past-Month Drug Use Among Hispanics in the United
States, by Age and Sex (by percent): NHSDA 1997 and 1998 Data Combined
Age Group Sex
All
Drug 12–17 18–25 26–34 35+ Male Female Persons
Any illegal drug
Hispanic 10.2 10.8 4.6 3.6 7.4 4.5 6.0
Puerto Rican 11.5 15.7 7.9 2.2 8.7 5.1 6.9
Mexican 9.9 10.4 4.2 4.1 7.5 4.8 6.2
Cuban 9.9 12.1 3.3 1.0 4.7 2.2 3.4
Central American 10.1 9.6 4.6 3.0 6.8 3.5 5.3
South American 16.5 1.8 * * 2.3 2.0 2.1
Other 8.1 10.7 7.7 7.8 11.9 5.7 8.2
Marijuana
Hispanic 8.0 8.4 2.8 2.3 5.4 3.1 4.3
Puerto Rican 10.7 14.6 4.6 1.4 6.8 4.4 5.6
Mexican 7.6 8.2 2.9 2.8 5.5 3.6 4.5
Cuban 6.5 7.9 2.9 0.3 3.5 0.9 2.1
Central American 8.0 5.0 1.5 2.3 5.2 1.0 3.2
South American 16.5 1.3 * * 2.1 2.0 2.1
Other 1.8 7.4 4.3 2.5 5.7 1.8 3.4
Cocaine
Hispanic 1.2 2.1 1.0 0.7 1.6 0.5 1.0
Puerto Rican 0.6 2.4 0.9 1.0 1.6 0.8 1.2
Mexican 1.2 2.2 1.0 0.7 1.8 0.4 1.1
Cuban 0.9 4.6 * * 1.0 0.1 0.5
Central American 1.0 0.9 0.7 0.6 0.9 0.5 0.7
South American 4.7 0.6 * * 0.2 1.2 0.6
Other 1.0 1.2 3.4 1.5 2.0 1.6 1.7
Alcohol
Hispanic 18.9 49.7 52.4 45.3 55.2 32.2 43.9
Puerto Rican 20.1 54.1 54.9 46.6 51.7 39.4 45.4
Mexican 18.7 47.7 52.6 44.8 56.1 29.6 43.2
Cuban 23.3 47.9 58.2 39.0 49.2 35.1 41.7
Central American 17.3 53.2 45.8 53.7 57.5 35.6 47.2
South American 23.9 66.5 62.0 38.6 56.4 32.8 46.0
Other 13.5 52.1 54.2 40.3 51.4 34.7 41.5
Heavy alcohol
Hispanic 3.1 9.5 7.0 5.7 10.4 2.1 6.3
Puerto Rican 2.4 11.9 5.4 6.1 8.6 4.3 6.4
Mexican 3.2 9.2 8.6 7.5 12.4 2.2 7.4
Cuban 2.8 4.6 4.5 0.3 3.0 0.6 1.7
Central American 2.5 10.7 4.4 2.1 6.6 1.2 4.1
South American 11.4 17.2 0.6 * 6.2 1.5 4.1
Other 0.9 3.3 * 4.5 7.9 0.1 3.2
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*Low precision, no estimate reported.
**Heavy alcohol use has been defined as “5 or more drinks on the same occasion on at least 5 or more days in the month prior to 
assessment,” in accord with National Household Survey on Drug Abuse specifications on pp. 99 and 102 of source materials.
SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of
Applied Studies, 1997–1998 public use datasets, 1999a and 2000a.
Table 9 (continued). Estimated Prevalence of Past-Month Drug Use Among Hispanics in
the United States, by Age and Sex (by percent): NHSDA 1997 and 1998 Data Combined
Age Group Sex
All
Drug 12–17 18–25 26–34 35+ Male Female Persons
Tobacco cigarettes
Hispanic 15.5 31.2 27.0 27.9 31.9 21.1 26.6
Puerto Rican 18.4 35.9 32.1 35.6 33.4 31.7 32.5
Mexican 15.2 29.7 27.4 29.2 32.5 20.8 26.9
Cuban 12.6 28.1 24.1 20.4 26.7 16.1 21.1
Central American 14.5 37.5 21.7 20.4 28.3 16.3 22.6
South American 26.6 36.4 40.9 27.5 40.2 20.3 31.5
Other 10.9 24.0 21.5 22.4 30.4 15.0 21.3
Table 10. Estimated Percentage of Women of Childbearing Age (15–44) Using Drugs, 
by Age, Race/Ethnicity, and Population Density: 1998
Any Illicit Drug Marijuana Cocaine Cigarettes
Age Race/ Population
Ethnicity Density Lifetime Past Year Past Month Lifetime Past Year Past Month Lifetime Past Year Past Month Lifetime Past Year Past Month
All All Total U.S. 44.6 13.3 7.3 42.4 10.9 5.8 13.3 2.2 0.9 66.9 34.6 30.9
ages Groups Nonmetro 37.9 10.5 5.1 35.5 8.6 3.9 8.8 1.9 0.6 68.6 39.8 36.8
Metro 46.1 14.0 7.8 44.0 11.4 6.3 14.3 2.2 1.0 66.5 33.4 29.6
White, NH Total  U.S. 51.2 14.2 7.6 49.3 11.7 6.2 15.8 2.4 0.9 73.8 37.8 33.7
Nonmetro 40.4 10.0 4.1 38.3 8.2 3.0 9.3 1.9 0.5 71.2 40.9 38.0
Metro 54.2 15.4 8.6 52.4 12.7 7.1 17.6 2.5 1.0 74.6 36.9 32.5
Black, NH Total U.S. 36.0 14.0 8.1 32.6 11.4 6.0 7.5 2.2 1.5 56.7 31.6 29.5
Nonmetro 25.4 9.9 6.6 21.3 7.0 4.5 4.0 1.6 1.0 58.3 33.7 31.3
Metro 37.9 14.7 8.4 34.7 12.2 6.3 8.1 2.4 1.7 56.4 31.2 29.2
Hispanic Total U.S. 26.2 10.4 6.1 22.8 8.0 4.5 8.3 1.6 0.9 49.7 25.2 21.3
Nonmetro 28.0 14.1 10.5 24.2 12.9 9.7 7.7 2.4 1.6 56.1 37.0 33.3
Metro 26.0 10.0 5.6 22.6 7.4 3.9 8.4 1.5 0.8 49.0 23.9 19.9
Others Total U.S. 20.2 6.4 3.0 19.7 5.2 2.9 6.2 0.2 0.1 38.5 21.2 19.9
Nonmetro 36.1 20.6 16.6 35.0 19.4 15.5 17.7 0.9 0.5 59.1 37.2 31.7
Metro 18.7 5.0 1.8 18.2 3.9 1.7 5.2 0.1 0.1 36.5 19.7 18.8
15–24 All Total U.S. 37.8 23.2 13.0 35.2 21.2 11.4 7.0 3.7 1.5 59.4 40.3 33.8
Groups Nonmetro 30.7 17.0 9.0 28.7 14.9 7.3 5.0 2.7 1.4 64.3 45.5 39.6
Metro 40.0 24.9 14.1 37.0 23.0 12.6 7.6 4.0 1.6 58.0 38.8 32.2
White, NH Total  U.S. 42.5 26.3 14.4 40.5 24.3 12.9 8.6 4.6 1.8 67.2 47.6 40.2
Nonmetro 32.8 17.3 8.5 31.0 15.3 7.0 5.4 2.6 1.1 68.6 50.0 43.8
Metro 46.0 29.4 16.4 43.9 27.4 15.0 9.7 5.3 2.0 66.8 46.8 39.0
(continued on next page)Drug Use in the General Population
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Table 10 (continued). Estimated Percentage of Women of Childbearing Age (15–44)
Using Drugs, by Age, Race/Ethnicity, and Population Density: 1998
Any Illicit Drug Marijuana Cocaine Cigarettes
Age Race/ Population
Ethnicity Density Lifetime Past Year Past Month Lifetime Past Year Past Month Lifetime Past Year Past Month Lifetime Past Year Past Month
15–24 Black, NH Total U.S. 30.2 19.4 11.9 26.2 17.6 10.1 1.0 0.5 0.4 42.3 24.7 21.1
Nonmetro 20.4 14.9 11.6 16.4 11.5 7.6 1.3 1.3 1.3 49.6 24.3 20.9
Metro 31.9 20.1 12.0 27.9 18.6 10.6 0.9 0.4 0.2 41.1 24.8 21.2
Hispanic Total U.S. 30.3 17.7 10.3 26.0 15.0 8.0 7.9 3.7 2.1 47.2 27.5 21.5
Nonmetro 28.1 21.8 13.9 24.6 19.6 12.5 7.7 5.8 4.3 47.6 31.9 27.0
Metro 30.5 17.2 9.9 26.2 14.4 7.4 7.9 3.4 1.8 47.1 26.9 20.8
Others Total U.S. 15.4 7.6 4.6 14.2 7.2 4.3 1.2 0.6 0.3 36.8 22.1 18.4
Nonmetro 17.8 5.7 3.0 17.3 4.9 2.0 1.7 1.4 0.6 39.9 30.0 20.5
Metro 15.0 8.0 4.9 13.6 7.7 4.7 1.1 0.5 0.3 36.2 20.5 18.0
25–29 All groups Total U.S. 42.3 9.1 3.6 40.2 7.1 2.9 9.5 1.3 0.5 63.9 34.9 31.1
Nonmetro 34.0 3.5 1.8 31.8 3.1 1.5 7.9 0.3 * 61.7 30.6 29.4
Metro 44.1 10.3 4.0 42.1 7.9 3.2 9.9 1.5 0.6 64.4 35.8 31.5
White, NH Total  U.S. 50.3 8.8 2.9 48.3 7.0 2.6 10.5 1.0 0.1 72.8 40.8 36.5
Nonmetro 37.1 2.2 0.7 34.8 2.0 0.7 8.2 0.2 * 65.3 31.1 30.6
Metro 54.0 10.7 3.6 52.2 8.4 3.1 11.1 1.3 0.1 74.9 43.5 38.2
Black, NH Total U.S. 38.6 14.4 7.7 35.5 10.8 5.7 7.0 3.2 2.2 57.8 27.0 24.4
Nonmetro 20.1 6.2 5.7 19.1 5.2 4.7 0.5 * * 56.6 41.0 33.9
Metro 41.1 15.5 7.9 37.7 11.6 5.8 7.9 3.7 2.5 58.0 25.2 23.1
Hispanic Total U.S. 21.3 7.0 3.5 19.1 4.6 1.9 8.6 1.1 0.4 43.7 21.8 18.0
Nonmetro 8.1 4.0 2.8 6.1 1.9 0.7 5.8 1.9 * 29.7 9.6 8.3
Metro 22.6 7.3 3.6 20.5 4.9 2.1 8.9 1.1 0.5 45.1 23.0 19.0
Others Total U.S. 14.4 4.6 1.9 14.0 4.3 1.8 7.9 0.1 0.1 30.4 21.2 20.9
Nonmetro 61.2 35.2 20.8 59.7 33.8 19.3 33.6 0.7 0.7 61.5 39.4 39.4
Metro 10.4 2.0 0.3 10.2 1.8 0.3 5.7 * * 27.8 19.7 19.4
30–44 All groups Total U.S. 49.2 8.9 5.1 47.2 6.2 3.5 18.0 1.5 0.8 72.0 31.3 29.2
Nonmetro 44.2 8.0 3.3 41.5 5.9 2.2 11.8 1.8 0.3 73.6 38.6 37.1
Metro 50.2 9.1 5.5 48.4 6.2 3.7 19.3 1.4 0.9 71.6 29.8 27.5
White, NH Total  U.S. 56.0 9.2 5.4 54.2 6.4 3.6 20.9 1.5 0.7 77.5 31.9 29.5
Nonmetro 46.7 7.3 2.1 44.4 5.1 0.9 12.3 1.9 0.2 74.8 37.6 36.2
Metro 58.2 9.7 6.2 56.6 6.7 4.3 23.0 1.4 0.8 78.2 30.4 27.9
Black, NH Total U.S. 39.1 10.0 5.5 36.2 7.3 3.2 12.3 3.1 2.1 66.4 38.1 37.3
Nonmetro 29.8 7.8 3.8 24.9 4.7 2.6 6.5 2.1 1.1 63.9 37.5 36.8
Metro 41.0 10.4 5.9 38.5 7.8 3.4 13.5 3.3 2.3 66.9 38.3 37.4
Hispanic Total U.S. 25.2 6.5 4.1 21.9 4.3 3.1 8.5 0.3 0.3 53.9 25.0 22.4
Nonmetro 35.1 11.7 10.8 30.5 11.7 10.8 8.4 * * 72.4 50.9 47.4
Metro 24.1 6.0 3.4 20.9 3.4 2.2 8.5 0.4 0.3 51.8 22.1 19.6
Others Total U.S. 25.1 6.3 2.6 25.0 4.4 2.5 8.7 * * 42.4 20.7 20.5
Nonmetro 57.7 41.7 41.3 55.4 40.1 40.1 40.1 * * 96.1 50.3 49.7
Metro 23.5 4.5 0.6 23.5 2.7 0.6 7.1 * * 39.8 19.2 19.1
*Low precision, no estimate reported.
NH: Non-Hispanic.
SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration, Office of Applied
Studies, 1998 public use dataset, 2000a.Drug Use in the General Population
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Hispanic origin of mother
Hispanic origin
Cuban
Central and South American
Mexican American





Table 11. Estimated Percentage of Live-Born Infants’ Mothers Who Reported Smoking































































































































*Includes data for 46 States and the District of Columbia in 1993–1999. Excludes data for California, Indiana, New York (but includes 
New York City), and South Dakota, which did not report tobacco use on the birth certificate.
SOURCES: National Center for Health Statistics, 2000; Ventura et al., 1998–2001.Drug Use in the General Population
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Table 12. Estimated Percentage of Respondents Who Believe That Selected Drugs 
Are Easy to Get for Themselves (Youth and Teens) and by Their Children (Parents), 
by Race/Ethnicity: 1997–2000
Drug and White Black Hispanic
Respondent 1997 1998 1999 2000 1997 1998 1999 2000 1997 1998 1999 2000
Marijuana
Youth
a 19 13 9 N/A 16 10 13 N/A 21 15 18 N/A
Teens
b 60 57 54 54 59 59 57 55 60 56 56 56
Parents
b 27 22 34 25 33 36 42 31 22 34 21 20
Cocaine
Youth
a 14 7 7 N/A 10 7 8 N/A 14 9 14 N/A
Crack
Youth
b 14 9 8 N/A 10 9 8 N/A 13 12 15 N/A
Cocaine/Crack
Parents
b 17 7 16 9 26 26 28 20 14 25 14 13
aEasy
bVery easy
N/A: Not available. As of 2000, youth target is no longer surveyed.
SOURCE: Partnership Attitude Tracking Study, Partnership for a Drug-Free America, 2001.
Drug and White Black Hispanic
Respondent 1997 1998 1999 2000 1997 1998 1999 2000 1997 1998 1999 2000
Marijuana
Youth 80 76 84 N/A 76 76 74 N/A 75 82 73 N/A
Teens 60 61 60 62 58 60 59 59 56 58 56 55
Parents 72 63 63 61 75 64 66 60 71 82 70 67
Cocaine
Youth 82 80 83 N/A 80 79 78 N/A 77 82 73 N/A
Crack
Youth 76 72 79 N/A 80 78 74 N/A 66 75 69 N/A
Cocaine/Crack
Teens 88 87 85 86 74 79 75 77 78 77 79 77
Parents 95 89 92 91 90 86 82 89 88 95 84 79
Inhalants
Youth 61 58 55 N/A 55 54 50 N/A 55 50 51 N/A
Heroin
Youth 58 59 58 N/A 54 51 45 N/A 54 53 46 N/A
Table 13. Estimated Percentage of Respondents Who Associate Danger/Great Risk 
With the Use of Selected Drugs, by Race/Ethnicity: 1997–2000
N/A: Not available. As of 2000, youth target is no longer surveyed.
SOURCE: Partnership Attitude Tracking Study, Partnership for a Drug-Free America, 2001.Drug Use in the General Population
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Table 14. Estimated Percentage of Respondents Who Agree With Selected Statements
About Specific Drugs, by Race/Ethnicity: 1997–2000
aAgree a lot.
bAgree strongly.
cAgree a lot/agree a little.
dAgree strongly/agree somewhat.
N/A: Not available. As of 2000, youth target is no longer surveyed.
SOURCE: Partnership Attitude Tracking Study, Partnership for a Drug-Free America, 2001.
White Black Hispanic
Respondent 1997 1998 1999 2000 1997 1998 1999 2000 1997 1998 1999 2000
Taking drugs scares respondent.
Youth
a 68 70 81 N/A 73 73 75 N/A 59 70 75 N/A
Teens
b 31 29 33 34 44 40 42 38 33 31 28 27
Smoking marijuana is okay sometimes.
Youth
c 13 12 11 N/A 21 13 20 N/A 29 16 19 N/A
Teens
d 19 15 14 15 17 17 13 14 18 16 13 17
Parents
d 24 27 24 35 20 24 19 20 17 16 16 14
If parents use marijuana, their children are likely to use marijuana.
Parents
d 75 70 72 72 56 61 67 55 71 74 79 70
It’s really hard to give my child reasons not to use marijuana.
Parents
d 20 14 15 17 18 21 25 19 28 22 36 13
Don’t want to hang around people who use drugs.
Youth
a 72 75 84 N/A 70 72 78 N/A 66 70 75 N/A
Teens
b 33 28 34 33 44 28 42 41 30 26 30 28
It’s okay to sell drugs to make money.
Youth
c 65 N/A N/A 10 9 N/A N/A 14 9 N/A N/A
Teens
d 21 19 17 17 31 31 26 27 27 25 24 2459
This chapter presents data on drug use among minority youth, including age at first use; prevalence of lifetime,
past-month, and past-year use; and longitudinal trends in prevalence of drug use. It also includes a special section
on drug use among American Indian youth. As described in Chapter 3, the lifetime prevalence estimates convey
“cumulative occurrence” of drug taking within the survey population, answering such questions as, “What 
proportion of the population has become an illegal drug user?” In comparison, the past-month estimates answer
questions such as, “What proportion has been a recently active illegal drug user?”, with recently active use
defined in terms of the 1-month interval up to and including the day of the assessment.
The most extensive surveys of drug use among U.S. adolescents have been completed as part of the National
Household Survey on Drug Abuse (NHSDA), described in Chapters 1 and 3, and as part of the Monitoring
the Future (MTF) study sponsored by the National Institute on Drug Abuse (NIDA), already described in
Chapter 1. These surveys provide some of the best data available for prevalence estimates of drug use among
young people in this country. Each surveillance tool has its own strengths and limitations. For example, in theory,
the NHSDA sample encompasses truants and dropouts, who are included within the population definition but
may be missing from the sampling frame. By comparison, dropouts are not included in the population definition
for the MTF study, which samples schools, classrooms within schools, and students within classrooms. Truants
are included within the population definition for the MTF study, but they may not be present on the day or
days of classroom assessment via self-report standardized questionnaire. Also contained in this chapter are data
from the Youth Risk Behavior Survey (YRBS), the National Longitudinal Survey of Youth (NLSY), and surveys
of American Indian/Alaska Native students and dropouts, which have been conducted by the Colorado State
University Tri-Ethnic Center for Prevention Research. Each of these studies has the strengths and limitations
noted with the NHSDA and the MTF investigations.
Recent estimates for the age-specific incidence of various drugs help shed new light on recent trends in drug
taking among youth in the United States. For example, based on a retrospective method for modeling past and
recent risk of starting to use marijuana, the NHSDA research team has estimated that the risk of starting to
smoke marijuana increased sharply during the 1960s. For youth ages 12–17 in 1965, the estimated risk of
becoming a new marijuana smoker in that year was just under 1 percent. By 1969–1970, the risk for this age
group had increased to about 3.3 to 4.9 percent per year. Thereafter, there were sustained increases in the risk
of starting to smoke marijuana from 1970 onward, with peak values of about 8 percent per year during the last
few years of the 1970s. Subsequently, the rate dropped to 4.3 to 4.5 percent per year for youth ages 12–17 in
the early 1990s—a reduced level not seen since the late 1960s. During the 1990s, these risk estimates again
increased, with the risk among this group about 8.8 percent in 1996. The 1996 risk estimate is larger than any
other value estimated in the series, and it was followed by risk estimates of 8.5 to 8.7 percent per year in 1997
and 1998 (Substance Abuse and Mental Health Administration 2001a).
Although these estimates are subject to the limitations of the NHSDA data and the retrospective method for
risk estimation, these are the best available epidemiological estimates for risk of becoming a marijuana smoker
in the United States. In addition, recent MTF estimates for the cumulative occurrence (lifetime prevalence) of
cocaine use among 8th-, 10th-, and 12th-graders also show increases between 1995 and 1998 (Johnston et al.
2001). The observation that youth ages 12–17 now may be experiencing record high levels of risk for becoming
marijuana smokers deserves our attention. It is possible that the retrospective method overstates the risk in the
most recent years of any given series. Nevertheless, even if the estimate is off by 10 percent or even 25 percent,
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substantial risk exists for becoming a marijuana smoker during adolescence, with levels of risk corresponding to
values estimated for the United States during the military conflict and war in Vietnam.
The same analytical procedures have been applied to the NHSDA data on cocaine, with similar provocative
results. For example, for youth ages 12–17 alive in the mid-1970s who participated in subsequent NHSDA
assessments, the risk of becoming a new user of cocaine is estimated to have been about 5 to 6 new users 
per 1,000 youths per year (Substance Abuse and Mental Health Administration 2001a). Peak levels of risk for
becoming a cocaine user during these adolescent years were observed between 1977 and 1989, with estimated
values between 7 and 11 new cocaine users per 1,000 youths per year, followed by a trough year of 4 to 5 new
users per 1,000 youths in 1991. During the 1990s, the estimated risk values have been increasing and now are
above 10 per 1,000 youths per year (i.e., 1 percent per year). For example, the risk estimate for 1997 is 13 new
cocaine users per 1,000 youths ages 12–17, and the risk of becoming a new cocaine user in 1998 is estimated as
14 per 1,000 per year (i.e., 1.4 percent per year). This apparent return to levels of risk last seen during the 
epidemic of the 1980s poses a challenge for new epidemiological investigation. If the estimation procedure is
valid, it is conveying information that signals a need for renewed public health action oriented toward cocaine.
Marijuana and cocaine are not the only two drugs showing recent increases in risk of initiation. For example,
in 1998, the estimated number of new users of hallucinogens among youth ages 12–17 is just over 650,000,
corresponding with an estimated risk of 2 to 3 percent per year. This estimate is four to five times greater than
the corresponding risk estimate for the “flower power” years of the late 1960s, and the risk level has doubled
since the late 1980s. Risk estimates for becoming a new illegal user of stimulant drugs in adolescence now are
at about one-half the level of risk of becoming a new user of hallucinogens (Substance Abuse and Mental Health
Administration 2001a).
These risk estimates convey values that were developed for the entire U.S. population and may not hold for all
subgroups within the population. For example, Gfroerer and Brodsky (1992) used NHSDA data and a similar
analysis methodology to estimate the risk of becoming a new cocaine user between 1976 and 1989, producing
separate estimates for non-Hispanic Whites, non-Hispanic Blacks, and Hispanics in the United States, already
presented in Figure 4 in Chapter 3. As depicted in that figure, Gfroerer and Brodsky (1992) observed that, for
Whites, the number of new initiates reached a peak in the early 1980s, while the number of new Black and
Hispanic initiates did not peak until later in the 1980s. Hence, the national epidemic of cocaine use in the
United States really may be subdivided into different experiences, with an earlier epidemic trend and peak for
White Americans and a later peak for Blacks and Hispanic Americans.
Because initiation of illegal drug use, alcohol, and tobacco smoking tends to occur during adolescence, NHSDA
and the MTF study assume crucial importance as we seek to monitor and understand the drug experience of
the U.S. population (Kandel and Logan 1984; Wagner and Anthony 2002; Substance Abuse and Mental Health
Administration 2001a). From a social and public health perspective, it also is important to monitor the trends
and patterns of drug use among youth because of links with other problem behaviors, including deviant and
delinquent activities (e.g., vandalism and starting fights), maladaptation within the family and in school, truancy,
and school dropout. For many youth, drug use becomes part of a more general clustering or syndrome of 
maladaptive behavior that involves conduct problems, failure at school, precocious sexual activity, unsafe sex and
other unhealthy behaviors, and affiliation with other deviant and other drug-using peers (e.g., see Jessor 1998) 
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AGE AT FIRST USE
A great many drug users begin using drugs before age 14 and almost all illegal drug use starts before age 35.
NHSDA estimates for the average (mean) age at first use of tobacco cigarettes, alcohol, marijuana, and cocaine
for adolescents ages 12–17 during selected years between 1991 and 1998 are presented in Table 15. Trends in
the average age of first use were similar across all racial/ethnic groups examined. Although the estimates fluctuate,
year-to-year variation in age at first use for these drugs has been relatively modest.
Comparison of age of first use by type of drug indicates average age at initiation for tobacco cigarettes rose 
modestly from 1991 to 1998 for all race/ethnicity groups shown in the table. For example, among White youth,
the mean age for starting to smoke tobacco cigarettes was estimated as 11.4 years old in 1991 and as 12.3 in
1998. Corresponding values for Black youth are 11.3 and 12.8; for Hispanic youth, the estimates are 12.0 and
12.7 (Table 15).
The mean age at first use of alcohol and the mean age for first use of marijuana showed relative stability and no
more than modest increases over this period for all race/ethnicity groups under study (Table 15). To some
extent, this stability is a function of studying a broad age range (ages 12–17) over short intervals (e.g., 1 to 2
year intervals). The populations of youth under study overlap considerably. For example, a 12-year-old in 1992
becomes a 13-year-old in 1993 and remains eligible for inclusion in the population as a 17-year-old in 1997.
This degree of continuity in the birth cohorts represented in each year of the survey tends to yield a relatively
stable estimate for the mean age of initiation of drug use, even when individual respondents are excluded from
participation in successive years of the survey.
The mean age of cocaine use has been relatively stable during the 1990s. However, coupled with the above-
mentioned increased risk of starting to use cocaine during the late 1990s, the slight decline in mean age of first
cocaine use for 1997 and 1998 may represent more than a random fluctuation around a grand mean. If the risk
estimates are correct for youth ages 12–17, there may be an actual trend toward declining mean age of first
cocaine use. This recent trend of declining mean age of first cocaine use has been described for the total
NHSDA survey population in its most recent series of reports (e.g., see Substance Abuse and Mental Health
Administration 2001a). 
The observed mean age of 13 years for Black adolescents in 1998 represents a sharp drop and may be a signal
of a changing dynamic of cocaine use in this population, when considered against a backdrop of relatively stable
estimates between values of age 14.0 in 1991 and age 14.3 in 1997. New values from more recent NHSDA data
will be needed to evaluate this possible trend, but public use datasets for NHSDA 1999 and 2000 are not
expected to be available until late 2002 or 2003.
PREVALENCE TRENDS
This section presents prevalence trends for estimated cumulative and recent occurrence of illegal drug use, alcohol
use, and tobacco cigarette smoking among minority youth. Data are for secondary school students, American
Indian/Alaska Native youth, and youth ages 12–21.
School-Attending Youth
The MTF Study, funded by NIDA, is a nationally representative cross-sectional sample survey of school-
attending youth in the United States, administered to 8th-, 10th-, and 12th-graders, with longitudinal followup
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of subsamples as these students progress into the college years and young adulthood. One of the major purposes
of the survey is to develop an accurate picture of drug use and related attitudes and behaviors among youth
(Johnston and O’Malley 1997; Johnston et al. 2001). Data presented in this report are from the MTF cross-
sectional surveys only.
Examination of racial/ethnic variations in MTF estimates for 2000, presented on the first page of Table 16, tend
to indicate that Hispanic 8th-graders are more likely to have started using marijuana, inhalants, LSD, other 
hallucinogens, and cocaine than are 8th-grade non-Hispanic Whites or Blacks (Table 16, first page). Among
12th-graders, Hispanic students are more likely to have started to use marijuana and cocaine, but the excess
cumulative occurrence of use is not observed for inhalants, LSD, or other hallucinogens. As depicted in the last
row of page one of Table 16, there is a slight tendency for Hispanic students to be more likely to be daily 
marijuana users, but the numerical excess is seen only for 8th-graders and 12th-graders, and these estimates may
be too imprecise for definitive interpretation.
Consistent with findings from NHSDA, as reported in Chapter 3, the MTF estimates for Black students show
generally lower values for all drugs except marijuana. For example, Black students are less likely to have become
cocaine users (“lifetime prevalence”), to have used in the year leading up to and including the date of the 
survey (“annual prevalence”), and to have used in the month leading up to and including the date of the survey
(“30-day prevalence”). By comparison, Black and White students have roughly comparable estimates for preva-
lence of marijuana use, whether the focus is on the lifetime experience (23.8 percent versus 19 percent among
8th-graders), the past year (16.1 percent versus 14.9 percent among 8th-graders), the past month (9.3 percent
versus 8.4 percent among 8th-graders), or daily use (1.0 percent versus 1.2 percent among 8th-graders), as
depicted in the first column of Table 16. Where differences emerge between the racial/ethnic groups for 
marijuana, the largest values tend to be observed for Hispanic students and the smallest for Black students.
With inhalant drug use, White and Hispanic students tend to have generally comparable prevalence estimates;
Black students have comparatively lower prevalence estimates. For example, among 8th-graders, an estimated
19.9 percent of Whites, 23.1 percent of Hispanics, and only 10.5 percent of Black students have tried inhalant
drugs. The same general pattern is seen for inhalant drug use among the 10th- and 12th-graders (Table 16, 
first page, columns 4–6). A similar pattern is seen for LSD and other hallucinogenic drugs, with Whites 
and Hispanics having larger and more similar values, and with Black students tending to have lower values
(Table 16, first page, columns 7–12).
Scanning across the lifetime or cumulative occurrence estimates for the different grade levels for each drug, there
is a tendency for the estimates to increase across grades 8 to 10 to 12. To some extent, the same is true for the
estimates of recently active drug use (i.e., use in the month prior to survey). An important exception is the
inhalant drug use group, which remains relatively stable from grade to grade, perhaps because inhalant drug use
in 8th grade is associated with dropping out of school or more frequent truancy by 12th grade. That is, students
who start to use inhalant drugs in high school may be especially more likely to drop out or to be truant than
other students in Grades 10 and 12; this association would contribute to a relative stability in the grade-specific
estimates for inhalant drug use.
Table 16 (second page) reports MTF estimates on crack-cocaine, cocaine other than crack, heroin, other opioid
drugs (e.g., morphine, codeine), and stimulant drugs. Here again, evidence exists of greater prevalence among
Hispanic and White youth for use of crack-cocaine and other heroin, and to some extent for heroin and other
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opioids, and stimulants; Black students have lower values at virtually every grade level. By grade 12, stimulants
become more prevalent among White than Hispanic students. Of note, an estimated 18.2 percent of White
12th-graders have tried stimulants at least once; the corresponding estimates for Blacks and Hispanics in 12th
grade are 4.9 percent and 15.1 percent, respectively.
Table 16 (third page) conveys the same general pattern. However, for barbiturate drugs (sleep preparations and
calmatives) and for tranquilizers, White 12th-graders tend to have larger prevalence estimates than Hispanic
youth, and Black seniors have the lowest prevalence values of the three groups. Prevalence estimates for Whites
and Hispanics are more similar for alcohol, for having been drunk, and for drinking five or more drinks on an
occasion (sometimes called “binge drinking”). For example, an estimated two-thirds of White and Hispanic 
seniors have been drunk at least once in their lifetimes. By comparison, the corresponding value for Black 
seniors is 40.9 percent. One hypothesis about this finding is that Black students who get heavily involved with
alcohol or other drugs are more likely than White and Hispanic students to drop out of school or become 
truant. However, the lower prevalence values also are seen for 8th-graders when truancy and dropout have
started to occur, but are less prominent as a cause of school absence on the day of a school survey. Until there
is evidence that drug-associated truancy and dropout problems exert a differentially greater influence on Black
8th-graders than on other 8th-graders, the observed lower prevalence of drug use among Black students merits
careful evaluation. Protective or resiliency conditions and processes among Black adolescents can be identified,
and it may be able to harness the evidence in prevention and intervention programs tailored specifically to this
important minority population, especially if the programs also can retain Black students through graduation
(Crum and Anthony 2000).
Data on daily tobacco cigarette use indicate that among 12th-graders, an estimated 25.7 percent of Whites
smoke daily, compared with 15.7 percent of Hispanic seniors and 8.0 percent of Black seniors (Table 16, fourth
page). The origins of the greater prevalence of daily smoking among White and Hispanic seniors may be seen
in the cumulative occurrence or lifetime prevalence estimates in the first row and first column of Table 16
(fourth page). For example, between 8th and 12th grade, a stronger association between race/ethnicity and risk
of starting to smoke tobacco emerges, with greater increases as we look from grade to grade for Whites and
Hispanics—among seniors, two-thirds of these students have started to smoke. In contrast, the risk of starting
to smoke apparently remains at lower levels for Black students, with occurrence of tobacco smoking remaining
below 50 percent even in 12th grade.
Smokeless tobacco use is most prevalent among White students, with Hispanics in an intermediate position.
Again, Black students are least likely to use this drug. An estimated 4.3 percent of White students have become
daily smokeless tobacco users by 12th grade. Corresponding estimates for Hispanic and Black seniors are below
1 percent.
By comparison, the pattern for steroid use follows that seen for other drugs, with both Whites and Hispanics
sharing higher prevalence values (e.g., lifetime prevalence of 2.8 percent to 3.4 percent among 12th graders).
Blacks are substantially less likely to have started to use steroids (1.3 percent by 12th grade).
Long span trend estimates for occurrence of drug use among high-school seniors are shown in Figures 5–9,
with distinctions between non-Hispanic Whites and Blacks, Hispanics, and a “Total” category. These long span
trend estimates are not available for 8th- and 10th-graders because MTF surveys of those grades did not start
until 1991.
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The long span trend data help sustain some of the general impressions gained from the numerical estimates 
presented in Table 16. For example, the generally lower prevalence values for Black seniors were present in the
earliest MTF surveys during the 1970s and have been sustained to the present. Indeed, for trends in prevalence
of daily tobacco cigarette smoking, the separation between Whites and Blacks has increased. In the late 1970s,
Hispanic seniors were less likely to have become and remained daily tobacco smokers, but in the early 1980s,
the curve crossed when daily smoking became more common among Hispanics than Whites (Figure 5). 
To some extent, these long span trend data on daily tobacco smoking are congruent with recent reports from
the Surgeon General’s office, which have noted that cigarette smoking prevalence increased in the 1990s among
African American and Hispanic youth after some years of substantial decline (U.S. Department of Health and
Human Services 1998). This increase, the report states, “is particularly striking among African American youth,
who had the greatest decline of the four groups during the 1970s and 1980s” (p. 6). The prevalence of cigarette
smoking among African American adolescents in the 1980s and 1990s has been lower than the prevalence
among any other racial/ethnic group (see Table 17). Also of note in the MTF data is that American
Indian/Alaska Native 12th-graders had the highest prevalence of tobacco cigarette smoking between 1976 and
1994, whereas Asian Americans/Pacific Islanders had the second lowest prevalence rates (Table 17). Data from
the Youth Risk Behavior Surveillance System (YRBSS) of the Centers for Disease Control and Prevention
(CDC) show similar patterns for the long decline of prevalence of cigarette smoking with recent increases
among African Americans compared with other racial/ethnic groups; similar patterns are evident with the other
minority groups mentioned above (data not shown in a table). 
Figure 6 shows generally parallel trends for Whites, Hispanics, and Blacks. However, for many years between
the late 1970s and the late 1980s, White seniors were more likely than Hispanic seniors to have become and
remained marijuana users. This situation changed in the early 1990s, with generally comparable prevalence
estimates for Whites and Hispanics during the last decade of the 20th century. By 1999, the marijuana preva-
lence estimates for Hispanics had become numerically larger than the estimates for non-Hispanic Whites, but
the observed estimates actually are not appreciably different from one another.
Figure 7 offers an interesting epidemiological puzzle. First, the observed low prevalence values for inhalant drug
use among Black seniors deserves scrutiny until we understand why inhalant drug use has not taken hold in this
segment of the U.S. population. Second, Hispanic seniors started with inhalant prevalence estimates lower than
those of non-Hispanic Whites in the late 1970s; however, during the intervening years, they lost and regained,
then again lost and regained the advantage associated with lower inhalant prevalence values. The size of the
observed differences between Whites and Hispanics generally is too great to explain as a manifestation of impre-
cision in the estimates. Some other explanation is needed.
To some extent, the trend data on prevalence of recently active cocaine use reflect the epidemiological experience
described above, with earlier peaks in the cocaine epidemic affecting non-Hispanic Whites and later peaks for
non-Hispanic Blacks and Hispanics. In the most recent years of the MTF data series, there are signs of increasing
prevalence of cocaine use among the two minority group populations of seniors, but these signs are not present
for non-Hispanic White seniors (Figure 8). These estimates do not contradict the NHSDA risk estimates for
cocaine in recent years. Whereas the NHSDA research team has completed analyses to focus attention on a 
possibly increasing risk of starting to use cocaine in recent years, the MTF estimates shown in Figure 8 are for
occurrence of recently active cocaine use (i.e., not for risk of becoming a cocaine user, but for probability of
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using cocaine in the recent past). This distinction between risk of becoming a drug user and probability of being
a drug user is a crucial distinction in drug dependence epidemiology (e.g., see Anthony and Helzer 1995).
Figure 9 depicts the estimated probability of being an LSD user and shows a now-familiar pattern of relatively
low prevalence estimates for non-Hispanic Black seniors. There were unstable fluctuations in the prevalence esti-
mates for Hispanic seniors in the late 1970s and early 1980s. Since then, non-Hispanic White seniors have been
more likely to use LSD than their Hispanic counterparts. However, evidence exists of increasing comparability
of the prevalence estimates for non-Hispanic White seniors and Hispanic seniors during the last years of the
20th century.
Figure 10 summarizes the prevalence of any illegal drug use among high-school seniors from 1977 through
2000, with estimates showing that the probability of being an illegal drug user is least likely for Black seniors.
Hispanic seniors, for a time, were less likely than non-Hispanic White seniors to be illegal drug users, but this
difference between non-Hispanic Whites and Hispanics disappeared in the early 1990s, for reasons that remain
unknown and understudied.
Data on trends in drug use for 8th- and 12th-graders are presented in Table 18, with separate estimates for boys
and girls and for racial/ethnic minority status. The prevalence of tobacco cigarette smoking among 12th-graders
fluctuated throughout the 1980–2000 survey period for females, increased since the early 1990s for males and
for Whites, and first declined and then increased for Blacks. Among 8th-graders, there is some evidence of a
possibly promising decline (or random fluctuation) in the final years of the 20th century.
Values for prevalence of marijuana use presented in Table 18 show the previously mentioned increases during
1990s. Fluctuations observed between 1998 and 2000 are so small as to be uninterpretable. It is of interest that,
among 8th-graders, both males and females and Whites and Blacks have prevalence estimates of about 14 to 
17 percent in 2000, versus corresponding values of roughly 14 to 20 percent in 1996. By comparison, among
12th-graders in 2000, the estimates are almost double these values and fall in a range of 30 to 40 percent.
Though subject to attrition (e.g., due to dropping out of school), the 8th-graders of 1996 became the 
12th-graders of 2000, and in the process the prevalence of marijuana use more than doubled for each group
except females. The estimate for female 8th-graders in 1996 was 16.9 percent and among female seniors in 
2000 had risen to 33.4 percent (Table 18).
Estimates for prevalence of being a student cocaine user shown in Table 18 do not reflect the previously men-
tioned apparent recent increases in risk of becoming a cocaine user among noninstitutionalized U.S. residents
ages 12–17. The observed variation in the MTF cocaine prevalence estimates over the past several years is rather
small, relative to fluctuations over the prior span of more than a decade. Whereas the senior class of 2000 had
marijuana prevalence values double between 1996 (when they were 8th-graders) and the time of the MTF 
survey in their senior year, the magnitude of cocaine use was somewhat smaller and substantially less than a 
doubling for Blacks in the graduating class of 2000. This process may reflect greater attrition of cocaine-using
Blacks during high school, but we have no definitive evidence on this research issue.
Some promising trend data on prevalence of inhalant drug use may be seen in Table 18 (second page). From
1996 to 2000, inhalant prevalence estimates generally declined for males and females and for Whites. The
inhalant prevalence estimates for Blacks are quite low, which makes detection of declining trends quite difficult.
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Table 18 reveals no recent striking increases nor decreases in prevalence of alcohol use. The pattern for so-called
“binge drinking” (five or more drinks on a single occasion) also is quite stable in recent years.
MTF data have also been analyzed to explore possible interactions between tobacco smoking among African
American and White youth and use of alcohol and other drugs. Table 19 shows that between 1976 and 1994,
the percentage of African-American 12th-graders who did not use tobacco cigarettes or illegal drugs in the pre-
vious month was higher than for White 12th-graders and increased more rapidly in every category of drug use.
Trends in the use of tobacco cigarettes, alcohol, and other substances among 12th-graders indicate that among
smokers and nonsmokers, African Americans were generally less likely than Whites to use drugs other than
tobacco cigarettes. Furthermore, concurrent use of tobacco cigarettes and other illegal drugs was lower and
showed greater declines for African-American 12th-graders than for White 12th-graders between 1976 and 1994.
CDC’s ongoing YRBSS, mentioned earlier in this chapter, monitors health risk behaviors among youth and
young adults, including their use of alcohol, tobacco, and other drugs. YRBSS includes a national school-based
survey conducted by CDC, in addition to surveys conducted by individual State and local education agencies.
Estimates from the 1999 YRBSS are presented in Table 20, with values for individual drugs and separate estimates
for boys and girls, race/ethnicity groups, and age groups. With use of alcoholic beverages and several other
drugs, the pattern from the YRBSS prevalence data resembles the pattern from the MTF data, with Whites and
Hispanics most often having the higher prevalence estimates and Blacks having lower prevalence values. For
example, among male students 18 and older, the estimated cumulative occurrence of alcohol use in their life-
time is close to 90 percent for Whites and Hispanics and close to 70 percent for Blacks. A similar pattern also
is seen for cocaine among male and female older students. Here also, we see that prevalence of cocaine use is
lower for Black students than for Whites and Hispanics, both males and females, at each of the three age levels.
The pattern is somewhat different for marijuana, with roughly equivalent estimates for Whites and Blacks
among the older students, but with a male-female difference in prevalence of use (Table 20). For example, the
prevalence estimates for cumulative occurrence of marijuana use are 65 to 66 percent for White males and Black
males, but are 51 to 52 percent for White and Black females. The corresponding estimate for Hispanic males is
about 60 percent (lower than the values for the other males) and for Hispanic females it is 53 percent (roughly
comparable to the values for the other females).
Male-female differences are present for virtually all of the drugs considered in Table 20, except in the estimates
for recently active alcohol use and for recently active cocaine use among the oldest students. For recently active
alcohol use among these students, there is a modest male-female difference for Whites, essentially no difference
for Blacks, and a male excess for Hispanics. For recently active cocaine use, there is a modest male-female 
difference for Whites, a possible female excess for Blacks, and a male excess for Hispanics. As discussed above
in relation to the MTF studies, it is possible that cocaine use is more prominent as a determinant of dropping
out of high school for Blacks than for other racial/ethnic groups. Cocaine use also may be more prominent as
a determinant of school dropout for Black male students than for female Black students. 
American Indian/Alaska Native Students
Since 1975, the Colorado State University Tri-Ethnic Center for Prevention Research, with support from NIDA
grant awards has conducted an ongoing survey of American Indian/Alaska Native students in grades 7–12
enrolled in Indian reservation schools. Results from the 1975 through 1997–1998 school year surveys are 
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provided in Tables 21–23. In addition, estimates from more recently conducted surveys and a substudy of
American Indian/Alaska Native school dropouts have been incorporated into these tables.
Although prevalence estimates for drug use have tended to be larger for American Indian/Alaska Native youth
on reservations than for non-Indian youth, the general trends in both groups have been parallel over the last 
several decades. A pattern of large increases in the late 1970s, a leveling off in the 1980s, and modest declines
in the 1990s has emerged for both American Indian and non-Indian youth. However, among non-Indian 
adolescents, there has been a general trend of increasing drug use, especially marijuana use, since 1992 (National
Institute on Drug Abuse 1998). During the mid-1990s, it appeared that American Indian/Alaska Native youth
on reservations might be spared this general trend, but more recent data suggest otherwise.
For example, as shown in Table 21, there has been a declining trend in the proportion of reservation American
Indian/Alaska Native youth who have started drinking alcohol (Table 21, row 1). However, the value of 
69-percent prevalence for marijuana use, observed during the 1996–1998 surveys, suggests a possible increasing
trend seen in marijuana use, in tandem with the previously mentioned increasing trend in general population
statistics.
Cumulative occurrence for many drugs in this survey showed peak values in 1980–1981 with subsequent
declines through the mid-1990s. An exception to this pattern was for use of psychedelics, which showed
increases from the early 1980s to the early 1990s and has remained relatively high, with prevalence estimates in
a range from 19 to 22 percent since 1991–1992.
As with other school-based surveys, drug use information from this survey of American Indians/Alaska Natives
is affected by school dropouts, and it is acknowledged that dropouts as a group may have more social and adap-
tational problems, including problems associated with drug use. Estimates for reservation-dwelling American
Indians/Alaska Natives suggest especially large school dropout rates. Although these dropout estimates are sparse
and highly variable, Beauvais et al. (1995) developed a method to correct the drug use prevalence estimates by
taking into account a 50-percent school dropout rate. The estimates in the last column of Table 21 include an
attempted correction for the drug use of school dropouts. To strengthen these estimates, Tri-Ethnic Center
investigators, including Beauvais, surveyed a sample of American Indian high-school dropouts. Their drug 
use experiences were assessed, and the results of this assessment have been weighted into a correction for the
prevalence estimates from the 1992–1994 surveys. As seen in comparing the last column of Table 21 with the
third-to-last column, the net effect of this correction for school dropouts is generally an increase in the estimated
prevalence values.
Table 22 compares estimates from the survey of reservation-schooled American Indian/Alaska Native students
with corresponding estimates from the MTF surveys for 1997–1998. Alcohol and marijuana show a somewhat
similar pattern across the grades under study. In 8th and 10th grade, the American Indian/Alaska Native youth
have larger prevalence estimates for drinking alcoholic beverages and alcohol intoxication than the non-Indian
youth surveyed in the MTF study, but in 12th grade the estimates for American Indian/Alaska Native and 
non-Indian seniors are roughly comparable. For virtually all of the other drugs considered, cumulative occurrence
(“lifetime prevalence”) was greater for American Indian/Alaska Native youth than for their non-Indian student
counterparts in the MTF survey. For example, an estimated two-thirds of the American Indian/Alaska Native
youths had started to smoke marijuana when they were surveyed in 8th grade; the values for 10th-graders and
12th-graders are 82 percent and 74 percent, respectively. The corresponding marijuana estimates for non-Indian
students are 23 percent, 42 percent, and 50 percent.
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The comparison for inhalant drugs may challenge a preconception about glue or gasoline sniffing on the reser-
vations. For example, among 8th-graders, non-Indian students are more likely than Indian students to have
started using inhalant drugs (21 percent versus 14 percent), and the same is the case for 10th-graders. It is only
in 12th grade that the American Indian/Alaska Native students are more likely that the non-Indian students to
have started using inhalant drugs (16 percent for Indian youth, 10 percent for non-Indian youth).
The cocaine experience of the American Indian/Alaska Native students also may challenge preconceptions. In
1997–1998, an estimated 20 percent of the reservation-dwelling students had tried cocaine, whereas only 9 percent
of the non-Indian seniors had done so. Similar differences are present in the estimates for cocaine use among
8th- and 10th-graders.
Striking differences also appear for both tobacco cigarettes and smokeless tobacco. In 8th grade, an estimated 
79 percent of American Indian/Alaska Native youth had started to smoke tobacco, compared with 47 percent of
non-Indian students. In 12th grade, an estimated 75 percent of the American Indian/Alaska Native seniors had
started to smoke tobacco, compared with 65 percent of non-Indian seniors. The pattern for smokeless tobacco
is comparable, with about 45 percent of the American Indian/Alaska Native 8th-graders having started to use
smokeless tobacco. By comparison, estimated cumulative occurrence for non-Indian students is only 17 percent.
Table 23 presents time trends in estimated cumulative occurrence of drug use among American Indian/Alaska
Native 4th- and 6th-graders. In 1980–1981, an estimated one-third of these students had tried alcohol. A sharp
decline occurred between 1981 and 1987, with no more than modest declines to 17 percent through 1994,
when the last survey of these grades was completed. The epidemiological pattern for marijuana is somewhat 
different, with sustained declines from 23 percent in 1980–1981 to 7 percent in 1992–1994. By comparison,
there has been little change in the estimates for use of inhalant drugs or tobacco cigarettes among students in
grades 4–6.
LONGITUDINAL TRENDS
Table 24 presents estimates on drug use for a cohort of young adults participating in NLSY (Bureau of Labor
Statistics 1996). To control for potential attrition effects, only those respondents remaining in the 1994 sample
were used for the analysis of all 4 years. Additionally, calculation of estimates for cumulative occurrence of 
drug use during the lifetime of these youths was achieved by summing the drug use reported for each of the 
survey years.
The table shows the estimated proportion of NLSY participants who had started to use marijuana in their life-
times, as well as prevalence estimates for more recent intervals, for non-Hispanic Whites, non-Hispanic Blacks,
and “Other” race/ethnicity groups. Between 1984 and 1994, the study population generally exhibited declines
in estimated 1-year prevalence of marijuana use (i.e., use in the year up to and including the date of assessment).
Between 1992 and 1994, some evidence emerges of increasing prevalence of marijuana use among non-
Hispanic African Americans. Prevalence of recently active marijuana use (use in the month before assessment)
tended to decline over the interval.
By studying the successive reports of individuals in the longitudinal sample, it was possible to ascertain that most
of the participants in the sample had started to use marijuana before or during 1984. For example, an estimated
66.5 percent of non-Hispanic White members of the study population had started marijuana use by the time
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of the assessment in 1984. Reassessed in 1994, an estimated 77.9 percent had started marijuana use. Roughly
14 percent of the marijuana users identified in 1994 had started since 1984, and the remainder had started in
1984 or before.
Table 24 also presents corresponding estimates for cocaine use. The estimated proportion using cocaine showed
declines for non-Hispanic Whites for the 1984–1992 period but a modest increase from 1992 to 1994. Among
African-American youth, there were increases in prevalence of cocaine use to 1988, a modest decline in 1992,
and a modest increase in 1994. Estimated cumulative occurrence of cocaine use doubled between 1984 and
1994 for non-Hispanic Whites and “Other” groups and tripled for non-Hispanic Blacks.
SUMMARY
Estimates from NHSDA help clarify that the risks of starting illegal drug use, alcohol use, and tobacco cigarette
smoking are concentrated during the adolescent and young adult years. NHSDA estimates provide new infor-
mation about the risks of starting to use each drug of interest during adolescence. The most recent evidence
indicates recent increases in risk of starting to use these drugs, with risk estimates as large or larger than have
ever been experienced since the 1960s—possibly with larger values than ever before in U.S. history.
The risk of starting illegal drug use and the probability of being an illegal drug user have not been constant over
the time spans examined in this chapter. The ebb and flow of the estimates reminds us that drug-taking behavior
represents a dynamic phenomenon. We appear to be entering a period of increased risk for youthful drug 
taking, with increasing numbers of new initiates for several different drugs during the last years of the 
20th century. One of the emerging trends involves initiation of LSD and other hallucinogen use (e.g., ecstasy).
If confirmed, these findings have important implications as plans are laid for prevention and intervention activ-
ities. In addition to validating the NHSDA risk estimation methodology, it will be important to study these
recent risk estimates for racial and ethnic minority groups. This chapter’s NHSDA estimates for becoming a
new illegal drug user are for the total population of civilian noninstitutionalized adolescents ages 12–17 in the
United States and are dominated by the experiences of non-Hispanic White adolescents. If we generalize from
epidemiological patterns for incidence of cocaine use between 1975 and 1990, as depicted in Figure 4, the
observed recent increases in risk of starting illegal drug use during adolescence may now be limited to non-
Hispanic White adolescents. If there is to be a new increase in risk of illegal drug use for the adolescent
racial/ethnic minority population groups in the United States, there may be a lag of several years before that
increase can be perceived in the national-level NHSDA statistics.
MTF estimates clarify changing epidemiological patterns in the prevalence of drug use among students, with
estimates for Hispanics substantially increasing and decreasing since the late 1970s, relative to estimates for non-
Hispanic Whites. Nonetheless, the most recent estimates indicate that non-Hispanic Whites and Hispanics
often have larger prevalence estimates, with non-Hispanic Blacks having lower prevalence estimates for many
illegally used drugs, alcohol, and tobacco.
Comparisons of drug use data for 8th-graders versus recent high-school seniors indicate dramatic increases 
during the school years, even when some drug users drop out of school and are surveyed in 12th grade. By 8th
grade, many students already have started to use alcohol, tobacco, and other illegal drugs, and between 8th and
12th grade, the prevalence of use often doubles or almost doubles. These increases are seen for each of the
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racial/ethnic groups under study, despite almost certain associations between use of these drugs, truancy and
other forms of school absenteeism, and dropping out of school.
Epidemiological studies of American Indian/Alaska Native youths in reservation schools have been completed
in parallel with the MTF studies for the entire Nation. These American Indian/Alaska Native surveys highlight
two epidemiological features. First, this racial/ethnic group may be at especially increased risk of drug involve-
ment, and there is special concern that early drug use may be associated with dropping out of school. Second,
trends in drug use among American Indian/Alaska Native students tend to be responsive to the broader influences
on trends in drug use for the rest of adolescent society in the United States. The trends for this minority group
may lag somewhat behind the more general trends. Nonetheless, the general impression is one of parallel or
slightly lagged trends, and for many drugs, an excess prevalence of use among the American Indians/Alaska
Natives who attend schools on reservations. When the American Indian/Alaska Native estimates are analyzed
with a method to correct for school dropout, the prevalence estimates become larger after the correction.
During the first half of the 21st century, changing demographic, social, economic, and family circumstances are
likely to have profound influences on the epidemiological patterns of drug experiences of young people in the
United States. The social and family circumstances of African-American youth changed markedly during the
last half of the 20th century, young African Americans disproportionately exhibit sustained troubling patterns
of arrest for drug-related crimes, conviction, and incarceration. Over the next several decades, social and family
circumstances for young Hispanics will change dramatically, while Hispanic Americans become increasingly
numerous and prominent within our Nation’s minority populations. If recent trends continue, contrasts
between the “haves” and the “have nots” will be more prominent and will affect all population groups, including
these racial/ethnic minority groups. If we are to understand the drug experiences of young people, and the links
between illegal drug use and health disparities affecting racial/ethnic minorities, it will be important to improve
our epidemiological surveillance operations for the methodological and measurement issues mentioned in this
chapter and in Chapter 3. It also will be important to sustain and strengthen research projects with specific, 
targeted research aims intended to probe these linkages in more detail than can be achieved via analyses of 
epidemiology’s surveillance data.
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Table 15. Estimated Average Age of First Use of Cigarettes, Alcohol, and Marijuana for
Youth Ages 12–17, by Race/Ethnicity: Selected Years
Drug and Race/Ethnicity of Student 1991 1993 1995 1996 1997 1998
Cigarettes
White, non-Hispanic 11.4 11.8 12.2 12.3 12.3 12.3
Black, non-Hispanic 11.3 11.8 12.7 12.6 12.8 12.8
Hispanic 12.0 12.0 12.8 12.8 12.7 12.7
Alcohol
White, non-Hispanic 12.6 12.9 12.8 13.1 13.1 13.1
Black, non-Hispanic 12.9 13.2 13.1 13.2 13.0 13.1
Hispanic 12.8 13.0 13.1 13.3 13.0 13.2
Marijuana
White, non-Hispanic 14.4 13.9 13.8 14.0 13.8 13.8
Black, non-Hispanic 13.7 14.0 14.1 14.0 13.8 13.8
Hispanic 13.1 13.7 13.9 13.6 13.5 13.5
Cocaine
White, non-Hispanic 14.3 14.6 14.6 14.7 14.8 14.7
Black, non-Hispanic 14.0 14.5 * 14.3 14.3 13.0
Hispanic 14.4 14.3 14.3 14.9 14.8 14.3
*Low precision, no estimate reported.
SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Service Administration, Office of Applied
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Table 17. Trends in the Estimated Percentage of 12th-Graders Who Were 
Previous-Month Smokers, by Race/Ethnicity and Gender: 1976–1999
12th-Grade Smokers 1976–79 1980–84 1985–89 1990–94 1995–99
Males
African-American 33.1 19.4 15.6 11.6 19.3
American Indian/Alaska Native 50.3 39.5 36.8 41.1 42.3
Asian/Pacific Islander 20.7 21.5 16.8 20.6 25.5
Hispanic 30.3 23.8 23.3 28.5 28.8
White 35.0 27.5 29.8 33.4 39.7
Females
African-American 33.6 22.8 13.3 8.6 10.8
American Indian/Alaska Native 55.3 50.0 43.6 39.4 51.7
Asian/Pacific Islander 24.4 16.0 14.3 13.8 17.5
Hispanic 31.4 25.1 20.6 19.2 24.4
White 39.1 34.2 34.0 33.1 39.5
SOURCE: Bachman et al., 2001; Institute for Social Research, University of Michigan, unpublished data.Prevalence of Drug Use Among Youth
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Table 18. Estimated Prevalence of Use of Selected Substances in the Past Year,
Cigarette Use in the Past 30 Days, and Binge Drinking in the Past 2 Weeks Among 
12th-Graders and 8th-Graders, by Sex and Race/Ethnicity (by percent): Selected Years
(continued on next page)
Use by Drug Type 1980 1985 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Cigarettes
All 12th-graders 30.5 30.1 29.4 28.3 27.8 29.9 31.2 33.5 34.0 36.5 35.1 34.6 31.4
Male 26.8 28.2 29.1 29.0 29.2 30.7 32.9 34.5 34.9 37.3 36.3 35.4 32.8
Female 33.4 31.4 29.2 27.5 26.1 28.7 29.2 32.0 32.4 35.2 33.3 33.5 29.7
White 33.0 31.3 32.3 32.2 31.8 33.2 35.2 36.6 38.1 40.7 41.7 40.1 37.9
Black 26.8 18.1 12.2 10.6 8.7 9.5 10.9 12.9 14.2 14.3 14.9 14.9 14.3
All 8th-graders N/A N/A N/A 14.3 15.5 16.7 18.6 19.1 21.0 19.4 19.1 17.5 14.6
Male N/A N/A N/A 15.5 14.9 17.2 19.3 18.8 20.6 19.1 18.0 16.7 14.3
Female N/A N/A N/A 13.1 15.9 16.3 17.9 19.0 21.1 19.5 19.8 17.7 14.7
White N/A N/A N/A N/A 16.2 17.8 18.9 20.7 22.7 22.8 21.5 20.1 17.7
Black N/A N/A N/A N/A 5.3 6.6 8.7 8.9 9.6 10.9 10.6 10.7 9.6
Marijuana
All 12th-graders 48.8 40.6 27.0 23.9 21.9 26.0 30.7 34.7 35.8 38.5 37.5 37.8 36.5
Male 53.4 43.1 29.4 27.2 24.4 29.0 35.1 38.1 39.4 40.9 41.7 41.4 39.2
Female 44.1 37.8 24.2 20.1 18.9 22.4 26.4 30.6 31.6 35.5 33.0 34.1 33.4
White 51.2 41.6 31.6 28.2 24.9 25.9 30.2 34.2 36.4 38.7 39.9 39.1 38.2
Black 37.9 33.4 13.7 11.4 11.5 14.2 20.7 26.8 30.2 30.4 30.0 30.4 30.0
All 8th-graders N/A N/A N/A 6.2 7.2 9.2 13.0 15.8 18.3 17.7 16.9 16.5 15.6
Male N/A N/A N/A 7.3 7.4 10.5 15.1 17.7 19.6 19.2 18.0 18.1 16.7
Female N/A N/A N/A 5.1 6.9 8.0 10.9 13.7 16.9 16.1 15.3 14.9 14.3
White N/A N/A N/A N/A 6.4 7.8 10.0 13.5 16.7 17.8 16.7 15.4 14.9
Black N/A N/A N/A N/A 4.1 5.7 8.9 11.9 14.0 15.3 16.0 16.3 16.1
Cocaine
All 12th-graders 12.3 13.1 5.3 3.5 3.1 3.3 3.6 4.0 4.9 5.5 5.7 6.2 5.0
Male 14.8 14.8 6.6 4.1 3.7 4.0 4.5 4.8 6.0 6.6 6.8 7.3 5.8
Female 9.8 11.2 3.8 2.6 2.4 2.3 2.8 3.1 3.5 4.2 4.5 5.0 3.9
White 12.8 13.0 6.3 4.6 3.3 3.1 3.5 4.0 4.5 5.5 6.3 6.7 6.2
Black 5.2 5.3 1.7 1.5 1.2 0.8 0.9 1.0 0.8 0.9 0.9 0.9 1.0
All 8th-graders N/A N/A N/A 1.1 1.5 1.7 2.1 2.6 3.0 2.8 3.1 2.7 2.6
Male N/A N/A N/A 1.4 1.5 1.9 2.1 2.5 2.7 3.1 2.9 2.8 2.6
Female N/A N/A N/A 0.9 1.5 1.5 2.1 2.6 3.1 2.5 3.1 2.7 2.6
White N/A N/A N/A N/A 1.2 1.3 1.6 2.3 2.8 3.0 2.8 2.6 2.5
Black N/A N/A N/A N/A 0.7 0.7 0.7 0.6 0.6 0.5 0.7 0.8 0.8Prevalence of Drug Use Among Youth
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Table 18 (continued). Estimated Prevalence of Use of Selected Substances in the Past
Year, Cigarette Use in the Past 30 Days, and Binge Drinking in the Past 2 Weeks Among
12th-Graders and 8th-Graders, by Sex and Race/Ethnicity (by percent): Selected Years
*To derive percentages for each racial subgroup, data for the specified year and the previous year have been combined to increase sample
sizes and thus provide more stable estimates.
N/A: Not available.
SOURCE: Monitoring the Future Study, University of Michigan; Johnston et al., 2001d.
Use by Drug Type 1980 1985 1990 1991 1992 1993 1994 1995 1996 1997 1998 1999 2000
Inhalants
All 12th-graders 4.6 5.7 6.9 6.6 6.2 7.0 7.7 8.0 7.6 6.7 6.2 5.6 5.9
Male 5.9 6.9 8.8 8.2 8.0 9.2 9.6 9.9 9.1 8.3 7.5 6.5 6.8
Female 3.5 4.5 4.9 5.0 4.5 4.8 6.0 6.2 6.1 5.2 5.1 4.9 5.1
White 5.3 5.9 7.2 7.6 7.2 7.6 8.6 9.1 9.0 8.6 7.9 7.0 6.4
Black 2.2 2.0 2.1 2.7 2.5 2.2 2.4 2.6 2.2 1.9 1.7 1.4 1.9
All 8th-graders N/A N/A N/A 9.0 9.5 11.0 11.7 12.8 12.2 11.8 11.1 10.3 9.4
Male N/A N/A N/A 9.0 9.2 10.4 11.2 11.5 10.3 10.5 10.6 9.5 8.9
Female N/A N/A N/A 9.0 9.8 11.9 12.2 14.0 14.1 12.9 11.6 11.1 9.9
White N/A N/A N/A N/A 10.1 11.3 12.4 13.8 14.6 14.1 13.3 12.1 10.9
Black N/A N/A N/A N/A 4.4 4.6 5.3 5.0 4.2 3.8 4.2 4.2 4.3
Alcohol
All 12th-graders 72.0 65.9 57.1 54.0 51.3 48.6 50.1 51.3 50.8 52.7 52.0 51.0 50.0
Male 77.4 69.8 61.3 58.4 55.8 54.2 55.5 55.7 54.8 56.2 57.3 55.3 54.0
Female 66.8 62.1 52.3 49.0 46.8 43.4 45.2 47.0 46.9 48.9 46.9 46.8 46.1
White 75.4 71.2 63.8 60.0 56.8 55.6 54.0 54.5 54.8 56.4 57.7 56.3 55.1
Black 47.6 42.8 35.8 33.7 31.7 32.4 33.8 35.2 36.5 34.3 33.3 32.2 30.0
All 8th-graders N/A N/A N/A 25.1 26.1 24.3 25.5 24.6 26.2 24.5 23.0 24.0 22.4
Male N/A N/A N/A 26.3 26.3 25.3 26.5 25.0 26.6 25.2 24.0 24.8 22.5
Female N/A N/A N/A 23.8 25.9 23.7 24.7 24.0 25.8 23.9 21.9 23.3 22.0
White N/A N/A N/A N/A 26.6 27.1 25.3 25.4 26.6 26.7 24.8 24.7 24.7
Black N/A N/A N/A N/A 18.6 19.7 19.4 18.7 18.1 17.9 16.1 16.1 16.0
Binge drinking
All 12th graders 41.2 36.7 32.2 29.8 27.9 27.5 28.2 29.8 30.2 31.3 31.5 30.8 30.0
Male 52.1 45.3 39.1 37.8 35.6 34.6 37.0 36.9 37.0 37.9 39.2 38.1 36.7
Female 30.5 28.2 24.4 21.2 20.3 20.7 20.2 23.0 23.5 24.4 24.0 23.6 23.5
White 44.3 41.5 36.6 34.6 32.1 31.3 31.5 32.3 33.4 35.1 36.4 35.7 34.6
Black 17.7 15.7 14.4 11.7 11.3 12.6 14.4 14.9 15.3 13.4 12.3 12.3 11.5
All 8th-graders N/A N/A N/A 12.9 13.4 13.5 14.5 14.5 15.6 14.5 13.7 15.2 14.1
Male N/A N/A N/A 14.3 13.9 14.8 16.0 15.1 16.5 15.3 14.4 16.4 14.4
Female N/A N/A N/A 11.4 12.8 12.3 13.0 13.9 14.5 13.5 12.7 13.9 13.6
White N/A N/A N/A N/A 12.7 12.6 12.9 13.9 15.1 15.1 14.1 14.3 14.9
Black N/A N/A N/A N/A 9.6 10.7 11.8 10.8 10.4 9.8 9.0 9.9 10.0Prevalence of Drug Use Among Youth
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Table 19. Estimated Percentage of African-American and White 12th-Graders 
Who Reported Using or Not Using Tobacco Cigarettes and Other Substances in the 
Past 30 Days
a: 1976–1994 Aggregate Data
aRefers to use of these substances in the last 30 days.
bEntries are percentage of the entire African-American 12th-grade population.
cEntries are percentage of the entire White 12th-grade population.
dAny illicit drug use includes any use of marijuana, hallucinogens, cocaine, or heroine or any use of other opiates, stimulants, barbiturates,
methaqualone, or tranquilizers not under physician’s orders. Methaqualone is excluded from the definition of illicit drugs for 1990–94 survey data.
SOURCE: Monitoring the Future Study, University of Michigan, public use data tapes, 1976–1994; Johnston et al., 2001d.
Cigarette Use Among African Americans
b
Use of 1976–79 1980–84 1985–89 1990–94
Substance Yes No Yes No Yes No Yes No
Alcohol
Yes 22.7 25.6 15.2 31.2 11.0 29.5 7.2 26.2
No 9.7 41.7 5.3 48.4 3.1 56.4 2.6 64.1
Marijuana
Yes 17.2 11.9 11.2 14.2 6.4 7.8 3.1 5.8
No 15.0 55.9 9.3 65.3 7.6 78.2 6.6 84.5
Cocaine
Yes 1.4 0.6 1.4 1.3 1.0 1.0 0.3 0.2
No 31.7 66.3 19.7 77.6 13.3 84.8 9.6 89.8
Any illicit drug use
c
Yes 17.6 12.9 11.4 15.2 6.6 9.3 3.3 6.8
No 14.0 55.5 8.8 64.6 7.0 77.1 6.2 83.7
Cigarette Use Among Whites
c
Use of 1976–79 1980–84 1985–89 1990–94
Substance Yes No Yes No Yes No Yes No
Alcohol
Yes 33.7 40.5 28.2 46.0 28.6 40.9 27.5 29.7
No 3.3 22.4 2.7 23.1 3.6 26.8 5.7 37.1
Marijuana
Yes 22.4 13.7 16.9 12.8 14.4 8.1 11.8 4.4
No 14.3 49.6 13.8 56.5 17.5 60.0 21.3 62.5
Cocaine
Yes 2.6 1.1 3.5 2.0 3.4 1.1 1.2 0.2
No 34.3 62.0 27.3 67.2 28.5 66.6 31.9 66.7
Any illicit drug use
d
Yes 23.3 14.8 18.9 15.5 16.1 10.0 13.3 5.9
No 13.3 48.6 11.7 53.9 15.7 58.3 19.6 61.2Prevalence of Drug Use Among Youth
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Table 20. Estimated Prevalence of Youth Age 12 and Older Having Used Alcohol,
Marijuana, Cocaine, or Crack-Cocaine in Lifetime or Past Month, 
by Age, Sex, Race/Ethnicity (by percent): 1999
Use by Drug and Race/Ethnicity Male Female
12–15 16–17 18+ 12–15 16–17 18+
Use in Lifetime
Alcohol
White 77.7 81.6 90.7 77.2 83.8 89.2
Black 66.4 80.1 71.3 70.8 78.4 79.6
Hispanic 70.2 89.5 86.9 80.8 88.1 82.5
Marijuana
White 40.4 49.9 66.0 27.3 50.0 51.8
Black 39.9 63.7 65.1 30.7 49.0 51.2
Hispanic 41.1 65.3 59.6 36.9 51.4 53.1
Cocaine or crack-cocaine
White 6.4 12.6 15.5 4.6 10.8 11.8
Black 2.7 3.1 2.0 0.8 2.2 1.3
Hispanic 14.8 21.0 17.7 11.3 13.9 8.3
Use in Past Month
Alcohol
White 45.7 57.4 65.7 42.2 51.9 61.5
Black 22.7 49.5 49.5 35.0 42.2 50.3
Hispanic 43.6 61.8 70.0 45.7 51.6 50.0
Marijuana
White 24.2 31.4 35.1 19.1 24.9 24.7
Black 19.1 36.5 46.7 14.3 24.6 31.5
Hispanic 28.9 39.8 32.4 22.4 21.0 23.2
Cocaine or crack-cocaine
White 3.6 6.8 4.1 1.7 3.4 3.5
Black 0.8 1.3 0.8 0.5 1.6 1.3
Hispanic 7.0 9.0 7.0 6.9 4.9 3.5
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Table 23. Estimated Percentage of American Indian 4th–6th Graders 
Who Reported Lifetime Use of Drugs: Selected Years
Drug 1980–81 1987–88 1989–90 1990–91 1992–94
Alcohol 33 22 21 18 17
Marijuana 23 16 10 8 7
Inhalants 14 14 15 12 10
Cigarettes 34 33 32 30 31
SOURCE: Tri-Ethnic Center for Prevention Research, Colorado State University, 1995, unpublished data.
Table 24. Estimated Percentage of National Longitudinal Survey of Youth Cohorts Who
Admitted Using Marijuana and Cocaine, by Race/Ethnicity and Year 
Drug by  1984 1988 1992 1994
Race/Ethnicity Lifetime Past Year Past Month Past Year Past Month Past Year Past Month Lifetime  Past Year Past Month
Marijuana
White, non-Hispanic 66.5 33.8 19.5 23.3 12.7 14.1 8.3 77.9 12.8 5.4
Black, non-Hispanic 57.7 31.5 21.0 20.4 11.4 10.5 4.9 75.0 11.5 4.4
Other 53.8 29.5 17.5 16.0 9.0 11.2 6.9 68.9 9.5 4.7
Cocaine
White, non-Hispanic 19.5 12.1 4.8 10.8 3.2 3.8 1.2 39.9 6.3 2.1
Black, non-Hispanic 10.2 6.8 2.8 8.2 3.5 4.8 1.9 32.7 7.4 3.1
Other 17.4 10.6 4.7 9.4 3.3 4.4 1.7 36.5 7.4 2.2
SOURCE: National Longitudinal Survey of Youth, Bureau of Labor Statistics, 1996.
Table 22. Estimated Lifetime Prevalence of Drug Use for American Indian and 
Non-Indian 8th-, 10th-, and 12th-Graders (by percent): 1997–1998
8th-Graders 10th-Graders 12th-Graders
Drug Indian Non-Indian Indian Non-Indian Indian Non-Indian
Alcohol 65 54 84 72 83 82
Alcohol intoxication 46 25 71 49 68 64
Marijuana 67 23 82 42 74 50
Inhalants 14 21 22 18 10 16
Cocaine 8 4 19 7 20 9
Stimulants 15 12 26 17 20 17
Sedatives 3 N/A 5 N/A 2 8
Heroin 4 2 4 2 5 2
Psychedelics 19 5 26 11 27 15
Tranquilizers 1 5 4 7 21 9
PCP 4 N/A 4 N/A 6 4
Cigarettes 79 47 87 60 75 65
Smokeless tobacco 45 17 41 26 41 25
Sample size 431 18,700 244 15,400 196 15,800
N/A: Not available.
SOURCES: Tri-Ethnic Center for Prevention Research, Colorado State University; Monitoring the Future Study, University of Michigan;
Johnston et al., 2001d-e.Prevalence of Drug Use Among Youth
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Figure 5. Trends in Prevalence of Daily Cigarette Use Among 12th-Graders, 
by Race/Ethnicity: 1977–2000
SOURCE: Monitoring the Future Study, University of Michigan, 2000; Johnston et al., 2001d.
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Figure 6. Trends in Prevalence of Marijuana Use Among 12th-Graders, 
by Race/Ethnicity: 1977–2000
SOURCE: Monitoring the Future Study, University of Michigan, 2000; Johnston et al., 2001d.
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Figure 7. Trends in Prevalence of Inhalant Use Among 12th-Graders, 
by Race/Ethnicity: 1977–2000
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Figure 8. Trends in Prevalence of Cocaine Use Among 12th-Graders, 
by Race/Ethnicity: 1977–2000
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Figure 9. Trends in Prevalence of LSD Use Among 12th-Graders, 
by Race/Ethnicity: 1977–2000
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Figure 10. Trends in Prevalence of Any Illicit Drug Use Among 12th-Graders, 
by Race/Ethnicity: 1977–1999
NOTES: Use of “any illicit drug” includes any use of marijuana, LSD, other hallucinogens, crack, other cocaine, or heroin, or any use of 
other narcotics, amphetamines, barbiturates, methaqualone (excluded since 1990), or tranquilizers, not under a doctor's order.
Beginning in 1982, the MTF survey question about amphetamine use was revised to reduce inappropriate reporting of 
nonprescription amphetamine use.The prevalence estimates dropped slightly as a result of this methodological change.
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This chapter provides data from the U.S. Department of Education on school dropout trends and data from
the Youth Risk Behavior Survey (YRBS) on risk behaviors such as fighting, carrying a weapon, and engaging in
sexual activity. The use of alcohol and other drugs by youth is associated with many social and health problems.
The leading causes of death among adolescents are accidents, homicides, and suicides, all of which are linked to
use of alcohol and other drugs. Alcohol use is mentioned as a factor in approximately one-half of homicides,
suicides, and deaths from motor vehicle crashes, (Kolbe et al. 1993; National Institute on Alcoholism and
Alcohol Abuse 2000). Alcohol and other drug use are associated with increased risk of dropping out of school,
contracting sexually transmitted diseases, and getting into trouble with law enforcement officials.
In many studies, risk-taking and deviant behaviors cluster more than is expected by random co-occurrence of
these behaviors (Kokatailo 1995; Jessor 1998). In some studies, the temporal ordering of these behaviors is clear.
For example, failing to complete high school is associated with increased later risk of becoming alcohol dependent,
even when drinking starts after age 18 (Crum et al. 1992); dropping out of school may precede many life 
problems, including unemployment, poverty, poor health, and greater complications arising from alcohol or
other drug abuse (Jillson-Boostrom 1993).
These interrelationships between alcohol, other drug use, delinquency, and risk-taking behaviors have been
observed in many cross-sectional and longitudinal studies. Even so, no study has produced definitive evidence
on the causal origins of this observed covariation of risk behaviors. What seems most likely is that in some
instances one risk behavior is a direct consequence of another risk behavior—the link between alcohol intoxi-
cation and unprotected or otherwise unsafe sex comes to mind as an example. In other instances, two risk
behaviors may be a manifestation of some underlying shared vulnerability, as exemplified by youth living and
growing up in socially disadvantaged neighborhoods with negligent parents who fail to provide adequate super-
vision and monitoring in the primary school years and beyond. In still other instances, the risk behaviors may
combine artifactually—a prominent concern when questionnaires on multiple risk behaviors fail to take into
account the shared methods covariation, whereby similar questions can induce response tendencies that yield
substantive covariation even when there is no substantive covariation (Ryan and Irwin 1992; Anthony et al.
2000).
SCHOOL DROPOUT TRENDS
Because of this Nation’s history of compulsory education for children, individuals who drop out of school have
long been a concern and an area of interest for researchers. In the last decades of the 20th century, the dropout
issue became particularly important because of increasing awareness of the exceptionally high dropout rates
among inner city and Hispanic youth (Dryfoos 1990; U.S. Department of Education 2000). This issue is of
particular interest to drug use researchers because the relationship between dropping out of school and using
drugs has been well documented (National Institute on Drug Abuse, 1993; Substance Abuse and Mental Health
Administration 2001b).
In the study of dropout rates, it can be useful to compare and contrast different indicators, each with its own
strengths and weaknesses. Three prominent dropout indicators are (1) the event dropout rate, (2) the status
dropout rate, and (3) the cohort dropout rate. The event dropout rate measures the number of students dropping
out of school during any given year as a function of time and the total number of enrolled students. This rate
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calculates only the number of students leaving a given school district and may not take into account students
who enroll in other school districts or students who leave school, return, and leave again. The status dropout
rate attempts to evaluate through surveys the proportion of individuals in a given age group who have com-
pleted school or are enrolled in school at one time. Because of its increased sensitivity to the cumulative annual
event rate, the status dropout rate always appears higher than the event rate. The cohort dropout rate is obtained
by following a single group of students across time and evaluating their school completion rates (Chavez 1993).
Status dropout rates for youth from various races/ethnicities and selected demographic characteristics are presented
in Table 25. Based on 1999 data, this indicator suggests that Hispanic youth are substantially more likely 
to have dropped out of school than youth in other groups such as non-Hispanic Whites (7.3 percent), non-
Hispanic Blacks (12.6 percent), and Asian/Pacific Islanders (4.3 percent, the lowest dropout rate) (Table 25, 
column 1).
Far in excess of their 14.8-percent representation in the general population of young people (Table 25, column
5), Hispanic youth account for almost 40 percent of all dropouts. By comparison, non-Hispanic Whites and
Asian/Pacific Islanders are underrepresented among dropouts (Table 25, column 4).
The interpretation of these statistics is complicated by imbalances in recency of immigration, regional distribution
of various racial/ethnic groups, and the distribution of material wealth and social capital, which also are related
to success in schooling. Regarding recency of immigration, both first- and second-generation Hispanic youth
have status dropout rates that are not as extreme as the mean value for Hispanic youths in general, as shown in
the lower rows of column 1 of Table 25. Among Hispanic youth born outside of the United States, for example,
the risk of having dropped out of school is 44.2 percent. Comparison values for first- and second-generation
Hispanic youth are 16.1 percent and 16.0 percent, respectively. Nonetheless, in comparing recent immigrants
and first- and second-generation youth, Hispanic youth are more likely to have dropped out (See Table 25, 
column 1).
Table 25 also shows considerable regional variation in status dropout rates. Youth are most likely to have
dropped out of school in the West and South. By comparison, youth in the Northeast and Midwest are about
66 percent as likely to have dropped out.
Based on data from 1996, Table 26 clarifies that socioeconomic status also can be an important determinant of
success in school (Table 26, column 1) and is associated not only with recent immigration status, but also with
race and ethnicity (e.g., Diez-Roux 2001). Nonetheless, when examined within socioeconomic levels, Hispanic
youth remain more likely to have dropped out of school than non-Hispanic Black and White youth. Even
within the lowest income level, Hispanic youth are more likely to have dropped out (42.4 percent) than are 
non-Hispanic Whites (13.9 percent) and non-Hispanic Blacks (21.9 percent).
Table 27 presents trend data on the event dropout rates for youth in grades 10–12 from October 1972 through
October 1999 by sex and race/ethnicity. These values reflect the percentages of students who had not graduated
from high school, among those who had been enrolled at the beginning of a new school year. As with the data
on status dropout rates, Hispanic youth consistently show the highest dropout rates among the three subgroups,
followed next by African-American youth. Year-to-year variation indicates that event dropout rates fluctuated
somewhat from 1972 to the mid-1990s for Hispanic youth, with values of 7.8 percent to 9.5 percent between
1996 and 1999. Declines also are seen for non-Hispanic Whites and Blacks, but the most recent data indicate
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persisting imbalances: 4.0 percent for non-Hispanic Whites, 6.5 percent for non-Hispanic Blacks, and 7.8 percent
for Hispanic students (Table 27, last row).
Students drop out of school for a variety of reasons, as illustrated in Table 28, based on self-report survey data
from the National Center for Education Statistics. Based on students’ answers to the survey questions, a large
percentage of all students who dropped out of school said they did not like school and were failing their classes
(42.9 and 38.7 percent, respectively). More African-American students reported being suspended or expelled
from school (24.4 percent) than did Whites (15.4 percent) and Hispanics (10.1 percent). African-American and
Hispanic students were more likely than White students to cite not feeling safe at school as an explanation for
dropping out (8.5 and 8.3 percent for African-American and Hispanic students, respectively, versus 4.8 percent
for White students). White students were more likely than African-American and Hispanic students to report
a drug or alcohol problem as their reason for dropping out (5.9 percent for Whites, compared with 2.1 and 
1.8 percent for African Americans and Hispanics, respectively). A large percentage of female dropouts reported
pregnancy as the reason (26.8 percent). The distribution of pregnancy by race/ethnicity indicated that African
Americans (34.5 percent) and Hispanics (30.6 percent) said they dropped out more frequently due to pregnancy
than did White students (25.6 percent).
Table 29 shows high-school completion rates and method completion by race/ethnicity for the 1995–1999
period. These data indicate that throughout this period, about 85 to 86 percent of youth ages 18–24 years 
completed high school, and 74 to 78 percent received their high-school diploma (Table 29, rows 1 and 2). The
number of youth reporting receiving some alternative to the diploma (e.g., GED certificate) has increased
slightly. In the most recent years (e.g., 1999), non-Hispanic Whites were most likely to have graduated from
high school and to have received a diploma, followed by non-Hispanic Blacks. Hispanics were least likely to
graduate, to receive the high-school diploma, and to receive an alternative such as the GED certificate.
Trend data on completion rates and status dropout by race/ethnicity for 1972 through 1999 are plotted in
Figures 11 and 12. The trends in status dropout and completion rates by race/ethnicity showed minor fluctuations
during this span of over two decades. Of greatest note is the persistent difference in the levels of status dropout
rates for Whites, African Americans, and Hispanics. In addition, the gap between the rates for African
Americans and Whites was closing for the first decade, but has not changed much since the mid-1980s.
RISK BEHAVIOR TRENDS
The use of alcohol and other drugs by youth can threaten their physical and mental health and can alter social
development. The YRBSS data describe student drug use and patterns of other behaviors that may place them
at greater risk of motor vehicle crash injury, other unintentional injury, homicide, suicide, heart disease, and
cancer (Kann et al. 1993). Transmission of HIV and other sexually transmitted diseases also can occur indirectly
as a consequence of alcohol and other drug use, which can impair judgment and reduce inhibitions about 
engaging in sexual intercourse (Blanken 1993).
Comparison of YRBSS data for students who have used marijuana, cocaine, or crack-cocaine and youth who
have never used these drugs shows a consistent pattern of association with other risky behaviors. As illustrated
in Table 30, YRBSS data from 1999 indicate that youth who reported a past or recently active history of smoking
marijuana are generally more likely to have reported engaging in other recent risk-related behaviors, such as
fighting, carrying a weapon, and not wearing a seat belt. This general pattern holds for White, Black, and
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Hispanic youth. For example, among White students reporting a history of marijuana use, about 43 to 44 percent
reported recent fighting, 21 to 22 percent carried a weapon, and 23 percent reported rarely wearing a seat belt.
Among White students with no reported history of marijuana use, the corresponding estimates are 23 to 
24 percent for fighting, 11 to 12 percent for carrying weapons, and 9 to 10 percent for rarely wearing seat belts
(Table 30, rows 1 and 5). The estimates are somewhat higher for youth who had been recently active users of 
marijuana, and intermediate for youth with past but no recently active marijuana use (Table 30, rows 9 and 13).
A similar pattern of associations between marijuana use and other risky behaviors holds for Black and Hispanic
students who participated in YRBSS (Table 30).
Similar patterns of association can be seen in the prevalence of risk-related behaviors for students who reported
past, recently active (past-month), and no use of crack-cocaine (Table 31). For example, among White youth
reporting recently active crack or other cocaine use, an estimated 20 to 21 percent reported having multiple sex
partners in the 3 months before assessment (Table 30, second page, row 9), as compared with 7 to 8 percent of
White students with recently active marijuana use (Table 30, first page), and 1 to 2 percent of White youth who
never had used crack or other cocaine (Table 30, second page, row 5). Corresponding values for Black youth are
50 to 51 percent, 28 to 29 percent and 14 to 15 percent, showing a similar pattern of association. The same
type of pattern of associations holds for Hispanic students who reported cocaine-crack use (17 percent), recently
active marijuana use (10 to 11 percent), and never having used crack or other cocaine (3 to 4 percent).
This pattern of association extends to use of condoms during most recent sexual encounters. For example, as
shown in Table 31, among White students who reported having used crack or other cocaine, an estimated 41
to 42 percent said they had used no condom in the most recent sexual encounter. Corresponding values for
Black and Hispanic cocaine-using students are 57 to 58 percent and 44 to 45 percent (Table 30, second page).
At the other extreme, students with no history of trying crack or other cocaine were more likely to have used
condoms; the prevalence of failing to use a condom was 24 to 25 percent for Whites, 51 percent for Blacks, and
28 to 29 percent for Hispanics (Table 30, second page). 
SUMMARY
In this chapter, the statistics help clarify the social disadvantage experienced by African-American and especially
Hispanic youth in the United States, as seen in dropout rates and failure to receive diplomas or GED certificates.
The statistics also clarify patterns of association linking lifetime and recently active use of illegal drugs like 
marijuana and cocaine to risk-related behaviors such as not wearing seat belts, having multiple sex partners, and
not using condoms
YRBSS data provide clear evidence of the patterns of association between risk-related behaviors, but fail to take
into account a possibility of a shared methods covariation that induces the patterns of association. Namely, 
students willing to report on their illegal drug use may also be more willing to report on their engagement in
other risky behaviors. As such, these statistics create new research questions that will need to be addressed if we
are to translate these initial observations into effective public health intervention strategies. This new research
on methodological and substantive sources of variation in the observed rates of risk-related behaviors represents
an important element of future research on health disparities affecting our Nation’s racial and ethnic minorities.
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Table 25. Rate, Number, and Distribution of Status Dropouts, by Sex, Race/Ethnicity, 
Age, Region, and Recency of Immigration: 1999
Status Number of All
Characteristics Dropout Rate Status Dropouts Population Dropouts Population
(percent) (thousands) (thousands) (percent) (percent)
Total* 11.2 3,829 34,173 100.0 100.0
Sex
Male 11.9 2,032 17,106 53.1 50.1
Female 10.5 1,797 17,066 46.9 49.9
Race/Ethnicity
White, non-Hispanic 7.3 1,636 22,408 42.7 65.6
Black, non-Hispanic 12.6 621 4,94 16.2 14.5
Hispanic 28.6 1,445 5,060 37.7 14.8
Asian/Pacific Islander 4.3 65 1,515 1.7 4.4
Age
16 3.5 139 3,995 3.6 11.7
17 6.7 278 4,137 7.3 12.1
18 12.6 489 3,870 12.8 11.3
19 13.6 559 4,121 14.6 12.1
20–24 13.1 2,366 18,050 61.8 52.8
Recency of Immigration
Born Outside the 
50 States and the 
District of Columbia
Hispanic 44.2 994 2,250 26.0 6.6
Non-Hispanic 7.0 133 1,909 3.5 5.6
First generation
Hispanic 16.1 240 1,494 6.3 4.4
Non-Hispanic 5.0 94 1,893 2.5 5.5
Second generation or more
Hispanic 16.0 211 1,316 5.5 3.9
Non-Hispanic 8.5 2,156 25,130 56.3 74.1
Region
Northeast 8.7 531 6,133 13.9 17.9
Midwest 8.3 676 8,177 17.7 23.8
South 12.7 1,516 11,902 39.6 34.8
West 13.8 1,106 8,021 28.9 23.5
*Due to relatively small sample sizes, American Indians/Alaska Natives are included in the total but are not shown separately.
SOURCE: U. S. Department of Education, National Center for Education Statistics, Dropout Rates in the United States: 1999 (based on the 
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Table 26. Status Dropout Rates for Persons Ages 16–24, 
by Family Income and Race/Ethnicity (by percent): 1990
Race/Ethnicity
a
Family Income Total White, Non-Hispanic  Black, Non-Hispanic  Hispanic 
Total 11.1 7.3 13.0 29.4
Family income
b
Low-income level 22.1 13.9 21.9 42.4
Middle-income level 10.8 8.3 9.0 24.9
High-income level 2.6 2.0 2.5 11.0
aNon-Hispanics who are neither Black nor White are not shown separately but are included in the total.
bFamily income in current residence. Low income is defined as the bottom 20 percent of all family incomes for 1994; middle income is
between 20 and 80 percent of all family incomes; and high incomes is the top 20 percent of all family incomes.
SOURCE: U.S. Bureau of the Census, Current Population Survey, October 1994, unpublished data.Youth Drug Use and Risk Behaviors
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Table 27. Event Dropout Rates
a for Persons Ages 15–24 Who Dropped Out of 




Year Total Male Female Non-Hispanic Non-Hispanic Hispanic
1972 6.1 5.9 6.3 5.3 9.5 11.2
1973 6.3 6.8 5.7 5.5 9.9 10.0
1974 6.7 7.4 6.0 5.8 11.6 9.9
1975 5.8 5.4 6.1 5.0 8.7 10.9
1976 5.9 6.6 5.2 5.6 7.4 7.3
1977 6.5 6.9 6.1 6.1 8.6 7.8
1978 6.7 7.5 5.9 5.8 0.2 12.3
1979 6.7 6.8 6.7 6.0 9.9 9.8
1980 6.1 6.7 5.5 5.2 8.2 11.7
1981 5.9 6.0 5.8 4.8 9.7 10.7
1982 5.5 5.8 5.1 4.7 7.8 9.2
1983 5.2 5.8 4.7 4.4 7.0 10.1
1984 5.1 5.4 4.8 4.4 5.7 11.1
1985 5.2 5.4 5.0 4.3 7.8 9.8
1986 4.7 4.7 4.7 3.7 5.4 11.9
1987 4.1 4.3 3.8 3.5 6.4 5.4
1988 4.8 5.1 4.4 4.2 5.9 10.4
1989 4.5 4.5 4.5 3.5 7.8 7.8
1990 4.0 4.0 3.9 3.3 5.0 7.9
1991 4.1 3.8 4.2 3.2 6.0 7.3
1992 4.4 3.9 4.9 3.7 5.0 8.2
1993 4.5 4.6 4.3 3.9 5.8 6.7
1994 5.3 5.2 5.4 4.2 6.6 10.0
1995 5.7 6.2 5.3 4.5 6.4 12.4
1996 5.0 5.0 5.1 4.1 6.7 9.0
1997 4.6 5.0 4.1 3.6 5.0 9.5
1998 4.8 4.6 4.9 3.9 5.2 9.4
1999 5.0 4.6 5.4 4.0 6.5 7.8
aThe event dropout rate is the percentage of those in grades 10–12, ages 15–24 who were enrolled in the previous October but were not
enrolled and had not graduated the following October.
bDue to relatively small sample sizes, American Indians/Alaska Natives and Asian/Pacific Islanders are included in the total but are not
shown separately.
SOURCE: U. S. Department of Education, National Center for Education Statistics, Dropout Rates in the United States: 1999 (based on the 
Current Population Survey), 2000.Youth Drug Use and Risk Behaviors
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Reason for Dropping Out Total Male Female Hispanic Non-Hispanic Non-Hispanic
School-related
Did not like school 42.9 43.6 42.2 48.0 28.8 45.5
Could not get along with teachers 22.8 24.6 21.1 24.6 27.8 21.5
Could not get along with students 14.5 17.7 11.6 15.6 18.4 13.6
Did not feel safe at school 6.0 7.0 5.1 8.3 8.5 4.8
Felt did not belong 24.2 25.8 22.7 16.0 25.9 26.6
Could not keep up with schoolwork 31.3 32.7 29.9 35.0 25.6 30.3
Was failing school 38.7 43.4 34.5 40.6 39.6 36.6
Changed school and did not like new school 10.6 10.5 10.7 12.3 9.1 10.2
Was suspended/expelled from school 10.5 21.6 10.0 10.1 24.4 15.4
Job-related
Could not work and go to school at same time 22.8 26.9 19.1 20.4 15.4 24.6
Found a job 28.5 35.9 21.8 34.1 19.1 27.5
Family-related:
Had to support family 11.2 10.4 11.9 15.8 11.8 9.9
Wanted to have family 7.5 6.4 8.4 9.1 4.6 8.2
Was pregnant 26.8 N/A 26.8 30.6 34.5 25.6
Became parent 14.7 7.7 21.0 13.4 2.0 15.1
Got married 12.1 3.7 19.7 13.4 2.0 15.1
Had to care for family member 11.9 9.5 14.0 8.5 14.7 10.7
Other
Wanted to travel 8.1 8.2 8.0 6.6 7.3 7.1
Friends dropped out 8.0 8.5 7.5 7.6 6.7 8.6
Had a drug and/or alcohol problem 4.4 6.1 2.8 1.8 2.1 5.9
N/A: Not applicable.
SOURCE: National Educational Longitudinal Study of 1988 Second Followup Survey, National Center for Education Statistics, 1992, 
unpublished data.Youth Drug Use and Risk Behaviors
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Table 29. High-School Completion Rates and Method of Completion for Persons Ages
18–24 Years, by Race/Ethnicity and Year (by percent): October 1995–October 1999
Race/Ethnicity and Completion Rate 1995 1996 1997 1998 1999
Total
Completed 85.3 86.2 85.9 84.8 85.9
Diploma 77.9 76.4 76.7 74.7 76.8
Alternative* 7.4 7.4 9.1 10.1 9.2
White, non-Hispanic
Completed 90.7 91.5 90.5 90.2 91.2
Diploma 82.9 81.0 81.1 80.2 82.0
Alternative 6.9 10.5 9.4 10.0 9.2
Black, non-Hispanic
Completed 84.5 83.0 82.0 81.4 83.5
Diploma 75.9 73.0 72.2 71.7 72.9
Alternative 8.5 10.0 9.7 9.6 10.7
Hispanic
Completed 62.8 61.9 66.7 62.8 63.4
Diploma 54.2 55.2 59.1 52.1 54.9
Alternative 8.6 6.7 7.7 10.7 8.5
*Completed high school by means of an equivalent test, such as a General Educational Development (GED) exam.
NOTE: Because of rounding, details may not add to totals.
SOURCE: U. S. Bureau of the Census, Current Population Survey, October 1999; U.S. Department of Education, 2000.Youth Drug Use and Risk Behaviors
98
Table 30. Estimated Percentage of Youth Engaging in Risk Behaviors, 
by Drug Users and Nonusers and Race/Ethnicity: 1999
aHad sex with four or more partners during 3 months preceding the survey.
bIncluded Hispanic or Latino and Multiple-Hispanic.
cIncluded American Indian/Alaska Native, Asian, Native Hawaiian/Other Pacific Islanders, and Multiple non-Hispanic.
SOURCE: Youth Risk Behavior Surveillance System, Centers for Disease Control and Prevention, 1999.
Carried a Rarely Multiple  Ridden in Used Drugs or Used No
Fight in Weapon in  Wears Sex Partners Car While Alcohol Before Condom During
Drug, Type of Use, Last Last a Seat During Last Driver Was Last Sexual Last Sexual
and Race/Ethnicity 12 Months 30 Days Belt 3 Months
a Drinking Encounter Encounter
Marijuana
Lifetime use
White 43.6 21.8 23.0 5.7 48.4 22.6 37.2
Black 50.0 26.7 26.6 23.8 43.9 21.8 63.9
Hispanic
b 54.7 29.9 17.8 8.4 53.7 21.2 43.0
Other
c 52.3 27.9 21.7 6.4 45.7 20.8 37.1
No lifetime use
White 23.7 11.9 9.1 0.6 18.8 2.4 15.6
Black 33.3 8.0 18.6 7.6 24.7 1.1 39.1
Hispanic 24.3 6.8 10.5 1.5 24.6 0.7 18.0
Other 23.9 13.1 7.3 1.1 12.8 1.8 15.2
Used last 30 days
White 48.5 24.8 27.1 7.7 60.2 30.0 39.0
Black 57.3 40.5 34.1 28.7 52.9 33.8 66.0
Hispanic 64.8 37.9 22.5 10.6 65.1 30.5 51.9
Other 64.2 41.2 23.9 9.7 54.2 27.2 40.9
No use last 30 days
White 27.5 13.4 11.4 1.2 22.3 5.0 21.0
Black 35.5 8.7 18.3 10.8 27.8 3.0 45.6
Hispanic 29.8 10.8 11.0 2.6 29.1 3.4 22.4
Other 27.8 12.7 10.6 1.5 19.1 5.0 20.2
Cocaine or crack
Lifetime use
White 53.9 34.6 31.6 12.8 62.4 43.8 41.3
Black 77.4 63.2 48.2 45.0 69.0 43.2 57.2
Hispanic
b 71.3 43.5 25.9 17.0 67.6 32.3 44.1
Other
c 59.1 51.6 29.3 18.9 47.1 40.8 47.5
No lifetime use
White 30.8 14.4 13.8 1.9 29.2 8.3 24.2
Black 40.3 16.3 21.8 14.9 33.6 10.7 51.0
Hispanic 34.4 14.4 12.5 3.1 34.5 7.3 28.5
Other 34.9 16.1 12.4 1.8 26.5 7.4 23.3
Used last 30 days
White 59.9 47.2 40.8 20.5 72.9 49.5 38.4
Black 80.3 74.6 41.3 50.3 63.3 58.4 31.9
Hispanic 82.1 54.6 37.8 23.7 77.3 44.3 44.8
Other 77.0 69.2 42.1 28.4 67.9 52.1 31.4
No use last 30 days
White 31.9 15.1 14.5 2.3 30.7 10.3 25.4
Black 40.7 16.6 22.2 15.1 34.1 10.9 51.3
Hispanic 37.1 16.3 12.9 3.9 36.8 8.8 29.8
Other 35.4 17.3 12.9 2.5 26.8 9.0 25.5Youth Drug Use and Risk Behaviors
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Figure 11. Status Dropout Rates for Persons Ages 16–24, by Race/Ethnicity: 
October 1972–October 1999
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Figure 12. Completion Rates for Persons Ages 18–24 Not Currently Enrolled in High
School or Below, by Race/Ethnicity: October 1972–October 1999
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This chapter presents data from three data sources: (1) the registry of cases of AIDS maintained by the Centers
for Disease Control and Prevention (CDC), (2) the panel of emergency rooms (ER) that provide information
about drug-related casualties as part of the national Drug Abuse Warning Network (DAWN), and (3) the panel
of medical examiner (ME) offices that report drug-related deaths to DAWN. These three data sources offer 
epidemiological observations on an important subset of the Nation’s total experience with drug-related morbidity
and mortality. These are important sources of data on health disparities that affect racial and ethnic minority
groups within the United States. As described in the Strategic Plan on Reducing Health Disparities (National
Institute on Drug Abuse 2001b; included as Appendix 2 in this report), a portion of these health disparities can
be traced directly or indirectly to illegal drug-using behaviors. Accordingly, the NIDA definition for health 
disparities research is as follows: “Basic, clinical, and behavioral research that addresses the magnitude and/or
impact of drug use within racial/ethnic minority populations, where the goal of the study is to determine 
differential use and/or effects of drugs on the racial/ethnic minority groups included in the study. Health 
disparities research addresses issues related to epidemiology, prevention, services, and treatment outcomes within
and across racial and ethnic populations” (NIDA 2001b).
There now is a broad profile of adverse social, behavioral, and health consequences attributed to illegal drug-using
behaviors, in part due to a well-recognized association between illegal drug use, smoking of tobacco cigarettes
and cigars, and heavy drinking of alcoholic beverages (e.g., see U.S. Department of Health and Human Services
1998; Furr et al. 2000; Substance Abuse and Mental Health Administration 2001a-b). Within the domain of
brain diseases and mental health, the spectrum of adverse health consequences extends from relatively time-lim-
ited and circumscribed acute panic attacks and transient delusion-like experiences to more severe and chronic 
syndromes associated with lesions to aminergic pathways in brain (Tien and Anthony 1990; Anthony and
Petronis 1991; Johannessen and Markey 1984; McCann et al. 2000). In the domain of more general medical
conditions, there is an equally broad range from acute palpitations and stroke to lung cancer and chronic con-
ditions such as hepatitis and liver cirrhosis, as well as infections and infectious diseases—hepatitis, HIV, and
AIDS, to mention just a few (e.g., see Petronis and Anthony 1989; Vlahov et al. 1990; Ford et al. 2000). 
At one end of the life span, the spectrum of drug-associated adverse health effects begins with fetal distress, low
birthweight, deficits in fetal growth, and other complications of pregnancy (e.g., see Bandstra et al. 2001). In the
adolescent and young adult years, self-inflicted injuries and homicides become more prominent in this spectrum
(e.g., see Petronis et al. 1990; Tardiff et al. 1997). Excess deaths also are associated with illegal drug use and drug
dependence, even in middle age and late life (e.g., see Neumark et al. 2000; Rosenberg and Anthony 2001). In
addition, illegal drug use has a prominent rank order among causes of the global burden of disease and disability
(Murray and Lopez 1996). Globally, some population projections indicate an increase in this rank ordering over
the next several decades, coupled with an increasing number of adolescents and young adults in many parts of
the world (Anthony and Helzer 1995).
For most of the 20th century, claims of association between illegal drug use and many of these negative conse-
quences were based primarily on case studies and anecdotes. During the past 25 years, clinical and epidemiological
research supported by NIDA and other agencies often has substantiated these claims (e.g., see National Institute
on Drug Abuse 1998), although it sometimes has challenged firmly held beliefs about drug-related harm 
(e.g., see Frank et al. 2001).
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Socioeconomic imbalances across race/ethnicity groups of the U.S. population represent a plausible source of
variation when comparisons are made for differences across historically disadvantaged minority group members.
To some extent, health disparities faced by racial/ethnic minority groups in the United States might be traced
back to illegal drug-using behaviors. These health disparities are not necessarily due to excess in illegal drug use in
these groups, but they may be associated with illegal drug use and associated conditions, such as delays in medical
recognition or inefficiencies in the care and management of the conditions once the conditions are detected.
Some of the observed health disparities also may be associated with a disproportionate representation of minority
group members among street-level lieutenants for drug trafficking, which may have substantial income-related
benefits as well as injury-related costs and risks (e.g., see MacCoun and Reuter 1992).
Disproportionate or not, the involvement of African-American young people in drug trafficking within dynam-
ically changing drug markets must be considered as a plausible partial explanation for an otherwise unexpected
excess in homicide death rates that affect this minority subgroup. For example, among White males ages 15–24,
the national death statistics in 1997–1999 indicated 10 to 13 homicides per 100,000 persons; the corresponding
values for African-American males in the same age group are 85 to 113 homicides per 100,000 persons.
Moreover, origins of the seven- to eightfold excess observed for males ages 15–24 in this particular contrast can
be seen in a three- to fivefold excess when this comparison is made for males ages 1–14, and an approximate
fivefold excess among males ages 25–44 (National Center for Health Statistics 2000; also see Chapter 7).
The observed African-American excess in homicide rates is not restricted to males. Compared with White female
homicide rates of 2.8 to 3.2 homicides per 100,000 persons in the 15–44 age group during 1997–1999, the 
corresponding values for African-American females in this same age group range from 11.5 to 14.5 homicides
per 100,000 persons. An excess also can be seen for younger females ages 1–14: recent values of about 1 homicide
per 100,000 persons are seen for White girls in this age group, versus recent values of 3.0 to 3.4 homicides per
100,000 persons for African-American girls of the same age (National Center for Health Statistics 2000).
Notwithstanding the importance of drug trafficking and homicides among African Americans, other drug-
related sources of mortality also emerge when examining comparative mortality statistics. For example, the U.S.
Department of Health and Human Services Task Force on African American and Minority Health found that
among African Americans, mortality rates for chronic disease and cirrhosis have been nearly twice as high 
as the rates among Whites; in the 1980s, cocaine-related deaths tripled among African Americans but only 
doubled among Whites. This excess in cocaine-related deaths may reflect inaccuracy in estimates of the preva-
lence of cocaine use, which in general show roughly comparable values for African Americans versus Whites, or
may reflect excess risk of cocaine-related harm once cocaine use begins—a topic of continuing inquiry
(Flewelling et al. 1992). 
Analyses of variation in mortality also highlight excess mortality rates for some of the drug-related causes 
of death among certain subgroups of the American Indian/Alaska Native populations in the United States. 
For example, between 1997 and 1999, the suicide mortality rates experienced by American Indian/Alaska
Native males ages 15–24 ranged from 36 to 42 suicides per 100,000 persons. Corresponding values for 
White males in this age group are just 23 to 26 suicides per 100,000 persons (National Center for Health
Statistics 2000). No excess of similar magnitude is seen for American Indian/Alaska Native females in 
this age group. One is left to speculate whether the observed excess in male suicide is attributable to heavy 
drinking, illegal drug use, or other life circumstances or processes that have a different effect on young male
American Indians/Alaska Natives.
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Noteworthy in comparing age-adjusted death rates for Whites versus Asian/Pacific Islander and Hispanic citizens
in recent years is that Whites generally have higher rates across the categories of causes of death. One exception
is homicide death rates, for which the Whites and Asian/Pacific Islanders have values that are not appreciably
different (3.8 per 100,000 persons versus 3.2 per 100,000 persons, respectively, in 1999). This exception is note-
worthy because Whites experienced excess mortality rates in virtually all other categories of causes of death
(National Center for Health Statistics 2001).
AIDS
AIDS surveillance data are gathered by CDC, which uses information collected by health departments in each
State, U.S. territory, and the District of Columbia. Between 1987 and 1995, the age-adjusted death rate for
AIDS and HIV disease more than doubled, from 5.6 to 16.3 deaths per 100,000 population. AIDS and HIV
disease remain high among leading causes of death for persons ages 25–44. However, since 1995, there generally
have been declines in mortality due to AIDS and HIV-related disease (16.3 deaths per 100,000 persons in 1995
to a projected 5.4 deaths per 100,000 persons for 1999).
Through December 2000, State and local health departments reported between 750,000 and 800,000 adolescent
and adult AIDS cases to CDC. Table 31 presents information reported through December 2000 for 130,104
female adolescent/adult AIDS cases, and Table 32 presents information about 635,451 male AIDS cases.
Among the over 130,000 female cases, just over 70,000 were Black, non-Hispanic, and roughly 25,000 were
Hispanic. Among the more than 635,000 male cases, just over 210,000 were non-Hispanic Blacks and 114,000
were Hispanics. As gauged against the relative sizes of these groups in the U.S. population, these numbers show
disproportionate overrepresentation of these racial/ethnic minorities among AIDS cases.
As shown in the cumulative total panel of Table 31, about two of five female AIDS cases have been traced to
injecting drug use (41 percent). This value is roughly comparable across all of the racial/ethnic minority groups
depicted in Table 31; Asian/Pacific Islanders are a noteworthy exception (16 percent). Heterosexual contact also
is a prevalent exposure category, representing 40 percent of female AIDS cases overall. As shown in the cumula-
tive total panel of Table 32, injecting drug use generally is less prominent as an exposure category for male AIDS
cases (22 percent), where men having sex with men accounts for almost three of five cases overall (56 percent).
Noteworthy racial/ethnic variation appears in the prevalence of these exposure categories. For example, among
men with AIDS, only 9 percent of White non-Hispanic cases are traced to injecting drug use and 74 percent
are traced to men having sex with men. The corresponding values are 34 percent versus 37 percent for non-
Hispanic Black men with AIDS, 35 percent versus 42 percent for Hispanic men with AIDS, 5 percent versus
72 percent for Asian/Pacific Islander men with AIDS, and 16 percent versus 57 percent for American
Indian/Alaska Native men with AIDS (Table 32). Summing across the two tables, about one-quarter or roughly
193,000 of the 766,000 adolescent/adult AIDS cases reported through December 2000 might be traced to
injecting drug use.
The estimated number of AIDS deaths in 1999 was 8 percent smaller than the value observed in 1998. The
number of AIDS deaths declined most among American Indians/Alaska Natives (16 percent), followed next by
non-Hispanic Whites (15 percent), Asian/Pacific Islanders (11 percent), and Hispanics (7 percent). Non-
Hispanic African Americans showed the smallest decline in death rate due to AIDS (3 percent) across that same
time span (Centers for Disease Control and Prevention 2001).
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DRUG-RELATED EMERGENCY ROOM EPISODES
Year-to-year variation in drug-related hospital ER statistics serves as one important manifestation of underlying
health risks associated with illegal drug use. Data on the occurrence rates for drug overdoses and other ER 
casualties associated with illegal drug use are important to the Nation’s surveillance and monitoring of its drug
problems. However, year-to-year variation of these ER statistics can be determined by factors other than variations
in the underlying risk of becoming a drug user or of developing drug problems. Over time, this variation also
depends on complex conditions and processes, including diverse life circumstances and dynamic social conditions,
and the relative street-level availability of toxic drugs and the introduction of new products, such as OxyContin
®
(sustained-release oxycodone). 
The example of heroin overdose serves a useful illustrative purpose. On one hand, a city with a shortfall in funds
for emergency medical services may show an increase in heroin overdose deaths, even when no change has
occurred in the underlying dynamics of the heroin-using population of the city. On the other hand, active 
programs to distribute Narcan
® (naloxone) or to use other harm-reduction methods may reduce or increase the
number of heroin overdose cases seen in the city’s ERs, depending on whether the victim survives to be taken
to the ER or dies and is taken directly to the morgue. Over time, and from place to place, variation in the number
of drug overdose cases also has depended on administrative counting procedures. For example, in many places,
a heroin overdose case has been counted as an ER admission even when the victim is dead on arrival (DOA)
and cannot be resuscitated by ER staff. In other jurisdictions, this type of DOA heroin overdose victim is
recorded as an ER admission only if the resuscitation efforts are successful; in all other cases, the “admission” is
to the hospital morgue.
As such, the range of sources of variation in number of DAWN episodes by time and place is crucial. This range
encompasses not only changes in prevalence of illegal drug use, but also changes in dosages used, potency, 
frequency of use, routes of administration, aging of drug users and other vulnerability characteristics of existing
users, and the combined use of two or more drugs (e.g., with alcoholic beverages). As noted above, there are
“threshold” factors, associated with decisions about whether to bring a DOA victim to the ER for resuscitation
attempts and whether the DOA victim will be recorded in the ER statistics before transfer to the morgue. There
also are “nosocomial” factors, relating to the quality of care provided in the ER, and other conditions and
processes under the control of ER personnel, supervisors, and hospital administrators. Research on these thresh-
old and nosocomial factors has been prominent in the epidemiology generally and in psychiatric epidemiology
specifically, but has not been prominent in discussions of statistics from DAWN surveillance activities or
research on drug overdoses generally.
DAWN, now operated by the Substance Abuse and Mental Health Services Administration (SAMHSA) Office
of Applied Studies, originated as a pilot project of the Bureau of Narcotics and Dangerous Drugs and the Drug
Enforcement Administration in the early 1970s. NIDA assumed responsibility for DAWN during the mid-
1970s and transferred this responsibility to SAMHSA more than 10 years ago. Over the years, DAWN’s profile
as an instrument of drug surveillance has changed considerably. Currently, DAWN may be described as a large-
scale, ongoing surveillance system that monitors potential adverse consequences of illegal drug use and other
drug-related emergencies, as abstracted from records of participating hospital ERs and selected ME offices
throughout the country. For the first decade or more of DAWN’s existence, the sample of ER and ME offices
represented a nonsystematic sampling of these facilities; there also was participation by other facilities, such as
youth emergency crisis services and telephone hotlines for callers with concerns about illegal drug use and 
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drug-related problems. Thereafter, the network was constrained to include only ER and ME facilities, and a
more systematic effort was made to derive a nationally representative sample suitable for projections to the 
entire Nation.
A DAWN report is supposed to be generated at the participating facility each time a patient or deceased indi-
vidual is found to have a drug-related problem or to have died a drug-related death. By design, a DAWN episode
report is submitted for each incident of this type. Data for each episode report, abstracted from medical records,
generally include demographic information about the patient (alive or deceased), circumstances about the
episode that prompted emergency care or an ME’s attention, and information about the drug and judgments
about the circumstances of drug use (e.g., whether the drug had been taken as an effort to commit suicide).
DAWN counts events rather than individuals. Individual drug users may contribute multiple ER episodes and
generate multiple drug mentions in any given year. Of course, an ME mention is an “absorbing” event—once
an individual drug user has appeared in the ME statistics, there is no subsequent reappearance in either ER or
ME statistics.
Interpretation of DAWN statistics requires attention to DAWN administrative decisions about drugs used in
combination. These administrative decisions can be appreciated best by considering specific cases. Consider a
hypothetical overdose victim brought to the ER with signs and symptoms of acute cocaine toxicity. Combining
information obtained through interviews with the victim and his friends with results from drug-screening tests,
the ER staff may be able to confirm that the victim had smoked a small amount of marijuana in a pipe early in
the evening and then had injected cocaine just before losing consciousness. This single ER episode will generate
a DAWN overdose report that mentions both cocaine and marijuana. If the victim had consumed a single can
of beer, this episode also would generate an “alcohol-in-combination” mention on top of the marijuana and
cocaine mentions just described. That is, a DAWN drug mention does not require causal attribution or any 
sorting of drugs into refined categories of “proximal cause,” “precipitating cause,” “non-causal concomitant,” or
other groups that might indicate which drug or drugs actually prompted the ER visit. However, alcohol-related
episodes are reported to DAWN only when alcohol is used in combination with another drug. For example, a
car crash victim who drank a six-pack of beer and then crashed his car will not appear in the DAWN statistics
if alcohol is the only drug involved. A different car crash victim who drank a six-pack of beer and is discovered
to have taken one puff on a marijuana cigarette will appear in the DAWN statistics, even if the car crash is
judged by the police or ER staff to be due to the alcohol intoxication. Hence, a DAWN “mention” or “drug-
related episode” does not imply causal attribution. It simply means that recent use of the drug was identified
either through interviews with the victim or acquaintances or through toxicological screening or formal drug
testing. This difference between a “DAWN drug-related ER mention” and a “drug-caused ER event” is crucial
in the interpretation of DAWN statistics. The relative frequency of individual drugs within the DAWN statistics
depends heavily on the prevalence of use of each drug in the population and is not necessarily a reflection of the
causal importance of each drug. Frequently used drugs appear often in DAWN statistics, even if they have not
caused an overdose and even if they have a noncausal peripheral involvement in the drug-related ER episode
(e.g., see Anthony and Trinkoff 1986).
Subject to these issues of interpretation, DAWN projections for the coterminous United States in 2000 indicate
almost 250 drug-related ER episodes per 100,000 residents age 6 and older (243.4 cases per 100,000 residents,
as shown in the first row of Table 33). Sorted into categories by whether cocaine, marijuana, and either heroin 
or morphine were mentioned in the DAWN ER report, data reveal 70.7 cocaine-related ER mentions per
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100,000 residents, almost 40 heroin/morphine-related ER mentions per 100,000 residents, and almost 
40 marijuana-related ER mentions per 100,000 residents. (As described in the prior paragraph, the terms 
“marijuana-related” or “cocaine-related” do not mean that the marijuana use or the cocaine use caused the ER
casualty, but that these drugs were mentioned as concomitant circumstances in relation to the ER visit.)
There is slight male excess in the projected occurrence of the ER episodes. Males accounted for almost 260 ER
episodes per 100,000 persons, compared with about 220 ER episodes per 100,000 females (Table 33, first column).
Substantial age-related variation emerges in the occurrence rates for ER episodes, with very low rates for children
ages 6–11, and the highest rates observed for young adults ages 18–25 (Table 33, first column). Studied drug-
by-drug, somewhat different age-related patterns emerge. For example, the highest rates of cocaine-related and
heroin-related mentions are observed for males ages 26–34 years of age, with females of this age having some-
what lower rates. Peak values for marijuana mentions are observed for individuals ages 18–25 (Table 33).
The youngest and oldest age categories merit special mention. Changes in demographic structure and drug
experience within the United States soon will necessitate respecification of these age categories. There no longer
is homogeneity of drug experience within the 6–11 age group, nor among adults age 35 and older. For example,
illegal drug-using behavior in the preadolescent years of childhood formerly was an extremely rare occurrence;
it now is more prevalent in the later primary school grades (e.g., see Johnson et al. 2001). Moreover, in com-
paring individuals ages 26–34 with adults age 35 and older, there is an apparent sharp drop in the occurrence
of ER episodes, perhaps leading the reader to believe that those ages 30–34 are at substantially higher risk of
being an ER casualty than individuals ages 35–39. However, the apparent drop in occurrence rates in the older
age group mainly is a consequence of grouping people ages 35–39 with the increasing numbers of U.S. residents
who are age 50 and older and for whom illegal drug use rates are quite low. The single “average” summary 
statistics for children under age 12 and for adults age 35 and older no longer serve well in this context, given
what we now know about age-specific prevalence of illegal drug use and the “aging” of the U.S. population. This
attention to more refined age categories will become a topic of greater importance in comparisons across
racial/ethnic minority groups because the demographic structure and age composition of these subgroups 
differ substantially.
Interesting male-female differences and racial/ethnic variations appear in the relative frequency of different
drugs mentioned in the DAWN statistics. In general, because alcohol use is a relatively frequent behavior 
for many Americans and often is concomitant with other drug use in the United States, the most frequently
mentioned drug in the DAWN statistics is “alcohol-in-combination” with other drugs. Alcohol-in-combination
appears in almost two in five of the DAWN ER episodes involving male patients (39 percent, as shown in 
Table 34) and in just over one-fourth of DAWN ER episodes involving female patients (28.7 percent, also in
Table 34). However, this ranking of alcohol-in-combination is not the case for DAWN ER episodes involving
non-Hispanic Black patients and Hispanic patients, for whom cocaine is the most frequently mentioned drug
(Table 34). Furthermore, heroin/morphine is the third-ranked drug group in the statistics for non-Hispanic
Blacks and Hispanic patients. Heroin/morphine also is prominent for all male patients, but not for all female
patients, among whom marijuana/hashish is in the third rank (Table 34).
Table 35 presents trends in the estimated numbers of drug-related ER episodes by race/ethnicity and age from
1994 to 2000. The total number of drug-related episodes was highest in 2000, increasing from almost 900,000
episodes in 1994 to almost 1.1 million episodes in 2000.
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By stratifying episodes in relation to race/ethnicity, it is possible to see that the percentage increase in total 
number of drug-related episodes from 1999 to 2000 was 12 to 13 percent for Whites, more than 20 percent 
for Hispanics, and almost negligible for Blacks (Table 35). Between 1999 and 2000, all age groups shown in
Table 35 exhibit increases in drug-related ER episodes, except for Blacks and the “Other” category, which most
likely is a result of a change in administrative coding practices.
In  1994, the total number of cocaine mentions in ER visits was 143,000 (Table 36). Cocaine mentions
decreased to 135,700 in 1995, but they have increased to nearly 175,000 mentions in 2000. In the ER cocaine
statistics for all race/ethnicity groups combined, there has been a demographic shift since 1998, when there were
more ER cocaine mentions for individuals ages 6–34 than for adults age 35 and older. Thereafter, the greater
number of ER cocaine mentions involved older adults, mainly as a consequence of greater occurrence of
cocaine-related ER visits (Table 36). African Americans are disproportionately represented among the ER victims
in these cocaine mentions for every age group except youth ages 12–17. During 2000, non-Hispanic Whites
and Blacks in the 26–34 age group had roughly equivalent numbers of ER victims in the cocaine mention 
category (about 19,000 to 20,000 victims), compared with 7,500 for Hispanics and smaller numbers for other
race-ethnicity groups. After yearly increases between 1994 through 1998 in the total number of Black
Americans mentioned in the DAWN cocaine statistics, there were declines in subsequent years. In contrast,
there were continuing increases for Whites and Hispanics. Among Americans age 35 and older, virtually all race-
ethnicity groups represented in the table showed increased numbers for 2000 versus 1999, consistent with the
previously described aging of the population in general and of active cocaine users within the U.S. population.
As with cocaine mentions, total mentions for heroin/morphine also increased, from 63,158 mentions in 1994
(Substance Abuse Mental Health Services Administration, 1999a) to 94,804 mentions in 2000 (see Table 37).
There were recent increases in the late 1990s for virtually all racial/ethnic groups represented in the table.
Scanning across age groups in 2000 (Table 37), the largest number of heroin/morphine ER mentions was
observed for adults age 35 and older (over 51,000 mentions). Reflecting the increased survivorship of the U.S.
population, and the aging of heroin/morphine users within this population, a substantial number of ER mentions
for the heroin/morphine drug group now involve older adults in virtually all racial/ethnicity groups within 
the population. 
Table 38 shows DAWN ER statistics for the methamphetamine/speed drug group, which increased during the
1980s and were at plateau levels during most of the 1990s, with large increases observed between 1993 and
1994. Total methamphetamine/speed mentions increased to 17,557 mentions in 1994 and then ranged between
10,000 and 18,000 mentions from 1994 to 2000.
Among racial/ethnic groups, a large increase between 1994 and 2000 occurred among Hispanics (201 percent),
but there were no appreciable increases during the last decades of the 20th century except for American
Indians/Alaska Natives and the “Other” subgroup (Table 38). Whereas the absolute number of methamphetamine/
speed cases recently has been increasing among Hispanics ages 12–17, this increase generally has paralleled
increases in the size of this Hispanic subgroup. Whether there also are increases in the risk of becoming a
methamphetamine/speed user or developing associated problems is unknown. 
DAWN ER mentions for marijuana/hashish (Table 39) have been increasing since 1994, and this trend sustains
increases observed since the late 1980s (National Institute on Drug Abuse 1998). For example, scanning all
groups combined, there were slightly over 40,000 mentions of marijuana/hashish in 1994. By 2000, the 
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number of the DAWN ER mentions had increased steadily to almost 100,000, more than doubling. This 
dramatic increase between 1994 and 2000 can be seen for each racial/ethnic subgroup represented in Table 39,
except for Black Americans. Among Blacks, there were steady increases in the number of DAWN ER mentions
for marijuana/hashish, from almost 15,000 in 1994 to more than 26,000 in 2000, but the number did not 
double over that period. 
Table 40 provides information about drugs used in combination, as well as patient dispositions, based on
DAWN statistics for 2000, the most recent year for which total statistics are available. Detection of multiple
drugs was modestly more likely for men represented in DAWN statistics than for women, but no appreciable
variation emerged across racial/ethnic groups represented in the table. Episodes were most likely to be associated
with an admission for White females (almost 60 percent) and were least likely to be associated with an 
admission for Hispanic males (about 40 percent). Other subgroups were intermediate, with females generally
somewhat more likely to be admitted than males in each of the three racial/ethnic groups represented in the
table. The sources of the observed variation remain open questions and may be due to differential prominence
of suicide and suicide-related behavior when women are seen in DAWN facilities for drug-related episodes;
or the sources of this variation might be traced back to race-related differentials in hospitalization coverage or 
third-party payment for health care.
Apportioned into four groups, the U.S. population age 12 and older is roughly 70 to 75 percent White, about
10 to 12 percent Black, approximately 10 percent Hispanic, and about 4 percent for other racial/ethnic sub-
groups, as depicted in Chapter 1 of this report. According to Table 41, the distribution of racial/ethnic groups
in DAWN ER mentions for 2000 does not follow this pattern. In that year, about 57 to 58 percent of the
DAWN ER mentions involved White patients, just over 21 percent involved Black patients, and nearly 11 percent
involved Hispanic patients. The reasons for overrepresentation of Blacks in these statistics is unknown and do
not seem to involve greater prevalence of illegal drug use among Blacks in the United States (see Chapter 3).
Table 41 also compares the racial/ethnic distributions, drug group by drug group, with some interesting 
patterns. For example, the racial/ethnic distribution of LSD is of note. Here, we see White patients represented
among LSD casualties roughly in proportion to their population representation, whereas Blacks appear to be
underrepresented among these victims (72.6 percent versus 6.3 percent). At the other extreme, Whites are
underrepresented among victims of DAWN cocaine-related and marijuana-related casualties, whereas Blacks are
overrepresented (roughly 34 percent versus 43 percent for cocaine, and 51 percent versus 27 percent for marijuana).
With mentions for amphetamines and for methamphetamine/speed, Hispanics are overrepresented (15 to 
16 percent) whereas Blacks are underrepresented (under 6 percent). These patterns merit more detailed scrutiny
in advanced epidemiological analyses that take into account local area variations in drug-taking behaviors, as
well as life circumstances, conditions, and process of the type mentioned early in this chapter.
DRUG-RELATED DEATHS AND INTENTIONAL 
AND UNINTENTIONAL INJURIES
ME data presented in DAWN reports are collected from a nonrandom sample and should not be evaluated 
as if they were statistically representative of the Nation or of the respective metropolitan areas. As has been 
discussed in relation to nonfatal DAWN ER mentions and episodes, DAWN defines a drug-related death as 
any death in which drug use is a contributory factor but not necessarily the sole cause; alcohol-in-combination
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is mentioned only when alcohol is mentioned concomitantly with some other controlled substance or related
drug of abuse. In consequence, causation of death by the drug is not implied. Some MEs may include cases
based on circumstantial evidence; others may report drug-related deaths confirmed only through toxicological
analyses. These circumstances necessitate caution before definitive interpretation of the DAWN data on 
drug-related deaths.
The heroin/morphine drug group, cocaine, and alcohol-in-combination rank at the top of the drugs mentioned
in connection with DAWN statistics for drug-related deaths (Table 42). For example, among male decedents,
heroin/morphine was mentioned in association with about 45 percent of deaths judged to be drug-related; the
corresponding value for female decedents was just over 33 percent. Cocaine was mentioned in association with
almost 45 percent of drug-related deaths for males and nearly 31 percent for female decedents. Alcohol-in-
combination was implicated in slightly over 37 percent of reports on male decedents, versus nearly 24 percent
for female decedents (Table 42).
The prominence of acetaminophen among drug mentions associated with female decedents represents an 
epidemiological puzzle, partly because it is a widely available and oft-used over-the-counter pharmaceutical
product. Acetaminophen may appear on this list of the top-10 ranked drugs or drug groups in the DAWN ME
statistics simply because acetaminophen is a commonly used drug in the United States—used often not only 
by drug-dependent females who die from drug-related causes, but also used frequently by females who do 
not die from drug-related causes and who do not engage in illegal drug use (e.g., see Anthony and Trinkoff
1986). Acetaminophen can be used in drug overdose attempts. Or, its presence in connection with a drug-
related death might be implicated via toxicological analysis or other forensic investigation (e.g., psychological
autopsy or post-mortem interview), even when the acetaminophen played no contributing causal role in the
occurrence of death.
The prominence of marijuana/hashish among the top-10 ranked drugs also may be explained in this fashion. It
certainly is possible for marijuana and hashish to be implicated in drug-related deaths (e.g., driving while intox-
icated). However, the potential for a “fatal drug overdose” is substantially more likely for heroin, morphine, and
cocaine than for marijuana and hashish. It is possible that the appearance of marijuana/hashish in Table 42 can
be traced back to the general prevalence of marijuana/hashish use in U.S. populations, with no implication that
this drug has caused the death observed in the DAWN statistics.
For racial/ethnic variations in relation to the DAWN ME mentions, the prominence of cocaine is noteworthy
in relation to Black and Hispanic decedents. Whereas cocaine is ranked third and is mentioned in connection
with 32 percent of White decedents, it is first-ranked and mentioned in connection with almost two-thirds 
of Black decedents and second-ranked and mentioned in connection with more than 45 percent of Hispanic
decedents. It is possible that the toxicity of cocaine accounts for this prominence, but we cannot rule out 
the possibility that MEs are more likely to test for cocaine metabolites when the decedent is a minority; we 
also cannot rule out the “prevalence” circumstances described above. That is, in some populations, recently
active cocaine use is more common among African Americans and Hispanic Americans. To the extent that
DAWN ME statistics draw more heavily on these populations, the overrepresentation of cocaine mentions in
DAWN ME statistics may correspond with this greater prevalence of recently active cocaine use within these
minority populations.
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The prominence of lidocaine and quinine detected among Black decedents may reflect greater occurrence of
narcotics overdose in this subgroup of the population (Table 42). Alternately, this prominence may simply be
an artifact of administrative procedures in ME offices, such as greater surveillance for lidocaine and quinine
among young adult Black decedents dying from other causes.
Figure 13 is based on DAWN ME statistics for 2000 and examines the manner of drug-related deaths by
race/ethnicity. Arranged in sequence, the columns within each racial/ethnicity subgroup pertain to so-called
“accidental” deaths, suicides, and deaths due to unknown or other causes. This arrangement yields an ogive (or
“backwards J”) pattern for all three racial/ethnic subgroups represented in the figure, with the accidental deaths
being most common, the suicide deaths being least common, and the other/unknown deaths being intermediate
in frequency. Among DAWN ME statistics, Hispanics are overrepresented among accidental deaths, and Whites
are overrepresented among suicide deaths. There is a disproportionate representation of Blacks among deaths
assigned to the “other/unknown” category, which may be a manifestation of race-related administrative practices
within ME offices.
SUMMARY
Data from CDC on HIV/AIDS cases indicate disproportionate representation of African Americans and
Hispanics among AIDS cases. Most striking is the finding that although African Americans and Hispanics 
collectively comprise about no more than 25 percent of the U.S. population, they now account for more than
50 percent of the reported AIDS cases.
Many men and women in the United States with HIV/AIDS have contracted the disease through injecting drug
use or via homosexual or heterosexual contact with injecting drug users. Through December 2000, among 
adolescent and adult women with AIDS, it was possible to trace the HIV infection back to injecting drug use
for 40 to 45 percent of the estimated 130,000 AIDS cases—about two in five cases. Women of Asian/Pacific
Islander heritage were an exception, with only 16 percent traced back to injecting drug use. The corresponding
value for the estimated 635,000 male AIDS cases is 22 percent—about one in five.
DAWN ER and ME statistics prompt new research questions about the overrepresentation of racial/ethnic
minority groups in certain categories. For example, with cocaine-related ER and ME mentions, we now cannot
say whether the apparent overrepresentation of Blacks is due to an excess risk of drug-related morbidity. It might
be due to other conditions or processes such as an excess in frequency or form of recently active illegal drug use
or to associated life circumstances. Social conditions and processes are likely to be important, including access
and availability to primary care services, nature of health benefits available to drug users, or a variety of other
factors. We cannot rule out the possibility that patients of African heritage are more likely to be asked about
their use of cocaine or are more likely to be tested for cocaine through toxicological methods.
At present, drug surveillance statistics such as these can help us raise questions about health disparities affecting
racial and ethnic minority groups. Nevertheless, by themselves, these surveillance statistics are unsatisfactory. In
general, they open new research questions, but they do not settle the questions with definitive or compelling
evidence. The CDC Web site (www.cdc.gov) provides useful surveillance data on this topic and related topics.
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Table 33. Estimated Rates of Emergency Department Drug Abuse Episodes and 
Mentions of Selected Drugs per 100,000 Population in the Coterminous United States,
by Sex and Age: 2000
Total Cocaine Heroin/Morphine Marijuana/Hashish  Total
Sex and Age Episodes Mentions Mentions Mentions Population
a
Total
b (6 years & up) 243.4 70.7 39.3 39.0 247,279,858
6–11 years 4.3 0.0 0.0 * 24,062,996
12–17 years 271.6 18.8 4.6 67.1 23,362,981
18–25 years 426.0 88.9 63.5 105.0 28,977,842
26–34 years 410.7 154.6 73.2 66.2 32,997,576
35 years & up 201.1 67.7 38.7 20.5 137,878,463
Male (6 years & up) 258.9 94.8 53.5 51.5 119,580,672
6–11 years 4.4 * 0.0 0.3 12,314,419
12–17 years 185.3 16.7 4.4 76.1 11,956,318
18–25 years 454.9 118.5 78.8 47.7 14,245,527
26–34 years 442.1 193.9 91.2 86.1 16,147,206
35 years & up 231.5 97.1 57.5 26.9 64,917,202
Female (6 years & up) 220.8 46.4 24.5 26.1 127,699,187
6–11 years 4.1 0.1 0.0 * 11,748,577
12–17 years 350.1 20.9 4.2 55.9 11,406,663
18–25 years 381.4 58.2 44.5 59.8 14,732,315
26–34 years 367.7 112.9 52.5 45.3 16,850,371
35 years & up 168.8 40.1 21.1 14.3 72,961,261
aAverage 2000 civilian noninstitutional population estimated by the Substance Abuse and Mental Health Services Administration based on a
procedure using three Census Bureau data files.
bTotal includes patients whose gender was unknown or not reported.
*Low precision, no estimate reported.
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.Adverse Social, Behavioral, and Health Consequences
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Table 34. Drug Mentioned Most Frequently by Hospital Emergency Departments, 
by Sex and Race/Ethnicity of Patients: 2000
Percentage of Percentage of
Rank Drug Name Total Episodes Rank Drug Name Total Episodes
Male Patients Female Patients
1A lcohol-in-Combination 39.0 1 Alcohol-in-Combination 28.7
2 Cocaine 36.6 2 Cocaine 21.0
3 Heroin/Morphine 20.7 3 Marijuana/Hashish 11.8
4 Marijuana/Hashish 19.9 4 Heroin/Morphine 11.1
5 Unspec. Benzodiazepine 4.2 5 Acetaminophen 8.3
6 Acetaminophen 3.1 6 Unspec. Benzodiazepine 5.3
7 Amphetamine* 2.9 7 Alprazolam 5.1
8M ethamphetamine/Speed 2.7 8 Ibuprofen 4.7
9 Hydrocodone 2.5 9 Aspirin 4.1
10 Alprazolam 2.4 10 Clonazepam 4.1
White Patients Black patients
1A lcohol-in-Combination 32.7 1 Cocaine 56.7
2 Cocaine 17.9 2 Alcohol-in-Combination 40.2
3 Marijuana/Hashish 14.6 3 Heroin/Morphine 23.3
4 Heroin/Morphine 12.1 4 Marijuana/Hashish 19.8
5 Acetaminophen 6.4 5 Acetaminophen 2.6
6 Unspec. Benzodiazepine 5.7 6 Unspec. Benzodiazepine 2.3
7 Alprazolam 5.4 7 Ibuprofen 1.9
8 Hydrocodone 4.5 8 PCP/PCP Combinations 1.7
9 Clonazepam 4.4 9 Aspirin 1.0
10 Ibuprofen 3.2 10 Hydrocodone 1.0
Hispanic Patients
1 Cocaine 34.8 6 Unspec. Benzodiazepine 4.6
2A lcohol-in-Combination 32.4 7 Amphetamine* 3.7
3 Heroin/Morphine 22.0 8 Methamphetamine/Speed 3.2
4 Marijuana/Hashish 17.2 9 Ibuprofen 3.0
5 Acetaminophen 6.4 10 Aspirin 2.5
*Does not include methamphetamine or other unspecified amphetamine.
NOTES: These estimates are based on a representative sample of non-Federal hospitals with 24-hour emergency departments in the 
coterminous United States.
Percentages are based on weighted emergency room episode estimates of 309,619 for male patients; 281,994 for female patients;
334,985 white patients; 133,776 black patients; and 68,282 Hispanic patients.
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.Adverse Social, Behavioral, and Health Consequences
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Table 35. Estimated Number of DAWN Hospital Emergency Department Visits, 
by Race/Ethnicity and Age: 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
Total  899,601 900,287 906,367 942,382 981,764 1,014,243 1,099,306
6–34 554,587 532,307 524,444 538,831 535,728 530,376 577,750
12–17 93,039 92,847 96,544 98,442 95,193 82,976 102,874
18–25 191,104 178,480 170,983 185,402 184,230 198,285 221,228
26–34 269,252 259,152 255,373 252,629 255,226 247,566 252,389
35+ 340,555 365,720 380,313 400,671 443,449 482,463 519,890
Unknown 4,458 2,261 1,609 2,879 2,587 1,404 1,666
White 499,194 503,778 496,036 524,359 555,379 589,670 632,313
6–34 310,786 300,488 293,298 309,107 313,082 318,011 342,196
12–17 62,292 62,374 65,770 68,424 65,526 55,116 67,789
18–25 108,303 101,319 96,364 106,847 112,381 124,954 136,423
26–34 139,432 135,590 130,183 132,701 134,353 136,981 137,292
35+ 187,143 201,983 202,407 214,004 240,792 270,895 289,347
Unknown 1,265 1,307 332 1,248 1,505 765 770
Black 240,582 240,266 233,643 236,437 238,955 234,742 235,083
6–34 139,445 132,698 117,298 116,157 108,120 101,488 97,012
2–17 11,936 12,015 8,909 8,629 6,462 7,322 7,991
18–25 43,635 40,070 31,101 33,449 29,526 30,890 30,755
26–34 83,733 80,337 77,009 73,676 72,034 62,948 57,921
35+ 100,691 107,272 115,510 119,613 130,501 132,985 137,728
Unknown 445 296 836 667 334 268 343
Hispanic 80,359 74,942 93,221 91,315 98,715 97,518 120,126
6–34 53,679 48,866 63,448 60,812 63,317 60,453 75,046
12–17 9,990 8,546 13,371 12,107 13,805 11,454 14,997
18–25 19,823 18,917 23,768 25,342 24,127 23,456 30,565
26–34 23,778 21,271 26,210 23,125 25,336 25,498 29,388
35+ 26,576 26,005 29,693 30,418 35,228 36,927 44,851
Unknown 104 71 80 85 170 138 229
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Table 35 (continued). Estimated Number of DAWN Hospital Emergency Department
Visits, by Race/Ethnicity and Age: 1994–2000
*Low precision, no estimate reported.
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
American Indian/
Alaska Natives 2,427 1,619 3,047 1,685 1,669 1,280 1,980
6–34 1,438 756 2,276 935 1,397 810 910
12–17 217 102 690 146 208 110 58
18–25 577 189 832 362 313 268 419
26–34 643 466 750 423 875 433 434
35+ 989 861 771 750 272 469 1,063
Unknown * 2 * 1 * * 8
Asian/Pacific 
Islanders 5,774 5,637 5,527 5,823 4,922 5,391 6,227
6–34 4,131 4,208 4,097 4,503 3,258 3,714 4,345
12–17 658 1,026 787 847 697 934 670
18–25 1,873 2,042 2,038 2,079 1,377 1,287 2,209
26–34 1,449 1,130 1,269 1,573 1,184 1,492 1,463
35+ 1,633 1,425 1,416 1,320 1,656 1,675 1,875
Unknown 9 5 14 * 7 2 7
Unknown 69,682 72,344 72,491 80,429 79,331 83,054 103,496
6–34 44,048 43,968 42,488 45,949 44,553 44,371 58,197
12–17 7,759 8,664 6,878 7,898 8,286 7,850 11,352
18–25 16,475 15,226 16,061 16,692 15,576 16,552 20,843
26–34 19,765 19,873 19,370 20,784 20,582 19,814 25,878
35+ 23,012 27,801 29,655 33,605 34,213 38,453 44,990
Unknown 2,622 575 348 875 565 230 310
Other 1,583 1,701 2,402 2,334 2,793 2,588 81
6–34 1,059 1,323 1,540 1,370 2,002 1,529 45
12–17 186 121 139 391 209 191 17
18–25 419 717 819 632 929 877 15
26–34 454 484 582 347 863 400 13
35+ 511 372 862 960 786 1,058 36
Unknown 12 5 * 4 6 1 * Adverse Social, Behavioral, and Health Consequences
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Table 36. Estimated Number of DAWN Emergency Department Visits 
With Mention of Cocaine, by Race/Ethnicity and Age: 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
Total  143,336 135,712 152,420 161,082 172,011 168,752 174,882
6–34 88,194 78,042 83,383 86,003 87,877 82,621 81,162
12–17 2,064 2,044 2,581 3,630 4,308 3,214 4,394
18–25 25,430 21,110 22,060 25,218 24,507 25,264 25,753
26–34 60,686 54,881 58,729 57,143 59,008 54,058 51,007
35+ 54,463 57,341 68,717 74,600 83,730 85,869 93,357
Unknown 680 328 319 480 403 261 362
White 40,813 39,950 44,715 50,867 52,954 56,724 59,820
6–34 28,038 26,278 27,715 31,016 31,121 33,045 32,795
12–17 771 990 1,158 1,925 2,380 1,465 2,114
18–25 9,309 8,544 8,413 10,490 10,477 11,930 11,655
26–34 17,959 16,744 18,145 18,598 18,212 19,607 19,025
35+ 12,732 13,636 16,960 19,756 21,738 23,637 26,856
Unknown 43 36 41 96 95 42 169
Black 77,106 73,414 77,984 82,260 84,556 78,017 75,889
6–34 43,756 38,298 37,097 37,996 35,767 30,144 26,027
12–17 378 456 433 489 315 489 407
18–25 10,625 8,090 6,778 8,203 6,425 6,099 5,865
26–34 32,751 29,745 29,880 29,300 29,023 23,515 19,752
35+ 33,178 35,017 40,699 43,980 48,660 47,782 49,729
Unknown 173 99 189 285 129 91 134
Hispanic 13,355 11,495 17,737 16,760 21,209 20,456 23,728
6–34 9,097 7,343 12,231 11,130 13,737 12,964 15,114
12–17 667 318 680 1,076 1,354 1,049 1,514
18–25 3,134 2,820 5,038 4,762 5,390 5,220 6,063
26–34 5,290 4,205 6,508 5,290 6,994 6,695 7,534
35+ 4,238 4,135 5,481 5,609 7,394 7,418 8,594
Unknown 19 17 26 21 78 74 20
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Table 36 (continued). Estimated Number of DAWN Emergency Department Visits 
With Mention of Cocaine, by Race/Ethnicity and Age: 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
American Indian/
Alaska Natives 273 139 159 93 103 72 140
6–34 60 73 104 59 52 44 67
12–17 7 3 2 6 1 3 3
18–25 14 28 16 21 16 14 23
26–34 38 41 86 32 35 26 41
35+ 213 66 55 34 51 28 69
Unknown * * * * * *  3
Asian/Pacific 
Island 483 296 339 494 476 503 699
6–34 385 189 226 309 374 327 466
12–17 16 10 9 1 4 3 12
18–25 88 73 79 98 125 62 127
26–34 281 106 138 210 245 262 327
35+ 98 106 111 186 102 175 228
Unknown * 1 1 * * * 5
Unknown 11,163 10,311 11,183 10,371 12,472 12,846 14,594
6–34 6,780 5,796 5,821 5,345 6,666 6,027 6,686
12–17 219 264 299 131 249 204 342
18–25 2,234 1,524 1,645 1,564 2,037 1,914 2,016
26–34 4,321 4,009 3,872 3,648 4,380 3,909 4,326
35+ 3,942 4,341 5,299 4,948 5,705 6,764 7,878
Unknown 441 173 63 77 101 55 30
Other 143 107 303 237 241 134 12
6–34 77 66 189 150 161 70 7
12–17 5 3 * 3 4 1 2
18–25 26 31 91 81 37 24 4
26–34 47 31 99 66 120 44 1
35+ 62 40 114 86 79 65 4
Unknown 4 1 * 1 * * * 
*Low precision, no estimate reported.
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.Adverse Social, Behavioral, and Health Consequences
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Table 37. Estimated Number of DAWN Emergency Department Visits 
With Mention of Heroin/Morphine, by Race/Ethnicity and Age, 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
Total 63,159 69,557 72,981 70,712 75,689 82,193 94,805
6–34 30,115 31,318 31,544 31,357 33,224 35,730 42,859
12–17 365 396 492 1,365 896 675 1,052
18–25 8,336 8,376 9,166 9,703 11,251 14,901 18,065
26–34 21,413 22,544 21,886 20,289 21,075 20,153 23,742
35+ 32,887 38,145 41,328 39,259 42,351 46,356 51,698
Unknown 157 93 108 96 113 106 247
White 22,516 26,113 24,696 25,895 28,041 31,827 38,426
6–34 12,216 13,249 12,729 14,018 15,089 17,441 22,235
12–17 250 225 247 1,090 489 398 701
18–25 3,570 3,680 4,532 5,062 6,705 9,461 11,606
26–34 8,395 9,344 7,950 7,865 7,895 7,582 9,929
35+ 10,285 12,849 11,947 11,859 12,919 14,355 16,075
Unknown 15 14 21 19 33 31 115
Black 25,996 27,047 28,295 26,490 27,616 28,646 30,934
6–34 10,566 10,733 9,941 9,393 9,070 9,343 8,986
12–17 29 97 41 46 42 148 50
18–25 2,989 2,904 1,969 2,172 1,696 1,901 1,716
26–34 7,547 7,730 7,932 7,176 7,330 7,293 7,219
35+ 15,381 16,274 18,295 17,053 18,503 19,266 21,913
Unknown 49 40 59 44 42 38 36
Hispanic 9,423 9,814 11,739 9,145 11,448 11,779 14,944
6–34 5,012 4,518 5,036 4,023 4,957 4,726 7,251
12–17 43 35 49 120 168 87 106
18–25 1,146 1,040 1,486 1,211 1,514 1,834 3,200
26–34 3,823 3,443 3,501 2,691 3,274 2,806 3,946
35+ 4,404 5,287 6,693 5,120 6,481 7,046 7,672
Unknown 6 8 9 2 11 7 20
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Table 37 (continued). Estimated Number of DAWN Emergency Department Visits 
With Mention of Heroin/Morphine, by Race/Ethnicity and Age, 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
American Indian/
Alaska Natives 83 87 78 128 58 40 76
6–34 35 32 30 22 22 16 36
12–17 * * 1 * * 1 1
18–25 9 12 15 4 6 10 12
26–34 25 20 15 18 16 5 23
35+ 48 55 47 106 36 23 39
Unknown * * * * * * 1
Asian/Pacific 
Island 127 223 178 248 358 175 290
6–34 66 94 99 104 220 106 202
12–17 1 2 8 9 * 1 60
18–25 20 34 34 47 110 61 86
26–34 44 58 57 47 111 43 56
35+ 61 129 78 144 137 69 88
Unknown * * * * * * *
Unknown 4,938 6,217 7,781 8,522 7,946 9,501 10,125
6–34 2,183 2,670 3,687 3,732 3,764 4,059 4,147
12–17 41 36 146 97 197 40 134
18–25 589 699 1,120 1,183 1,199 1,616 1,444
26–34 1,553 1,935 2,420 2,452 2,368 2,403 2,569
35+ 2,669 3,517 4,075 4,759 4,158 5,412 5,903
Unknown 86 30 20 31 24 30 75
Other 76 56 214 284 222 225 10
6–34 37 22 22 65 102 40 1
12–17 * * * 3 * *  * 
18–25 12 7 10 22 21 17 * 
26–34 26 16 12 40 81 22 1
35+ 38 33 192 219 117 185 9
Unknown * * * * 2 *  *
*Low precision, no estimate reported.
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.Adverse Social, Behavioral, and Health Consequences
121
Table 38. Estimated Number of DAWN Emergency Department Visits With Mention of
Methamphetamine/Speed, by Race/Ethnicity and Age, 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
Total 17,537 15,934 11,002 17,155 11,485 10,448 13,506
6–34 13,199 11,706 7,828 12,451 8,250 7,121 9,044
12–17 1,960 1,438 1,028 1,810 1,081 808 1,120
18–25 5,432 4,787 3,728 4,718 3,482 3,289 3,711
26–34 5,804 5,481 3,004 5,924 3,686 2,988 4,211
35+ 4,327 4,221 3,165 4,696 3,230 3,316 4,456
Unknown 11 7 9 7 6 10 4
White 12,223 10,259 6,779 11,802 8,449 7,180 8,600
6–34 9,294 7,383 4,907 8,199 6,051 4,865 5,548
12–17 1,609 758 752 1,371 974 529 754
18–25 3,730 2,858 2,407 2,655 2,558 2,202 2,333
26–34 3,952 3,767 1,679 4,172 2,520 2,134 2,462
35+ 2,924 2,871 1,870 3,596 2,398 2,308 3,050
Unknown 6 4 2 7 * 6 2
Black 983 927 800 866 490 637 837
6–34 444 675 339 555 266 327 606
12–17 15 17 15 7 8 14 8
18–25 80 176 90 218 71 110 201
26–34 350 483 235 330 187 166 397
35+ 539 251 461 311 223 309 229
Unknown * 1 *  * 1 1 3
Hispanic 2,607 2,865 1,674 2,553 1,479 1,489 2,177
6–34 2,122 2,230 1,382 2,245 1,161 1,117 1,731
12–17 279 428 203 287 58 175 237
18–25 1,018 1,156 670 1,237 565 578 688
26–34 825 646 509 721 537 364 804
35+ 483 635 292 309 318 370 446
Unknown 2 * * * * 1 *
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Table 38 (continued). Estimated Number of DAWN Emergency Department Visits 
With Mention of Methamphetamine/Speed, by Race/Ethnicity and Age, 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
American Indian/
Alaska Natives 22 157 86 14 9 9 136
6–34 21 23 9 14 3 6 5
12–17 2211*  1 *  
18–25 10 15 4 8 * 4 3
26–34 863531 1
35+ 1 133 77 * 7 3 131
Unknown ****** *
Asian/Pacific 
Island 79 243 68 105 65 104 183
6–34 65 222 59 86 49 86 155
12–17 16 116 6 10 9 3 41
18–25 32 84 29 36 23 67 77
26–34 17 22 24 40 17 16 38
35+ 14 21 9 19 16 18 27
Unknown ***** *
Unknown 1,612 1,473 1,428 1,680 985 982 1,573
6–34 1,248 1,164 1,042 1,223 716 711 1,000
12–17 37 117 49 67 32 85 81
18–25 560 489 520 503 264 320 409
26–34 651 557 472 653 420 306 509
35+ 360 308 379 457 265 270 573
Unknown 4 1 7 * 5 1 * 
Other 11 10 167 135 8 47 * 
6–34 5 9 90 130 4 9 * 
12–17 2 * 2 67 * *  * 
18–25 1 9 7 61 2 8 * 
26–34 1 * 82 2 3 1 * 
35+ 6 1 76 4 4 38 * 
Unknown ****** *
*Low precision, no estimate reported.
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.Adverse Social, Behavioral, and Health Consequences
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Table 39. Estimated Number of DAWN Emergency Department Visits With Mention of
Marijuana/Hashish, by Race/Ethnicity and Age, 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
Total 40,035 45,259 53,770 64,721 76,841 87,067 96,426
6–34 31,681 35,269 41,308 47,485 55,815 61,605 68,047
12–17 6,513 7,972 9,980 11,057 13,137 12,730 15,678
18–25 13,671 14,798 15,722 19,385 22,895 27,266 30,413
26–34 11,489 12,473 15,433 16,912 19,760 21,410 21,841
35+ 8,308 9,877 12,387 17,039 20,789 25,387 28,271
Unknown 46 113 75 196 237 75 108
White 18,810 20,883 24,503 31,892 38,432 45,395 49,015
6–34 15,330 16,863 19,582 24,141 29,656 33,665 34,604
12–17 3,955 4,579 5,537 6,988 8,400 7,505 8,909
18–25 6,421 7,211 7,398 9,276 11,588 14,840 15,441
26–34 4,953 5,061 6,496 7,874 9,658 11,156 10,174
35+ 3,465 3,944 4,906 7,669 8,709 11,707 14,374
Unknown 15 76 16 82 67 23 36
Black 14,896 16,895 18,936 21,056 24,430 25,607 26,446
6–34 11,113 12,297 13,068 14,296 15,396 15,889 16,903
12–17 1,148 1,753 1,962 1,536 1,553 1,749 2,167
18–25 4,913 4,780 4,899 5,986 6,444 7,239 7,895
26–34 5,045 5,752 6,196 6,763 7,391 6,875 6,817
35+ 3,770 4,575 5,837 6,668 9,005 9,697 9,508
Unknown 13 22 32 92 29 21 35
Hispanic 3,100 3,743 6,301 6,735 7,666 9,064 11,739
6–34 2,607 3,046 5,439 5,252 6,063 6,886 9,544
12–17 850 701 1,551 1,722 2,020 2,135 2,801
18–25 1,051 1,540 1,981 2,260 2,525 3,038 4,193
26–34 706 804 1,899 1,155 1,514 1,709 2,539
35+ 491 691 855 1,470 1,548 2,169 2,177
Unknown 3 7 7 13 55 9 17
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Table 39 (continued). Estimated Number of DAWN Emergency Department Visits 
With Mention of Marijuana/Hashish, by Race/Ethnicity and Age, 1994–2000
Race/Ethnicity
and Age 1994 1995 1996 1997 1998 1999 2000
American Indian/
Alaska Natives 55 136 63 58 112 66 123
6–34 42 57 36 47 95 52 37
12–17 9 13 8 16 54 13 15
18–25 9 26 16 10 21 21 8
26–34 24 18 11 21 20 18 13
35+ 13 77 27 11 17 13 86
Unknown * 1 *  * * *  * 
Asian/Pacific 
Island 206 196 267 297 280 461 468
6–34 190 177 234 277 171 421 391
12–17 27 53 59 50 37 125 79
18–25 140 79 139 163 82 154 235
26–34 23 45 36 62 51 142 78
35+ 16 19 28 20 109 40 76
Unknown * * 4 * * * 1
Unknown 2,924 3,337 3,647 4,514 5,817 6,285 8,624
6–34 2,371 2,773 2,910 3,323 4,352 4,559 6,558
12–17 512 859 858 720 1,061 1,189 1,703
18–25 1,121 1,137 1,265 1,591 2,196 1,880 2,636
26–34 736 775 787 1,013 1,093 1,489 2,218
35+ 542 558 720 1,182 1,378 1,704 2,049
Unknown 11 6 17 9 86 22 18
Other 44 69 53 169 104 189 11
6–34 29 57 38 149 81 132 10
12–17 12 14 6 24 11 15 4
18–25 16 25 23 100 38 94 4
26–34 1 18 9 25 33 22 2
35+ 11 13 15 19 23 57 1
Unknown 4 * * * * * * 
*Low precision, no estimate reported.
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.Adverse Social, Behavioral, and Health Consequences
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Table 40. Percentage of DAWN Hospital Emergency Department Drug Abuse Episodes, 
by Selected Episode Characteristics, Sex, and Race/Ethnicity: 2000
Males Females
Episode Characteristics
1 White Black Hispanic White Black Hispanic
Drug concomitance
Single-drug episodes 40.1 40.3 42.9 45.0 46.4 48.3
Multi-drug episodes 59.9 59.7 57.1 55.0 53.6 51.7
Patient disposition
Treated and released 44.9 54.1 55.9 37.6 52.0 48.3
Admitted to hospital 50.9 42.9 39.8 59.5 45.0 49.2
Other 4.2 3.0 4.3 2.9 3.0 2.5
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.
Table 41. Comparison of Race/Ethnicity Distribution for Total DAWN Hospital
Emergency Episodes With Race/Ethnicity Distribution for Selected Drug Mentions: 2000
Race/Ethnicity
Selected Drug Mention White Black Hispanic
Percentage of Total DAWN ER episodes 57.5 21.4 10.9
Percentage of ER drug mention
Heroin/morphine 40.5 32.6 15.8
Methadone 67.9 10.4 8.6
LSD 72.6 6.3 9.7
PCP/PCP combinations 42.1 35.1 12.5
Cocaine 34.2 43.4 13.6
Marijuana/hashish 50.8 27.4 12.2
Amphetamine 63.9 5.6 15.4
Methamphetamine/speed 63.7 6.2 16.1
SOURCE: Office of Applied Studies, Substance Abuse and Mental Health Services Administration, Drug Abuse Warning Network, 2001a.Adverse Social, Behavioral, and Health Consequences
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aExcludes data on homicides, deaths in which AIDS was reported, and deaths in which "drug unknown" was the only substance mentioned.
bIncludes opiates not specified as to type.
cDoes not include methamphetamine or other unspecified amphetamines.
NOTES: Percentages are based on raw medical examiner drug abuse cases counts of 8,516 male decedents and 3,083 female decedents.
Percentages are based on total raw medical examiner drug abuse case counts of 7,042 white decedents, 3,023 black decedents, 
and 1,286 Hispanic decedents.
SOURCE: Substance Abuse and Mental Health Service Administration, Drug Abuse Warning Network, 1999 Annual Report.
Table 42. Drugs Mentioned Most Frequently by Medical Examiners, 
by Sex and Race/Ethnicity of Decedents: 1999
Percentage of Percentage of
Rank Drug Name Total Episodes
a Rank Drug Name Total Episodes
a
Male Patients Female Patients
1 Heroin/Morphine
b 45.3 1 Cocaine 33.3
2 Cocaine 44.8 2 Heroin/Morphine
b 30.6
3A lcohol-in-Combination 37.2 3 Alcohol-in-Combination 23.6
4 Codeine 12.4 4 Codeine 10.7
5 Diazepam 6.7 5 Diphenhydramine 8.6
6 Marijuana/Hashish 6.5 6 Diazepam 7.6
7M ethamphetamine/Speed 6.3 7 Amitriptyline 7.3
8 Methadone 5.1 8 d-Propoxyphene 6.8
9 Diphenhydramine 4.4 9 Methadone 6.7
10 Amphetamine
c 4.1 10 Acetaminophen 6.5
White Patients Black patients
1 Heroin/Morphine
b 41.4 1 Cocaine 64.1
2A lcohol-in-Combination 33.0 2 Heroin/Morphine
b 39.5
3 Cocaine 32.1 3 Alcohol-in-Combination 31.2
4 Codeine 12.4 4 Codeine 11.4
5 Diazepam 9.3 5 Marijuana/Hashish 4.7
6M ethamphetamine/Speed 7.9 6 Diphenhydramine 4.6
7 Marijuana/Hashish 6.6 7 Lidocaine 4.5
8 Methadone 6.4 8 Quinine 4.1
9 Diphenhydramine 6.3 9 Methadone 3.9
10 d-Propoxyphene 5.6 10 Diazepam 2.9
Hispanic Patients
1 Heroin/Morphine
b 46.7 6 Methadone 4.9
2 Cocaine 45.2 7 Lidocaine 4.7
3A lcohol-in-Combination 42.9 8 Marijuana/Hashish 4.0
4 Codeine 11.8 9 Diazepam 3.6
5M ethamphetamine/Speed 5.4 10 Amphetamine
c 3.3Adverse Social, Behavioral, and Health Consequences
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Figure 13. Manner of Drug-Related Death, by Race/Ethnicity, 
DAWN Medical Examiner Data: 1999
































Drug-related crime is considered one of the major problems facing the United States today. This problem
encompasses concern about public safety and crime-related injuries suffered by our citizens, as well as the high
cost of law enforcement to control drug-related crime (Miller 1992, Harrison and Backenheimer 1998). Much
has been learned from recent efforts to evaluate different approaches to reduce drug-related crime. Nonetheless,
as reported recently by a committee of the National Research Council, much remains to be learned before we
can be certain about the policy instruments chosen to control drug-related crime (Manski et al. 2001).
A casual visit to local drug courts provides convincing evidence that drug use is linked to criminal offending
such as theft and assault. Perpetrators testify that the use of methamphetamine, cocaine, heroin, and alcohol is
at the root of their crimes and caused them to violate the law. Victims often explain that they were intoxicated
and made vulnerable to attack by virtue of their own drug use. However, this abundance of testimonial evidence
must be counterbalanced by an appreciation that many of the perpetrators were prone to criminal offending
and might have committed the crime even if drugs never had been used. Many perpetrators have a history 
of aggressive misbehavior, social maladaptation, and delinquency that stretches back well before their drug use
ever started.
Several lines of research are shedding new light on the link between drugs and crime. Goldstein and Brownstein
proposed and refined a tripartite descriptive framework that has inspired one of these lines of research within
criminology (Goldstein 1985; Brownstein and Goldstein 1990). Although their conceptualization drew primarily
from experience during the late 1970s and early 1980s cocaine epidemic, the tripartite framework also has been
applied to other drugs. In brief, they sorted drug-related crimes into offenses that may be understood as a con-
sequence of acute drug intoxication per se, those of a more economic-compulsive nature arising from longer
term neuroadaptation that follows repeated drug use, and those that are more systemic and interlinked with
social context and individual propensities that promote criminal activity, even when the perpetrators are not
drug users (e.g., with respect to high-level drug trafficking). Crimes of the first “pharmacological” type include
assaults that might be precipitated by paranoia or delusions caused by the use of phencyclidine (PCP), sustained
methamphetamine use (e.g., “ice smoking”), or cocaine self-administration. Examples of crimes of the second
“economic-compulsive” type include shoplifting, theft, and robbery with a goal of securing enough money to
buy enough heroin to stave off withdrawal symptoms. Crimes of the “systemic” type include intergang violence
such as drive-by shootings intended to intimidate or kill street-level drug dealers who have crossed boundaries
of local market control. This type of crime also includes the criminal activity of drug users who would have been
committing crimes even if they never had used drugs (e.g., due to predisposing liabilities and susceptibilities 
of complex origin—history of child abuse, incomplete socialization, difficult temperament, and antisocial 
personality disorder).
Evidence from highly controlled laboratory studies and epidemiological field research has clarified the importance
of acute pharmacological effects with respect to aggression. Nonetheless, it is important to note that drug 
self-administration does not always produce aggression or aggressive behavior. The link between drug use and
aggression, if any, is heavily dependent on factors such as the specific drug being studied, the setting and 
conditions of drug use, and other explanatory conditions and processes.
Chapter 7. DRUGS AND CRIMEDrugs and Crime
In  many respects, the evidence to date is most compelling with alcoholic beverages; it is less compelling 
with drugs like marijuana, LSD, and ecstasy (methylenedioxymethamphetamine). With cocaine and other 
psychostimulant drugs, there is mixed evidence: Under some circumstances and with some species of laboratory
animals, there appears to be a release of aggression or aggressive behavior after drug exposure, but not under all
circumstances and not with all species. The category of pharmacologically induced crimes encompasses the role
of intoxication as a predisposing vulnerability for victims of crime (e.g., see Coker et al. 2000).
Evidence from ethnographic, criminal justice, clinical, and social survey research has clarified the importance of
the economic-compulsive type of drug crimes described by Goldstein and Brownstein. In this respect, fine-
grained investigations of day-to-day behavior of street-level drug users have been important and have disclosed
cycles of drug-taking behavior followed by drug withdrawal states and drug-seeking behavior, followed by more
drug use (e.g., Grapendaal 1992; Nurco et al. 1991; Nurco 1998; Lipton et al. 1998; Britton 1998; Conroy
1999). As observed, this cycle sometimes includes gainful employment to secure income for drug purchases and
sometimes involves shoplifting, petty theft, robbery and assault, procurement, or prostitution. 
Observational studies of the criminal behavior of drug users before, during, and after treatment and incarceration
also have helped illuminate possible links between drug withdrawal symptoms and criminal activity. At least
during the initial periods of treatment and unless there is relapse to drug use, there are reductions in criminal
offending. There is some evidence that individuals using drugs several times a day are more likely to be involved
in criminal activity than are those who are less regular in their drug use. In one study, heavily dependent drug
users were found to commit four to six times more crime during periods of heavy drug use than during periods
when they were relatively drug free. These links between drug use and crime seem to have been exacerbated 
during the late 20th-century epidemic of crack-cocaine smoking. Whereas most of the evidence on these 
relationships has been derived from nonexperimental observational studies, a few randomized clinical trials have
tended to confirm these findings from observational research, with reductions in criminal activity being
observed even within the more highly standardized and controlled confines of experimental research, especially
when social and psychological services have been provided in addition to pharmacological treatments (Hunt et
al. 1984; Nurco et al. 1989; Brecht et al. 1990-91; Miller 1992; Bureau of Justice Statistics 1996; Bell et al 1997;
Lipton et al. 1998; Nurco 1998; Wexler et al. 1998; McClellan et al. 1998; MacDonald et al. 1999; Harwood
et al. 2001).
There is a small but growing base of evidence on the more systemic form of drug-related crime. Recent studies
on the neighborhood and gang contexts of drug use and drug trafficking are informative, and some studies 
provide suggestions for community action to reduce drug and crime problems (e.g., Fagan and Chin 1990;
Hillenbrand and Davis 1993; Waldorf 1993; Clapp 1995; Popkin et al. 1995; Surratt 1995; Curtis 1998;
Fleisher 1998; Van Nostrand and Tewksbury 1999; Barton 1999). Several pioneering investigators have probed
the generally neglected world of high-level drug traffickers (Natarajan and Belanger 1998).
During the late 20th century, it became virtually impossible to study interrelationships between drugs and crime
in the United States without paying attention to the life circumstances of U.S. citizens who are members of
racial/ethnic minority groups. The recent surge in arrests, convictions, and incarcerations across the United
States has been fueled mainly by increases in drug-related law enforcement, prosecution, and judicial activity.
For example, Federal prison drug-related sentences increased by 290 percent between 1980 and 1995; more
than one-half of all Federal offenders sentenced to prison in 1996 were convicted of drug offences (Bureau of
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Justice Statistics 1996). In general, members of racial/ethnic minorities are more likely to be arrested, more likely
to be convicted once arrested, and more likely to be incarcerated once convicted; the disproportionate representa-
tion of minority group members is especially true for drug-related offenses of virtually all types (e.g., Blumstein
and Beck 1999; A. Blumstein, personal communication). Processes of selection that yield disproportionate 
representation of minority group members, including police practices such as racial profiling, must be taken into
account when examining and drawing interpretations from administrative and social statistics on drugs and
drug-related crimes (e.g., see Bush-Baskette 1998; Leiber and Stairs 1994; Kalunta-Crumpton 1999).
The manifestations of links between drugs and crime also appear in medical statistics from hospital emergency
rooms (ERs) and medical examiners. For example, in a 1991 review of hospital ER records for individuals
treated for violence-related injuries, about 14 percent of the records indicated the victim or someone else
involved in the incident had been drinking alcohol or using drugs (Bureau of Justice Statistics 1996).
Research on causes of homicide in three metropolitan areas indicates that about 25 percent to 50 percent of all
homicides are drug related (Bureau of Justice Statistics 1996). Homicide in general and drug-related homicides
disproportionately affect African Americans. For example, the National Center for Health Statistics has reported
a range of age-adjusted homicide death rates that indicates 20 to 30 homicide deaths per 100,000 non-Hispanic
Blacks for each year between 1995 and 1999 (National Center for Health Statistics 2000). During that same
period, the corresponding values were much lower for American Indian/Alaska Natives (9–11 homicide deaths
per 100,000), Hispanics (8 to 13 homicide deaths per 100,000), non-Hispanic Whites (3–5 homicide deaths
per 100,000), and Asian/Pacific Islanders (3 to 5 homicide deaths per 100,000).
The other administrative statistics on drugs and crime reported in this chapter come from two sources: the
Arrestee Drug Abuse Monitoring (ADAM) Program of the National Institute of Justice (NIJ) and Bureau of
Justice Assistance (BJA), which represents a refinement and more rigorous form of the former NIJ/BJA Drug
Use Forecasting (DUF) system, and the National Household Survey on Drug Abuse (NHSDA). Co-funded by
NIJ and BJA, the ADAM Program measures recently active drug use among booked arrestees at multiple
selected sites in major metropolitan areas across the United States. The primary purpose of ADAM is to monitor
illegal drug use among booked arrestees in major U.S. cities. It provides information about the effectiveness of
local drug policies and practices and provides a solid basis for resource allocation decisions. By collecting urine
samples and periodically interviewing arrestees, ADAM has become a consistent tool for tracking drug use
trends among this difficult-to-study population of users. In reports on these statistics, ADAM administrators
urge cautious interpretation because ADAM sites do not constitute a nationally representative sample and
because of other methodological reasons. Nonetheless, the ADAM statistics now provide our most complete
view of drug experiences among booked arrestees in the United States. Methodological limitations of the
NHSDA data (e.g., reliance on self-report) have been described in Chapter 1 of this report and elsewhere 
(e.g., see Anthony et al. 2000; Manski et al. 2001).
DRUG USE AMONG BOOKED ARRESTEES
The following information is from a standardized data set and reports based upon all DUF and ADAM urinalysis
tests from 1987 to 1999 (see Table 43). The data show interesting trends in marijuana use across races and
through time, as indicated by tests to screen for recently active marijuana use (i.e., use within the 2 to 4 weeks
before testing). 
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In the table’s first column, rows 1–13 show time trends for Whites. This range of values is relatively stable, with
positive marijuana test values between 23 and 40 percent. The lowest values (25 percent and 23 percent) occurred
in 1990 and 1991. By 1998–1999, the percentage was 36 percent, almost as large as the largest values in the
series, 39 to 40 percent, which were observed in 1987 and 1988. Similar trends and values were observed for
Blacks and Hispanics, also with relatively low values in 1990–1991, and with values of 33 to 42 percent
observed in 1998–1999.
Due to sample size limitations, DUF and ADAM provide much less information about American Indian/Alaska
Native and Asian/Pacific Islander groups; the precision of these estimates is constrained, as is their capacity for
national projections. Nonetheless, the observed values for the final years of the 20th century indicate values for
American Indian/Alaska Native arrestees that are not too distant from values observed for the above-listed
groups; that is, the recent drug-taking experience of American Indian/Alaska Native arrestees seems not to differ
substantially from the recent drug-taking experience of nonminority arrestees. Values for Asian/Pacific Islanders
are generally lower than values observed for the other groups (Table 43). Whether this difference is an artifact
of sampling or methodology is unknown. There is a firmly established site-to-site variation in the prevalence of
positive marijuana urinalysis test results and in the trends over time (Golub and Johnson 2001), and there is no
ADAM site in Hawaii, where marijuana experience may be substantially different from what is observed on the
U.S. mainland (National Institute on Drug Abuse 2001a). Whether the observed trends are artifacts of changes
in the DUF/ADAM methodologies is an item on the agenda for future research; some investigators believe that
the methodologies of recent years are stable enough to warrant discussion of an emerging marijuana use epidemic
among arrestees in many (but not all) of the areas with ADAM coverage (Golub and Johnson 2001).
The DUF/ADAM values for cocaine urinalysis results reflect the experience of booked arrestees not only for
cocaine hydrochloride powder (whether insufflated, injected, or taken by mouth), but also for other forms of
cocaine, such as crack, freebase, and coca paste; this bioassay cannot discriminate one route of administration
or dosage form from another. It also is noteworthy that the sensitivity of the test for cocaine metabolites in urine
is high for the first 24 hours after cocaine use, but then declines. Whereas the urinalysis test for marijuana might
detect marijuana used up to 1 month or so before arrest, the corresponding urine test for cocaine will have a
detection window of less than 1 week, and often has sensitivity for no more than 1 to 3 days, depending on
individual circumstances and conditions of use, metabolism, biotransformation, and excretion.
With respect to cocaine of all forms, the African-American arrestees were more likely to test positive in every
year under study, with higher values in the first DUF years (e.g., 56 to 63 percent) and with tangibly lower values
in the most recent years (e.g., 41 to 45 percent). In these recent years, corresponding values for Whites and
Hispanics have been somewhat lower (25 to 26 percent and 31 to 32 percent, respectively), but the lowest values
have been observed for Asian/Pacific Islander and American Indian/Alaska Native arrestees (18 to 19 percent
and 12 to 15 percent, respectively). Whether these differences reflect true between-group variations in the preva-
lence of actual cocaine use in the U.S. population is unknown. For example, the White-Black difference is not
observed in self-report data on cocaine use from the NHSDA and the Monitoring the Future (MTF) surveys,
and the magnitude of the observed differences might well be due to race-biased selection processes that lead an
individual to be identified, apprehended, booked, and sent to an arrest facility with ADAM coverage. That is,
cocaine-using African Americans may be more likely to be apprehended and booked for arrest than are cocaine-
using individuals of other racial/ethnic subgroups (e.g., see pertinent discussion by Manski et al. 2001).
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The third column of values in Table 43 shows DUF/ADAM evidence on the arrestees’ experience with heroin,
methadone, morphine, oxycodone, codeine, and other opiate or opioid drugs, whether administered for legitimate
medical reasons (e.g., methadone maintenance, pain relief, and cough suppression) or for extramedical reasons
(e.g., to get high). Note that in recent years White, Black, and Hispanic arrestees all are equally likely 
to test positive for the opiate/opioid drugs. Values for the other two racial/ethnic minority groups are 
somewhat smaller.
NIJ began testing arrestees for methamphetamine use in 1991. The two racial/ethnic arrestee groups with the
highest values are Whites and Asian/Pacific Islanders. By comparison, African-American arrestees are extremely
unlikely to test positive for methamphetamines (e.g., 0.8 percent in 1999); Hispanics are intermediate (6 percent).
DRIVING UNDER THE INFLUENCE OF ALCOHOL OR ILLEGAL DRUGS
NIDA has made a concerted effort to support research projects on links between drug use, delinquency, and
crime, including highly controlled experimental research in laboratory settings, clinical studies, epidemiological
studies, ethnographies, and anthropological investigations. In the 1970s, NIDA initiated a line of NHSDA
research on drugs and criminal activities, which has been sustained and elaborated by the Substance Abuse and
Mental Health Services Administration.
In recent years, NHSDA assessments have included questions on various illegal activities. One question asked
of respondents is whether, during the 12 months before being interviewed they had driven any kind of vehicle
while they were under the influence (DUI) of alcohol or illegal drugs. Table 44 presents data on driving under
the influence by age, sex, and two broad race/ethnicity groups (White/Black), based on estimates from NHSDA
1998. Within the noninstitutionalized population surveyed for NHSDA (age 12 and older), an estimated 10.3
percent reported DUI behavior, but this estimate is heavily influenced by a large number of youth ages 12–15
who do not drive. A more informative value is presented for people ages 18–25, among whom about one-fifth
reported DUI episodes (21.7 percent), with males ages 18–25 almost twice as likely to be DUI drivers than
females in the same age group. Estimates for adults age 26–34 and for those age 35 and older are somewhat
lower than the observed values for those ages 18–25, but the male-female differences are maintained even in the
older age groups.
DUI driving is substantially more likely among Whites, both male and female, than among African Americans.
For example, about one in three White males ages 18–25 were DUI drivers (31.1 percent); the corresponding
value is 13.3 percent for African-American males ages 18–25. Whereas the occurrence of DUI driving generally
shows a marked decline across the three older age groups depicted in Table 44, this is not the case for African-
American males and females younger than age 35. Among African Americans ages 18–25 and 25–34, the 
estimated prevalence values for DUI driving are 9.3 percent and 8.9 percent, respectively (Table 44).
Males are more likely to drive under the influence of alcohol or illegal drugs across all age and racial groupings,
with the exception of the 12–17 age group. In this youngest age group, adolescent girls are just as likely as 
adolescent boys to have been DUI drivers. Given the level of precision of these DUI estimates, the male-female
differences for youth ages 12–17 are so small as to be negligible.
133Drugs and Crime
SUMMARY
Links between drugs, delinquency, and crime continue to inspire investigators from a broad range of disciplines—
from the bench and laboratory sciences such as pharmacology to the clinical and field research sciences such as
epidemiology, criminology, and ethnography (e.g., see Anthony and Forman 2002). Studies on these links have
special policy implications and warrant continuing public scrutiny (e.g., see Manski et al. 2001).
Criminal justice and medical statistics are sufficient to draw our attention to disparities in how drugs and crimes
affect U.S. racial/ethnic minority groups. African Americans, especially, exhibit excess rates of arrest, conviction,
and incarceration for drug-related crimes and of homicide in general and drug-related homicide in particular.
These observed excess rates of criminal justice incidents and medical casualties are not consistent with other 
evidence on the drug experiences of African Americans in the United States (e.g., from NHSDA and MTF). As
such, this is a topic that deserves special focus in research on the social and health disparities affecting our
African-American citizens.
Subject to the methodological constraints already discussed, data from the DUF/ADAM Program are used to
examine the drug experiences of booked arrestees in selected sites across the United States. In recent years, the
percentage of White arrestees testing positive for marijuana (34 to 36 percent) has been approaching the 
percentage of African-American arrestees testing positive (39 to 42 percent), and the percentage of African-
American arrestees testing positive for opiate/opioid drugs (6 to 8 percent) has been approaching the percentage
of White arrestees testing positive for these drugs (9 percent). Corresponding values for other racial/ethnic
minority groups are generally not too distant from the values observed for Whites; or are lower (e.g. for the
Asian/Pacific Islander arrestees.)
Data for cocaine and for methamphetamine present the most noteworthy variation across booked arrestee 
subgroups. African-American arrestees are most likely to test positive for cocaine after booking, whereas they 
are extremely unlikely to test positive for methamphetamine. In recent years, Asian/Pacific Islander arrestees are
observed to have the lowest test-positive values for cocaine, among all subgroups studied, but 11–14 percent 
are testing positive for methamphetamine, which is close to the observed value for Whites (13–15 percent). The
ADAM data on methamphetamine experiences of Asian/Pacific Islander Americans is convergent with other
data sources, especially where these other data sources represent the experience of Hawaiians and other Pacific
Islanders specifically (e.g., see Furr et al. 2000; Substance Abuse Mental Health Services Administration 1997,
1998, 1999b, 2000a, 2000b, 2001a).
Data from NHSDA illuminate the experience of Americans driving under the influence of alcohol or illegal
drugs. Overall, in 1998, nearly twice as many Whites had driven under the influence as had African Americans.
This disparity is even more pronounced among White youth, who are two to three times more likely to have
driven under the influence during that 12-month interval. A general male excess in the occurrence of DUI 
driving appears for both White and African-American subgroups of the population, but it is not present for 
adolescents (ages 12–17). This is a pattern of DUI findings that merits future research, especially if the absence
of a male-female difference among adolescents is a signal of a future increasing trend for DUI driving in birth
cohorts born within the past two decades.
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The DUF/ADAM data provide a reminder of the heterogeneity within the broad “minority” category that often
is used to designate members of African-American, Hispanic, Asian/Pacific Islander, and American
Indian/Alaska Native groups. Without attention to this heterogeneity, we would not be able to discover the 
disparate experience of African-American arrestees with cocaine, nor the excess burden of Asian/Pacific Islanders
with methamphetamine.
This chapter does not speak to the heterogeneity within the major racial/ethnic minority categories, due to 
sample size constraints. In future revisions of this report, it should be possible to take advantage of the continued
growth in ADAM and NHSDA samples to shed new light on variations within minority groups, such as we
have illustrated in Chapter 3. In addition, new data from the Centers from Disease Control and Prevention, the
National Longitudinal Study of Youth, and other sources can be tapped to provide a more complete picture of




Table 43. Estimated Prevalence of Positive Urinalysis Tests from the 
Arrestee Drug Abuse Monitoring Program: 1987–1999
Race/Ethnicity and Year Marijuana Cocaine Opiates Methamphetamine*
White
1987 39 26 13 N/A
1988 40 31 13 N/A
1989 30 32 11 N/A
1990 25 26 10 N/A
1991 23 29 9 7
1992 27 32 9 7
1993 29 31 10 14
1994 27 30 9 17
1995 28 29 10 14
1996 35 28 9 10
1997 34 26 9 13
1998 36 25 9 14
1999 36 26 9 15
Black
1987 36 56 10 N/A
1988 35 63 10 N/A
1989 21 61 8 N/A
1990 16 53 8 N/A
1991 15 56 6 0.3
1992 22 55 6 0.3
1993 26 54 7 0.6
1994 28 53 7 0.8
1995 30 50 7 0.8
1996 40 43 6 0.3
1997 39 41 6 0.7
1998 40 42 7 0.7
1999 42 45 8 0.8
(continued on next page)Drugs and Crime
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Race/Ethnicity and Year Marijuana Cocaine Opiates Methamphetamine*
Hispanic
1987 34 43 22 N/A
1988 34 51 21 N/A
1989 25 43 18 N/A
1990 21 36 15 N/A
1991 20 38 13 2
1992 23 39 12 3
1993 25 37 13 5
1994 25 36 12 6
1995 25 33 11 7
1996 34 29 9 5
1997 33 26 8 8
1998 34 32 8 5
1999 33 31 9 6
American Indian/
Alaska Native
1995 37 19 7 4
1996 29 23 9 6
1997 36 14 5 6
1998 37 19 5 4
1999 34 18 4 3
Asian/Pacific
Islander
1995 9 20 5 7
1996 14 11 2 9
1997 17 9 3 14
1998 17 12 2 13
1999 22 15 1 11
Table 43 (continued). Estimated Prevalence of Positive Urinalysis Tests from the 
Arrestee Drug Abuse Monitoring Program: 1987–1999
*The denominator of prevalence includes all the arrestees.
N/A: Not applicable.
SOURCE: National Institute of Justice, Arrestee Drug Abuse Monitoring Program, 2001a-c.Drugs and Crime
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Table 44. Estimated Percentage of People Having Driven a Vehicle Under the Influence
of Alcohol or Illegal Drugs in the Past 12 Months, by Race, Sex, and Age: 1998
Age Group
Race and Sex 12 and Older 12–17 18–25 26–34 35+
All races
Both sexes 10.3 3.5 21.71 4.3 8.0
Male 14.6 3.7 27.9 19.4 12.3
Female 6.3 3.2 15.4 9.4 4.3
White
Both sexes 11.2 3.9 24.6 15.7 8.7
Male 15.7 4.1 31.1 20.8 13.1
Female 7.0 3.7 17.7 10.5 4.8
Black
Both sexes 5.4 1.7 9.3 8.9 3.9
Male 8.3 1.8 13.3 14.1 6.4
Female 3.0 1.6 5.5 4.6 2.1
SOURCE: National Household Survey on Drug Abuse, Substance Abuse and Mental Health Services Administration. Office of Applied 
Studies, 2000a.139
This report examines issues linked to health disparities now experienced by members of racial and ethnic 
minority groups within the United States, with specific attention to the drugs of primary focus in the mission
statement of the National Institute on Drug Abuse (NIDA). Available information indicates that use of these
drugs may be harming the health and social well-being of these population groups disproportionately, based 
on their reported use of these drugs. Adverse consequences suffered by some of our racial/ethnic minority 
populations include excess risks of arrest, conviction, and incarceration for drug-related crimes, against a 
background of statistics that suggest no excess involvement in illegal drug use. These adverse consequences
extend to overrepresentation in statistics of drug-related morbidity and mortality, disruption of educational
achievement (e.g., greater failure to earn the regular high-school diploma), and social disadvantage.
The report draws attention to some of the open research questions that must be pursued as elements in a future
agenda of research on drug use and health disparities. For example, it has been suggested, without strong 
evidence, that African Americans may be at greater risk than Whites to fatal and nonfatal health consequences
of drug taking due to a greater preference for injecting drug use, more frequent choice of drugs such as crack-
cocaine, or to differences in access to health care opportunities. At present, there is no good evidence to settle
these questions. For example, we can state that African Americans are overrepresented among decedents found
to have used cocaine, but we do not know whether this overrepresentation is artifactual and due to a greater
likelihood of testing for cocaine when the decedent is African in heritage. Furthermore, we can note that White
women seen in hospital emergency rooms for drug-related reasons are more likely to be admitted to the hospital
than all other subgroups examined, but we do not know whether this difference is attributable to better hospi-
talization coverage by third-party payers—or whether it is explained by other reasons.
Currently available epidemiological data on drug use of racial/ethnic minorities disclose several important signs
of differences in reported use. Among youth, Asian and Pacific Islanders often have been found to be less likely
to report illegal drug use than other groups. This difference is pronounced for alcohol, possibly due to racial/
ethnic variations in genetic susceptibility to toxic ethanol responses (e.g., the flushing syndrome) and does not
appear to be present for methamphetamine, at least among Pacific Islanders. It also is of interest that African-
American youth consistently report less involvement in drug use than do White youth, whereas Hispanic youth
often have been found to have greater prevalence of drug use than African-American youth and only slightly
less use than White youth. Patterns of illegal drug use among American Indian/Alaska Native youth have 
generally been neglected and merit greater scrutiny, both on and off reservations, with close attention to possible
methodological explanations for observed excess drug involvement of this minority subgroup. 
The just-described variation may have causal importance and may reflect true differences in the drug involvement
of minority and nonminority populations in the United States. If so, this variation has important implications
for public health interventions, with targeting to the individual needs of specific minority populations. On the
other hand, it is possible that the observed variation is no more than methodological artifact, due to the incom-
plete resolving power of our available evidence on drug involvement across and within these populations. If 
the variation can be traced back to methodological artifacts, then there are different implications for public
health action.
Chapter 8. SUMMARY AND FUTURE DRUG ABUSE 
PROGRAM NEEDS AND RESEARCH NEEDSSummary and Future Drug Abuse Program Needs and Research Needs
This report presents interesting findings for patterns of association linking illegal drug use to other risk-related
behaviors among racial/ethnic groups. Data from the Youth Risk Behavior Survey indicate risky sexual practices
were reported in connection with reports on illegal drug use. For example, youths who reported cocaine use
were more likely to report multiple sex partners and failure to use condoms; this pattern was observed for each
of the racial/ethnic minority groups under study, including White students. Data on AIDS cases, minority and
nonminority alike, indicate that HIV infection often can be traced back to injecting drug use of the victim or
to heterosexual or homosexual activities with an injecting drug user. Each of these findings may have useful
implications for conceptualizing prevention, referral, and treatment programs that can effectively address drug
use among racial/ethnic groups, even if the findings do not inform delivery of services directly.
The issues represented by AIDS, infectious diseases, drug use, and race/ethnicity are particularly important. The
preponderance of African Americans and Hispanics among injecting drug users with AIDS is at least in part due
to a failure of prevention programs at the local, State, and national levels, perhaps connected with insufficient
funding for targeted prevention programs oriented toward the needs of minority populations. Other life 
circumstances, conditions, and processes merit attention, such as differences in drug use practices and general
health status of minority groups, but at the end of the day, the observed excess in AIDS-related morbidity and
mortality is a failure of our past and current public health and prevention programs.
Higher HIV seroprevalence and other infectious disease rates among African Americans and Hispanics support
an argument for improving our current profile of interventions intended to reduce these infections and their
consequences. More research is needed to identify the best intervention choices from among those presently
available and to design new choices that represent real improvements over existing programs and techniques,
with selections most appropriate to the minority group of interest. To be sure, the burdens of HIV and AIDS-
related diseases, disabilities, and family suffering will continue to mount over the coming decades as we deal
with the failure of our prevention and intervention programs to date.
Of course, there are limitations to our understanding of health disparities connected with alcohol and other
drug use of American minority populations, just as there are limitations to our understanding of that for White
and non-Hispanic Americans. Changing social and demographic characteristics of illegal drug users merit close
scrutiny in future research, as more illegal drug users move into middle age and beyond. It is possible that there
are developmental and social status delays in so-called “maturing out” of illegal drug use. Some of these delays
may occur more frequently in association with minority group membership and they require greater attention
among developmental scientists. At the same time, legitimate concern exists about the inadequacy of our 
current epidemiological statistics on these topics, giving good reason to improve our data. For example, known
distortions will occur when there is a reliance on drug arrest and treatment data, due to race-related differentials
in arrest rates and facility admission rates. To the extent that the U.S. Census and our social surveys fail to 
enumerate young minority group members, there are additional methodological sources of bias in our 
epidemiological estimates on the illegal drug-taking behavior of these subgroups, even if self-reports and other
measurements had 100-percent validity.
An improved conceptual framework and better theoretical models for conditions and processes affecting risk
and protection against illegal drug use also are needed. The most recent empirical research by Wallace and
Muroff (2002) suggests that associations that link illegal drug use to suspected risk and protective factors are not
necessarily the same for African-American children and teenagers as for nonminority youth.
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Research on drug use among racial/ethnic minorities has not advanced to a stage that allows policymakers and
program managers to make the intervention choices required to reduce drug-related health and social problems.
To  some degree, this inadequacy of past and current research may be understood as a consequence of the 
illegality and sensitivity of the behaviors and problems under study. It is not altogether clear that definitive 
evidence is possible when potential participants can decline to participate and often choose not to provide 
information that is essential for valid measurement of behavior or diagnosis of health-related and social distur-
bances. Nonetheless, improvements can be made and must be made if there are to be effective reductions in
drug-related health disparities.
To date, we have an accumulation of data that might help a clinician choose between alternative interventions
for drug-dependent individuals within different race-ethnic groups within the U.S. population. However, 
definitive evidence is lacking for these issues, such as knowing the extent to which special alternatives are essential
to achieve mutually valued results with members of these groups when they are in target populations for 
prevention, early intervention, treatment, or long-term rehabilitation. Consensus exists that program efficacy
and effectiveness might be increased with greater attention and sensitivity to race, culture, and ethnicity.
Ignorance of or inattention to these issues may result in evidence that is misleading or wrong. At least as a work-
ing hypothesis, investigators must entertain the possibility that racial, ethnic, and cultural conditions and
processes will influence virtually every arena of the NIDA research mission, ranging from the initial stages of
drug involvement to serious drug dependence and fatal complications of drug use.
It is important to note that some progress has been made in research. For example, an increasing number of
studies of illegal drug use among minorities have been completed over the past two decades. These studies have
comprised general population studies and special investigations of presumed high-risk groups, such as school
dropouts, runaways, or arrestees. Even so, for reasons discussed in this report, the current estimates of illegal
drug use in minority populations may misrepresent the extent of the problem, and the magnitude of the 
misrepresentation is unknown or understudied. Available data suggest that research can both effectively assess
and meet the needs of racial and ethnic minority groups and strengthen school-based drug prevention and 
intervention programs and those in the community at large. However, research on selection processes is needed
in these contexts, including studies of (1) processes that influence who remains in school and can be influenced
through school-based programs, (2) processes that help protect or increase the resilience of minority and 
nonminority students even when they drop out of school, and (3) the role that educational systems might play
with public health systems to reduce, delay, or eliminate illegal drug use in the population at large.
Race and ethnicity are difficult concepts and much controversy remains about how best to sort individual 
members of a population into racial/ethnic minority groups. Current definitions of race/ethnicity tend to 
oversimplify a complex set of personal, social, and biological attributes or tend to neglect social context 
(e.g., marginality). Increasing immigration creates a dynamically changing set of circumstances. In consequence
of immigration and different rates of acculturation or assimilation, tremendous diversity is found among 
individuals of the same racial or ethnic group.
Although considerable interest exists in having data on race and ethnicity, the breakdowns are often restricted
to “White” “Black” and “Other.” As introduced in Chapter 1 of this report, when information is collected on
minority groups, the information rarely takes into account the heterogeneity of the population. We have data,
for example, on drug abuse among American Indians in general, but there are more than 200 American Indian
tribes for which we have almost no specific data. In addition, although some national-level data on drug use by
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race and ethnicity are stratified by age and male-female differences, rarely are factors such as education or
income status entered into the analysis. Data on Hispanic and Asian/Pacific Islander subgroups, illustrated in
this report, indicate there are important distinctions in reported drug use within these populations. More
research is needed to create a stronger base of evidence on these differences.
Limitations of the available data have been described throughout this report. To some extent, these limitations
can be addressed as national statistics and surveillance systems implement the most recent recommendations
and standards for classification of racial and ethnic groups. Nonetheless, challenges with reliability and validity
of evidence will remain, even when improved classifications are in place. For example, concern continues about
underenumeration of young minority group members in survey research and the possibility of underreporting
of illegal drug involvement due to English language difficulties. These limitations merit attention in method-
ologically oriented research designed to yield lasting improvements in our national statistics and surveillance
efforts, as well as more refined research in other domains of inquiry supported by NIDA and other Federal 
agencies.
Some additional improvements may result if there are deliberate efforts to:
■ Include more minority researchers in leadership roles within the scientific community;
■ Increase collaboration with people of color when plans are being laid for each new research agenda, with
identification of funding priorities that are culturally appropriate and sensitive;
■ Encourage meaningful analyses of existing databases on various stages of drug involvement across a range
of racial/ethnic minority groups; 
■ Identify conceptually motivated constructs and theories in new research on health disparities as they 
are manifest across the various stages of drug involvement and in response to prevention and treatment
interventions; and
■ Develop and implement new lines of research on race- and ethnicity-related discrimination, quality of 
life, self-sufficiency, and other factors important to an understanding of the processes through which health
disparities emerge.
In closing, NIDA is reconceptualizing its mission in addressing health disparities affecting racial and ethnic
minority groups in the U.S. population, with an appreciation that the definition of “minority” will change 
during the 21st century. This reconceptualization process cuts across all NIDA divisions and branches, including
basic laboratory science research in neuroscience and pharmacology, but may be most visible in epidemiological
and clinical studies of racial, ethnic, and cultural factors associated with the causes and consequences of illegal
drug use for all racial/ethnic groups. These studies include case-control as well as longitudinal studies and exper-
iments that attend to the various characteristics of the populations under study. More research is needed to
examine the natural history and clinical course of drug problems as experienced by the array of racial and ethnic
populations of the country and the differential influences on and consequences of illegal drug use over time.
These studies will help target the factors most important in the initiation and continuation of drug use among
racial/ethnic populations and identify the culturally relevant factors associated with drug use. Further examination
of cultural factors also may help shed light on the protective mechanisms among subpopulations, resiliency
processes that help sustain susceptible populations, and contextual influences on risks associated with drug use.
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To the extent that NIDA-supported investigators are successful in this research arena, our Nation’s policymakers
and program managers will be better able to respond to observed health disparities and to reduce these disparities
through health-promoting intervention choices.
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NIDA asks readers of this report to make suggestions that can be
used to improve future revisions of the report. These comments
and suggestions may be sent to Dr. Leslie Cooper at:
lc58q@nih.gov
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Health disparities research within the context of programs conducted or supported by the National Institute on
Drug Abuse (NIDA) refers to studies involving human subjects that focus on one or more minority population
groups (e.g., African Americans, Asian/Pacific Islanders, Hispanics, and Native Americans). Racial/ethnic
minority populations are adversely affected by the stigma of drug abuse and its effects leading to misperceptions
about drug abuse and addiction in minority communities and the way in which prevention and treatment are
delivered to them. The common perception is that minority groups, particularly Blacks and Hispanics, use drugs
more than Whites—even though epidemiologic data show little difference in overall use by race/ethnicity. In fact,
in some instances minority groups are less likely to use licit or illicit drugs. 
While the prevalence of drug abuse is similar for minorities and Whites ages 12–17 with the progression of drug
use into early adulthood, the adverse consequences tend to be greater for minorities than for Whites. This is 
evident in arrest, sentencing, and incarceration rates; school dropout rates, and the rates of drug-related hospital
emergency room visits. Because of the extreme differences in the consequences of drug use for racial/ethnic
minorities, there is an urgent need to better understand factors such as socioeconomic status, discrimination,
culture, neighborhood/environmental conditions, access to health care, and employment status, which place
minorities at risk for drug use and its adverse consequences. Disparities are readily apparent in the reported rates
of HIV/AIDS infection, violence and victimization, incarceration, school dropout, and morbidity in ethnic
minority communities. Science-based information is needed to inform prevention, treatment, and health services
targeted at minorities and to reverse the effects of the stigma attached to drug addiction.
Health disparities and minority-related research have been defined as follows:
■ Health Disparities Research—Basic, clinical, and behavioral research that addresses the magnitude and
impact of drug use within racial/ethnic minority populations, where the goal of the study is to determine
the differential use and/or effects of drugs on the racial/ethnic minority groups included in the study.
Health disparities research addresses issues related to epidemiology, prevention, services, and treatment 
outcomes within and across racial and ethnic populations. 
■ Minority-Related Research—Research that includes racial/ethnic minorities as participants but where the
goals, aims, and hypotheses of the study do not specifically address drug use and/or its effects as they
are experienced by racial/ethnic minority populations. 
■ Coding—For coding purposes, 100 percent of the funded amount for projects that meet the definition for
health disparities research should be included in NIDA’s Health Disparities Research budget reporting.
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Mission and Introduction
The mission of the National Institute on Drug Abuse (NIDA) is to lead the Nation in bringing the power of
science to bear on drug abuse and addiction by (1) providing strategic support and conduct of research across
a broad range of disciplines and (2) ensuring the rapid and effective dissemination and use of the results of that
research to significantly improve drug abuse and addiction prevention, treatment, and policy.
Unlike other diseases, drug addiction poses many peculiar challenges to health researchers, providers, and public
health officials in the search for effective prevention and treatment strategies and policies. These challenges
emanate primarily from the fact that drug abuse and addiction are usually the result of illegal activity and drug
abusers are often viewed as morally corrupt or weak-willed individuals who engage in not only voluntary self-
and socially destructive behavior but also criminal activity. In short, despite the fact that we know unequivocally
that addiction is a disease like any other medical disease, it remains a stigmatized disease. And this stigma spills
over to all aspects of drug abuse research, prevention, and treatment (e.g., obtaining measures of use, addressing
safety and legal concerns, and providing early intervention are compromised by efforts to hide the disease and
denial of dependency). 
Racial/ethnic minority populations are perhaps most adversely affected by this stigma and its effects, leading to
misperceptions about drug abuse and addiction in minority communities and the way in which prevention and
treatment is delivered to them. For example, the common perception is that minority groups, particularly Blacks
and Hispanics, use drugs more than Whites even though epidemiologic data show little difference in overall use
by race/ethnicity. In fact, in some instances minority groups are less likely to use licit or illicit drugs. There are,
however, great differences in the consequences of drug use for racial/ethnic minorities, creating a great need to
better understand the unique prevention, treatment, and health services needs of these communities.
NIDA has made a concerted effort, particularly over the last 6 years, to better understand and address the drug
abuse and addiction research needs of racial/ethnic populations, focusing on research areas where there are 
significant gaps in knowledge and/or clear disparities in prevention and treatment. In 1993, NIDA established
a Special Populations Office, which has two overall goals: (1) to encourage increased research on drug abuse in
minority populations in NIDA divisions and (2) to encourage and enable increased minority participation in
drug abuse research. Moreover, NIDA formed an institute-wide work group, the Consortium on Minority
Concerns, which meets monthly to address research and research development issues of concern to minority
populations. Each program division and office is represented on the Consortium. 
Several institute-wide initiatives and policies were implemented, which has led to progress in research that
addresses health disparities and the underrepresentation of minority scholars in drug abuse research. Some of
these initiatives include:
■ Historically Black Colleges and Universities (HBCU) Initiative. This was designed to encourage HBCUs 
to become involved in drug abuse research and to assist them in developing the capacity to conduct drug
abuse research. Some selected outcomes of this initiative include increased support of HBCUs through the
NIH competitive process (which has led to research on underresearched areas such as developing prevention
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programs for rural African-American youth, understanding risk for drug abuse in African-American youth
at developmental transition points), establishment of a center on drug abuse research at Howard University
(which has since received a substance abuse grant from the Robert Wood Johnson Foundation), support of
an established research scientist cooperative agreement program at four HBCUs in collaboration with the
Office of Research on Minority Health (ORMH) (North Carolina Central has recruited a distinguished
NIDA scientist with three independent awards—this has already led to collaborations for student and 
faculty research and training opportunities with Wake Forest University and the University of North
Carolina, and increased activity on the campuses around substance abuse awareness and prevention. 
■ Enhancement of the Underrepresented Minority Supplement Program. NIDA instituted a new policy 
for the funding and receipt and review of minority supplement applications. In the last 5 years, NIDA 
has more than doubled its support of Minority Supplements in amount of funds allocated yearly to the 
program and nearly doubled the number of new awards made (from FY 1994 to FY 1999). NIDA also
established a policy to include Asians and Pacific Islanders in behavioral and clinical work because they are
underrepresented in these areas of drug abuse research. Former recipients are applying for and receiving 
independent research awards, and often these recipients focus on disparities research issues and/or intend 
to mentor other underrepresented students and scholars. 
■ Summer Research with NIDA. To address concerns about the insufficient pipeline of minority researchers,
NIDA established a summer program to place minority high-school and undergraduate students with
extramural scientists. Response has been very positive from students and investigators. This summer marks
the fourth year of the program. Initially started with ORMH funds, NIDA completely supports the program
now. Thirty-nine students were placed in 1999, some of them returning to the same investigators. 
■ Minority Recruitment and Training Program. This is an intramural summer research program for students
and faculty. It accepts minority high-school, college, graduate and medical students, and faculty members.
About 25 students are placed each summer. One of NIDA’s HBCU principal investigators is a former 
participant in this program. A successful minority student development program at Temple University
requested that some of their students be placed with NIDA’s intramural program based on the reputation
of this program and its director. 
■ Minority Work Groups. Work groups comprised of experts in substance abuse and addiction or health
concerns of minority populations have been created. These Work Groups advise the NIDA Director on
research and research development needs of the particular minority communities that will lead to effective
prevention and treatment approaches for each group. Work groups exist for African-American, Hispanic,
and Asian/Pacific Islander communities. A Native American work group meeting will be held in May
2000. Some outcomes of the work of these groups include new principle investigators, identification of
candidates for the supplement program, new opportunities for NIDA to interact with professional and
community groups, new ideas for research, new study section members, and increased mentoring and 
collaboration among group members.
■ Development of public announcements (PAs) and requests for applications (RFAs). NIDA released a new
program announcement, Minority Institution’s Drug Abuse Research Program, to support minority institu-
tions wishing to develop their capacity to conduct drug abuse research. Two new programs were funded
under this PA last year. One will focus on Hispanic issues in drug abuse prevention. Another, in Puerto
Rico, was recently approved for funding and it will focus on Hispanic populations. An RFA, the HBCU
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Cooperative Agreement, was released in collaboration with ORMH. Four projects were funded under this
RFA: One will focus on prevention interventions with urban African-American youth and one will focus
on prevention issues and perinatal care in minority populations. All include research training opportunities
for minority faculty and students.
■ Research Development Technical Assistance Workshops. NIDA offers technical assistance to minority 
and women scholars in developing research studies on drug abuse and addiction. Participants are provided
information on conceptual and methodological concerns in drug abuse and addiction research in addition
to information on the NIH grants application and review processes. Many of the participants in this 
program have become NIDA/NIH grantees, NIH peer reviewers, and grantees of other agencies and 
foundations.
As a result of these activities and individual division activities, NIDA has experienced approximately a 97-percent
growth in minority researchers since FY 1993. With this growth in minority researchers (although all are not
involved in minority-focused research) and an intense focus on drug use and addiction in minority communities,
we have observed an increase in applications and awards that focus on drug abuse disparities and needs in
minority communities.
This proposed strategic plan reflects NIDA’s insights and knowledge gained from our efforts to address health
disparities among racial/ethnic groups over the last few years. In addition, the plan incorporates the recom-
mendations made by the expert work groups described above and an extensive review of NIDA’s research 
programs and activities conducted by staff. 
Over the next 5 years, NIDA will strive to (1) improve our understanding of the incidence and causes of drug
abuse and addiction in all racial/ethnic groups recognizing the diversity by gender, socioeconomic status, and
other factors within racial/ethnic populations, (2) strengthen and expand the community and research infra-
structure for conducting research within racial/ethnic populations, (3) improve prevention and treatment for
racial/ethnic groups at highest risk for addiction and medical consequences of drug use and addiction, and 
(4) widely disseminate information on drug use and the disease of addiction in racial/ethnic communities 
identifying best approaches to prevention and treatment.
Area of Focus #1: Epidemiology of Drug Abuse, Health Consequences and Infectious Diseases
among Minority Populations
Introduction/Background. Having a good knowledge base on the incidence and patterns of drug use, abuse,
and addiction is critical to assessing the need for and shaping the content of prevention and treatment programs.
Current surveys such as the NIDA-supported Monitoring the Future study (a national survey of 8th-, 10th-,
and 12th-graders) and the Substance Abuse and Mental Health Services Administration (SAMHSA)-supported
National Household Survey on Drug Abuse (NHSDA—a national survey of persons 12 and older residing in
households) provide important information on drug use patterns and trends. However, they are limited in the
extent to which they reveal indepth information about racial/ethnic groups. For example, neither survey has
adequate representation of Native Americans, Alaska Natives, Asians, or Pacific Islanders. Although this 
may change beginning with the increased sample size in the 1999 NHSDA survey, there is still concern about
obtaining adequate adolescent samples for these subgroups. African Americans and Hispanics are included, but
their numbers are not sufficient to form reliable subgroups to investigate within group profiles (e.g., develop
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separate profiles for Mexicans and Puerto Ricans). Moreover, there are selection biases that disproportionately
affect minorities that may suppress their numbers in these general surveys. For example, Hispanics have a higher
school dropout rate than other groups and therefore may be more likely to be excluded from the school surveys
and may be difficult to reach in household surveys. Since dropout rates correlate with higher risk for deviant
behavior, we may be missing information on a group with a high risk for drug abuse and addiction. 
More work is needed to better understand the causes of drug use in minority communities. Promising studies
are underway on risk and protective factors especially on the role of culture, religiosity, ethnic identity, family,
peer, and environmental/community level factors in drug initiation. For example, minority youth tend to initiate
drug use later than White youth. Yet, when African Americans start using, they seem to progress to addiction
faster. Among Hispanic youth, drug use seems to increase with increased acculturation to U.S. norms and with
years and generations in the United States. We know little about predictors of use in Pacific Islander and Asian
subpopulations. 
Better measures and designs are needed to appropriately assess drug abuse and addiction and related behaviors
in racial/ethnic populations. 
Minority populations are disproportionately affected by HIV/AIDS and other infectious diseases that are a 
consequence of using drugs and engaging in other risky behaviors. African Americans and Hispanics, especially
women, comprised 54.7 percent of the AIDS cases reported to the Centers for Disease Control and Prevention
(CDC) in 1998. This percentage is far greater than their representation in the general population. Other studies
indicate a plethora of ways in which minorities may be adversely affected by drug abuse-related diseases:
■ Women, particularly African-American women, are at higher, unique risk for HIV/AIDS;
■ Injection drug users are at increased risk for mycobacterium tuberculosis infection (TB) and Hepatitis B
and C infection (HBV and HCV, respectively);
■ A possible association exists between vascular injury of the neonatal central nervous system and the level of 
prenatal cocaine exposure; and 
■ Hispanic homeless are more likely to share needles. 
We know relatively little about the varying patterns of initiation of drug use and addiction among women of
diverse racial and ethnic groups.
NIDA has continuously attempted to respond to the need to understand the patterns and causes of drug abuse
in all populations through several activities, such as releasing PAs and RFAs and convening conferences 
and meetings. For example, in 1998 NIDA reissued its "Epidemiologic Research on Drug Abuse” PA, which
encourages numerous epidemiologic strategies, including monitoring of trends over time of drugs of use/abuse,
identification and measurement of health problems associated with drug abuse, and international epidemiology
of drug abuse. Applications submitted in response to this PA are expected to guide the development of inter-
ventions; define subpopulations; identify groups at risk for various health conditions, such as HIV, TB, hepatitis,
poor pregnancy outcomes, ADHD, mental disorder, and other conditions (predisposing and consequential to
drug use/abuse); inform and influence local state and Federal health agencies; and provide guidance for public
policy. Investigators have been strongly encouraged to conduct analyses by race/ethnicity.
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NIDA staff has been working actively at numerous meetings to increase the number of grant applications in
such areas as HIV in the African-American population, health care/primary care access and utilization among
minority drug abusers with HIV infections, and epidemiology of HIV in the Caribbean.
Goal 1: Improve the knowledge base on the patterns and origins of drug abuse and addiction in 
all racial/ethnic populations including producing estimates of racial disparities on the incidence and
prevalence of drug use and addiction within those populations, examining both risk and protective factors.
Action Plan 
■ Expand research to
● Assess, within and across racial/ethnic groups, the magnitude, incidence, and prevalence of drug abuse,
analyzing by gender;
● Identify and assess both individual and community/environmental vulnerability, risk, and protective 
factors for drug use and abuse and related consequences in various racial/ethnic populations, analyzing 
by gender;
● Develop better sampling methods for hard-to-reach minority populations and more effective ways to
reduce survey nonresponse and increase the validity of self-reported drug use and associated behaviors;
and
● Support the secondary analysis of data obtained under NIH-supported research pertinent to 
understanding the epidemiology and etiology of drug abuse in racial/ethnic populations, including 
analyses by gender. 
Goal 2: Identify and examine issues of health disparities in drug abuse and associated infectious diseases,
particularly HIV/AIDS within racial/ethnic populations, including analyses by gender. 
Action Plan 
■ Expand research to
● Increase scientific knowledge about the medical and health consequences of HIV infections in 
women and men of racial/ethnic minority groups, including assessing the magnitude, incidence, and
prevalence of HIV/AIDS and other sexually transmitted diseases, HBV, HCV, TB, and their impact on
racial/minority populations; identifying the associated risk and protective factors for HIV/AIDS and
other sexually transmitted diseases, HBV, HCV, TB, mental disorders and socioeconomic status among
racial/minority populations; and identifying subgroups within racial/minority groups at greatest risk
(e.g., homeless, homosexuals, and prison inmates). Develop and implement appropriate intervention
strategies for reducing risk factors among women and men in these groups;
● Increase access to, utilization of, and adherence to antiviral therapies by HIV-infected ethnic minority
male and female drug users through identifying new, simplified, and innovative strategies/approaches
and mechanisms to complement and improve traditional approaches for individuals in this population;
and
● Increase scientific knowledge on how gender and other factors such as community, culture, education,
and socioeconomic status affect HIV transmission within racial/ethnic populations. 
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Goal 3: Identify both the short- and long-term effects of drug use, abuse, addiction, and violence and
their interrelationships on the overall health (including physical, mental, and emotional health) of men,
women, and children in racial/ethnic populations.
Action Plan 
■ Expand research to
● Identify and assess issues of comorbidity across the age span for all racial/ethnic groups and the 
relationship between drug abuse, comorbid conditions, and health disparities within and across those
groups and by gender within these groups;
● Investigate health and developmental disparities across racial/ethnic groups for children and adolescents
who have experienced prenatal drug exposure and/or early use of illicit drugs by gender within these
groups;
● Identify and review the state of knowledge and availability of data on the coexistence of substance abuse
and mental/emotional disorders and the presence of health disparities across and within racial/ethnic
groups, including analyses by gender;
● Identify the impact of the drug-using environment on racial/ethnic women and men living under those
conditions. Assess proposed strategies for interventions to reduce drug abuse in these groups;
● Evaluate the role of stress (e.g., cultural adaptation) in initiating and escalating drug use/abuse and its
impact on various male and female racial/ethnic populations. Sensitivity and responsiveness of the needs
of the target audience must be considered in all instrument development, administration, analysis, and
evaluation of the data; and
● Explore the contextual relationships between drug use, violence, employability, school performance, 
family structure, and economic well-being of the community. Sponsor a series of workshops and 
meetings with grantees and others to explore the current state of the knowledge.
Area of Focus #2: Prevention of Drug Abuse and Addiction
Introduction/Background. NIDA has made great strides in the last few years in its prevention research 
program. The Institute has supported two long-term minority prevention research centers that focus on African
Americans, Hispanics, and Native Americans, as well as several other research projects that include ethnic
minorities. Results from these and other research studies suggest that racial/ethnic populations may have special
prevention needs and that prevention strategies may have to be specific to their culture and circumstances to be
successful. For example, research indicates that including culturally specific components in “generic” prevention
programs enhances effectiveness with African Americans. 
Epidemiologic data show that race/ethnic groups differ in patterns of drug use, preferences, and accessibility 
and risks requiring prevention programs that attend to these needs. For example, Hispanic youth are more likely
to be school dropouts, making school-based prevention programs unlikely to reach Hispanic youth at greatest
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risk. African Americans have late (or delayed) onset of drug use, suggesting that they may be more in need of
prevention programs after high school, in their late adolescent/early adult years. Native Americans on 
reservations need prevention programs at an early age and such programs must be acceptable to tribal councils.
Second-generation immigrants may be at higher risk for drug use than first-generation immigrants. Moreover,
the heterogeneity or diversity within racial/ethnic groups must be acknowledged in prevention efforts (e.g., gender,
socioeconomic status, education, cultural styles, rural-urban differences, and the specific risk factors for these
subgroups need to be better understood to inform prevention efforts). 
More prevention programs are needed to reach minority populations in high-risk settings and neglected, hard-
to-reach areas or communities. This includes, for example, persons in correctional facilities (more likely to be
African Americans and Hispanics), persons in rural areas, migrant workers/seasonal farm workers (often
Hispanic and Haitian), children in drug-abusing families, and minority women addicts (who are at great risk
for infectious diseases). More research is needed on prevention efforts with Asian/ Pacific Islanders and Native
Americans/Alaska Natives and their subgroups.
Goal 1: Support prevention research targeting racial/ethnic minorities to (1) understand the drug abuse and
HIV/AIDS prevention needs of minority populations across the life span, with specific attention to very early
and late onset initiation of use and diversity in vulnerability to use across the life cycle (e.g., immigrant groups
adapting to new environment, transition points, and stress); (2) understand how to develop culturally appro-
priate prevention interventions and how to adapt “generic” prevention models for specific minority populations;
(3) examine the effectiveness of mass media prevention/education messages that target specific minority popu-
lations; (4) develop more prevention interventions that reach minority populations in contexts such as the family,
church/faith community, and other community programs to ensure that prevention expertise becomes a 
permanent part of the community; (5) address the complexities and requirements of developing effective 
prevention programs for diverse groups within multiethnic, multicultural settings (e.g., schools with multiethnic
student bodies and persons with multiple ethnic identification or affiliations); and (6) identify how cultural
norms affect gender differences in drug use and risk factors.
Action Plan
■ Develop research opportunities in the above areas.
Goal 2: Ensure that racial/ethnic minority populations are fully incorporated into the planning and
implementation of NIDA’s Next Generation of Prevention Research Initiative, designed to gain a better
understanding of the factors that account for prevention program effectiveness.
Action Plan
■ NIDA staff will review plans for the next generation studies to make certain that concerns of racial/ethnic
minorities are adequately addressed.
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Goal 3: Develop effective, culturally specific drug abuse prevention strategies for minority populations
who are at increased risk for drug abuse, such as individuals in detention or correctional facilities, the homeless,
and persons who have been abused or neglected, and those groups who are underserved, such as those living on
Indian reservations or in rural areas, migrants or seasonal farmworkers, and youth in the early stages of cultural
adaptation and acculturation.
Action Plan 
■ Expand research opportunities in this area.
Area of Focus #3: Addressing Disparities in Treatment and Health Services Research
Introduction/Background. NIDA currently supports several activities that focus on racial/ethnic groups and 
cultural factors in treatment for addiction. For example, the Behavioral Therapy Development Program 
supports several studies that are evaluating family-based treatment approaches for drug-using minority youth
(based on research findings suggesting that family variables are more influential in substance use in certain
minority youth). Some of these studies suggest that treatment engagement procedures may be different for
Mexican-American and Cuban youth. Analyses will be conducted to ascertain whether outcome differences are
due to cultural factors associated with Mexican-American and Cuban families or other factors. A study was
recently funded that is evaluating the efficacy of adding a culturally relevant, community-based community
reinforcement enhancement to an existing residential treatment program for homeless, crack-using, African-
American women with children. This study is using the Black church as a vehicle for implementing the inter-
vention. To advance the current knowledge base about potential ethnic differences in nicotine dependence,
NIDA is supporting a study that will design and test the efficacy of smoking cessation programs in treating
Chinese-American smokers. 
NIDA’s newly established National Drug Abuse Treatment Clinical Trials Network (CTN) will provide yet
another vehicle for NIDA to ensure that minority populations are included in both NIDA’s treatment research
protocols and in conducting treatment research. The CTN will provide a much-needed national research and
dissemination infrastructure to more rapidly and systematically bring new science-based addiction treatments
into real-life treatment settings. 
Considering the severe consequences of drug abuse and addiction on racial/ethnic populations, NIDA realizes
that minority populations need to be more fully included in treatment research and clinical trials. Moreover,
more attention needs to be directed at examining medical, social, and cultural factors that may influence adher-
ence to treatment and treatment outcomes. For example, some minority populations are included in NIDA-
supported clinical trials of pharmacotherapies and behavioral therapies; however, data are not completely
analyzed by race/ethnicity to better understand behavior in treatment or outcomes of treatment. In some clinical
research studies, there have been difficulties in enrolling and retaining adequate numbers of minorities in order
to conduct meaningful data analyses. Other research indicates that race/ethnicity may be important in physio-
logical responsiveness to drugs. For example, pharmacokinetic studies indicate that there are differences in some
ethnic populations in their ability to metabolize different drugs. 
Racial/ethnic minorities may experience more difficulties in obtaining the most appropriate health care services.
Research suggests that they may be more vulnerable to gaps and lack of coordination in systems of care and that
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they may encounter bias in treatment assignments. The need for services appears to differ by race/ethnicity 
(e.g., one study suggests that Latinos may require more intensive services). 
Goal 1: Increase the number of treatment research studies that focus on racial/ethnic differences and
improve dissemination of the study results.
Action Plan
■ Ensure that all racial/ethnic minority populations are fully included in NIDA’s newly established National
Drug Abuse Treatment CTN as clients, advisors, and research staff. Ensure that a sufficiently large sample
is recruited in each study to allow for analyses by specific racial/ethnic groups;
■ Develop a strategy to obtain more input from minority populations for the NIDA research agenda;
■ Encourage research to develop and test behavioral treatments that are culturally and gender sensitive and
relevant for racial/ethnic minorities; encourage studies of behavioral treatments, alone and in combination
with pharmacological treatments, for racial and ethnic minority drug abusers, including adolescents,
women, and those involved with the criminal justice system;
■ Develop systems to encourage NIDA grantees to include sufficient numbers of minority populations, 
analyze the data that are collected on racial/ethnic minorities, and publish the results;
■ Encourage research to develop validated, reliable clinical screening and assessment instruments in languages
other than English for use in clinical research with non-English speaking subjects;
■ Expand NIDA’s intramural clinical research to address treatment issues by race/ethnicity, and further
develop the program focusing on smoking cessation techniques with minority youth; and 
■ Sponsor a series of workshops and meetings with grantees and the minority advisory groups to explore the
current state of knowledge, identify gaps in the research, and make recommendations for future research.
The professional organizations representing different minority populations should also participate in this
process.
Goal 2: Determine the factors that contribute to differences, if any, experienced by racial/ethnic minority
populations in access to services and outcomes of treatment in managed care and other service systems.
In addition, assess the impact of welfare reform on substance abuse services provided to ethnic minorities,
especially minority women.
Action Plan
■ Expand the treatment and prevention services research portfolio to better understand the organization,
management, financing, and delivery of services and to enhance the integration of treatment and prevention
strategies and programs into existing community level service delivery systems; and
■ Sponsor workshops and meetings with grantees and the minority advisory groups to explore the current
state of knowledge, identify gaps in the research, and make recommendations for future research. The 
professional organizations representing different minority populations should also participate in this
process.
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Area of Focus #4: Addressing Racial/Ethnic Disparities in Basic and Clinical Neurosciences
Introduction/Background. Research is needed to better understand racial/ethnic differences in genetic 
vulnerability and/or resilience to drug abuse and addiction; neurotoxicity; and neurobiological and behavioral
processes underlying tolerance, dependence, and relapse. Pharmacokinetic studies have revealed distinct 
differences in some ethnic populations in the ability to metabolize different drugs, indicating a clear biological
basis in response to drugs. Studies focusing on the interaction between racial/ethnic differences and the effects
of drugs on underlying neural and behavioral processes will provide the basis for more targeted treatment and
prevention approaches in different populations.
Goal 1: Increase the number of neuroscience, clinical neuroscience, and basic behavioral science studies
that focus on racial/ethnic differences.
Action Plan
■ Provide support to key investigators to over sample underrepresented groups in their studies.
■ Require NIDA program staff to emphasize the importance of inclusion of minority subjects to all principal
investigators conducting human subject research and to work closely with those who are deficient in their
minority recruitment;
■ Provide avenues for publication of basic research findings comparing subgroups, including NIDA sponsored
publications such as NIDA monographs;
■ Provide information on strategies for recruiting underrepresented groups into basic human subject based
research; and
■ Expand research that directly targets minorities in the basic and clinical neurosciences and behavioral 
sciences, with the intent of addressing minority health disparities.
Area of Focus #5: Infrastructure Development and Enhancement
Introduction/Background. NIDA recognizes that conducting scientifically valid health disparities research
requires a research infrastructure that includes well-informed and trained scientists, knowledgeable and cooper-
ative communities (e.g., community-based organizations, professional associations, faith communities, and
tribal councils), and academic institutions with competency and interest in health disparities research. NIDA
has made concerted efforts to build this critical infrastructure for health disparities research. We have worked to
increase the number of underrepresented scholars involved in drug abuse research and to increase our support
of useful and appropriate research on drug abuse in minority communities. Several initiatives, programs, and
activities have been implemented to eliminate this underrepresentation; examples include establishing expert
work groups on racial/ethnic populations, strengthening the Minority Supplement Program, developing an
HBCU Initiative, providing technical assistance in grants development, and developing program announce-
ments and RFAs to build the minority research infrastructure. NIDA plans to build on these already successful
programs and expand them to increase training and career development opportunities for underrepresented
minorities. In addition, NIDA plans to increase the numbers of researchers and research studies that focus on
abuse and addiction in minority communities and to, in general, stimulate interest and enhance competency in
conducting research for eliminating disparities experienced by racial/ethnic populations related to drug abuse
and addiction.
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Goal 1: Ensure proper resource requirements through training/career development.
Action Plan
Student Development and Support. NIDA will continue to support its current activities to increase the 
number of underrepresented students entering drug abuse research careers. This includes the Minority
Recruitment and Training program sponsored by the intramural program, the extramural Summer Research
with NIDA program for minority high-school and undergraduate students, and the Minority Supplement 
program. In addition:
■ NIDA will encourage applications for short-term training grants (T35) from drug abuse and addiction
programs particularly those involved in the National Drug Abuse CTN to offer summer research training
experiences for promising undergraduate and graduate minority students.
Faculty and Investigator Development. NIDA will continue to support its current activities to increase the
number of faculty and scholars conducting drug abuse and addiction research. This includes the Minority
Supplement Program, the Research Development Technical Assistance program, and the online research grants
development program. In addition, NIDA will:
■ Develop a Visiting Scholar Program to recruit and train African-American, Hispanic, and other minority
drug abuse researchers, with a special outreach to scholars from minority programs and institutions such 
as HBCUs, HSIs, and tribal colleges to spend time in selected research programs learning state-of-the-art
methodology. The small grant mechanism (R03) could be used to support a period of training in laboratories
using state-of-the-art technologies to examine a variety of aspects of drug abuse and addiction;
■ Develop a Career Development Award (K01) for minority faculty interested in all areas of drug abuse and
addiction research. This program would be aimed at faculty seeking a period of protected time to devote to
developing drug abuse research projects at their institutions. Special efforts will be undertaken to increase
the number of minority researchers in prevention and clinical research;
■ Establish a Minority Clinical Research Scholars Program in the NIDA Intramural Research Program;
■ Develop a plan with the Center for Substance Abuse Treatment to bring more minority scientists into drug
abuse and addiction clinical research. Explore the possibility of supporting minority supplement grants on
Center for Substance Abuse Treatment research and evaluation projects; and
■ Establish a Minority Clinical Research Scholars Fellowship as part of NIDA’s CTN program.
Academic Institution Development. NIDA will continue its efforts to increase the capacity of academic insti-
tutions, especially minority colleges and universities, to conduct drug abuse research. This includes the Minority
Institutions Drug Abuse Research Program and the HBCU Initiative. In addition, NIDA will:
■ Develop partnerships between institutions with well-established drug abuse research programs and minority
institutions that are interested in developing capacity in this area. Collaborate with ORMH on plans to
establish partnerships between drug abuse research centers and minority institutions;
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■ Establish a NIDA Minority Access to Drug Abuse Research Careers Program through the National
Research Services Act (NRSA) to encourage and engage promising minority undergraduate scientists in
drug abuse and addiction research; and 
■ Support or examine the possibility of establishing Training Centers (T32s) in the basic neurosciences and
behavioral sciences, and clinical neurosciences at HBCUs and other minority education-oriented colleges
and universities. Encourage the participation of minority students at already existing centers.
Professional and Community Development. NIDA will continue its efforts to involve the broader commu-
nity in addressing health disparities in racial/ethnic communities caused by drug abuse and addiction. This
includes the various expert work groups on African-American, Hispanic, Asian-American and Pacific Islander,
and Native American and Alaska Native communities. In addition, NIDA will:
■ Encourage clinical minority professional organizations to create and administer clinical minority research
development programs through the K–12 mechanism. This can be modeled after the successful American
Psychiatric Association and American Academy of Child and Adolescent Psychiatry programs to recruit 
and train minority clinicians interested in drug abuse and addiction research;
■ Host writing workshops to facilitate publications in peer-reviewed journals by minority scholars;
■ Develop opportunities (e.g., forums at professional meetings) to discuss drug abuse research needs, plans,
and opportunities with key stakeholder groups to include practitioners and consumers; and
■ Support workshops or programs to train investigators on conducting responsible drug abuse research 
in racial/ethnic minority communities. Consider creating guidelines for ensuring that such research is
appropriate and sensitive.
Area of Focus #6: Public Information/Outreach/Education and Dissemination
Introduction/Background. There are special challenges and problems in creating culturally appropriate 
information for special populations. To meet these challenges, NIDA has organized and convened ethnic 
advisory panels for Latinos, Asian/Pacific Islanders, and African Americans to improve our outreach to these 
various ethnic and minority groups. Acting on the advice of these experts, NIDA has:
■ Developed Spanish translations of two popular marijuana pamphlets, Marijuana: Facts for Teens and
Marijuana: Facts Parents Should Know;
■ Created a radio public service announcement (PSA) campaign on marijuana abuse for African-American
males ages 13–25;
■ Produced over 30 fact sheets about drug abuse and addiction in Spanish as part of our fax-back system,
“INFOFAX”;
■ Marketed the “INFOFAX” series, as well as the NIDA Web site via a Spanish art card distributed to 
appropriate outlets nationally;
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■ Given financial and editorial support to Pro Salud, a national publication marketed to Hispanic 
communities; and
■ Developed Spanish translations of the drug abuse Problem-Oriented Screening and Assessment Instrument
for adolescents.
In addition to these efforts NIDA routinely distributes all of its press releases to media outlets designed to reach
special populations.
Goal 1: Educate racial/ethnic minority populations about drug abuse and addiction prevention and
treatment. Also, identify and improve mechanisms for dissemination of research findings within and
across minority groups. NIDA is focusing on four key cultural minorities at present: Asians/Pacific Islanders,
Hispanics, Native Americans, and African Americans. Based on discussions with members of our cultural
minority advisory panels, we have also identified some subpopulations with special needs (e.g., Vietnamese,
Cambodian, Filipino, and other Pacific Islanders). 
Action Plan
■ Develop a series of radio PSAs and educational videos targeting Hispanic women. Hispanic women have 
a strong influence in health and lifestyle decisions within the Hispanic community. In addition to PSAs, a
Hispanic family-targeted brochure and video highlighting specific drugs of abuse known to be a problem
in various Hispanic communities (as well as among mainstream youth) will be provided as collateral 
materials. A comprehensive marketing plan to get the PSAs aired and the brochure distributed includes
forming partnerships with appropriate Hispanic organizations and persons of influence (such as journalists
and entertainers etc.). NIDA will work closely with the NIH Hispanic Initiative Coordinator during the
preparation of all related materials;
■ Create a year 2001 calendar for Native Americans that will be used to provide information about drug
abuse. It will be marketed broadly in the Fall 2000 via appropriate organizations, the media, and other 
venues (e.g., Native American-owned businesses and Indian Health Service clinics);
■ Create television drug abuse PSAs and videos in Spanish, which will be distributed to appropriate Hispanic
outlets. The PSAs and videos will follow the theme of NIDA’s national campaign, “Addiction is a Brain
Disease,” in an effort to educate the Hispanic community about the disease of addiction;
■ Translate and adapt other popular NIDA publications into Spanish, including Principles of Drug Addiction
Treatment. When completed, these materials will be packaged as a comprehensive set and broadly distributed
to Hispanic-oriented schools, health organizations, and community groups. Provide 
targeted training to Hispanic substance abuse treatment providers on effective treatment methods; and
■ Enhance NIDA collaboration with minority professional organizations through forums such as the NIDA
Constituent Conference and NIDA Town Meetings.
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Goal 2: Put research into practice in minority communities by providing science-based prevention and
treatment information to service providers serving these populations.
Action Plan
■ Translate Preventing Drug Use Among Children and Adolescents: A Research-Based Guide and Principles of
Drug Addiction Treatment: A Research-Based Guide into Spanish and distribute them to caregivers and 
service providers who work with Hispanic populations;
■ Distribute the “NIDA Toolkit” to service providers working in minority communities. The toolkit is a
national NIDA initiative to get the latest treatment information, including a set of NIDA treatment 
manuals, to service providers across the Nation;
■ Develop an outreach program to community leaders of specific special populations groups that will enable
them to help families understand drug abuse problems within their communities and give those families
the culturally appropriate tools for prevention and treatment;
■ Translate the NIDA treatment manuals into Spanish and distribute them to treatment providers who work
with minority populations; and
■ Develop a research-based prevention guide for persons working with racial/ethnic minority groups.
Goal 3. Educate the research and practice community about the state-of-the-art in drug abuse and 
addiction research with racial/ethnic minority populations.
Action Plan
■ Sponsor a national conference on drug abuse and addiction research and racial/ethnic communities;
■ Develop a guide and Web site that offers information on research with racial/ethnic populations.
Information such as current research, research findings, and valid measures would be available;
■ Provide guidelines and training on how to conduct research with racial/ethnic groups, including information
on cultural styles and ethical issues; and
■ Identify and improve mechanisms for dissemination of research findings within and across minority
groups.
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